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Benzodiazepines exert their anxiolytic, anticonvulsant, muscle relaxant, and sedative-hypnotic 
properties by allosterically enhancing the action of GABA at GABAA receptors via their 
benzodiazepine binding site. After 50 years of clinical use, the molecular basis of this 
interaction still is not known as all attempts for structural resolution failed so far. In the 
absence of a crystal structure, protein homology modeling and molecular dockings are the 
only source for structure-based binding mode hypotheses for benzodiazepines. But two 
obstacles make this undertaking extraordinary challenging. First, the homology models were 
quite uncertain due to the low target-to-template sequence identity. And secondly, although 
standard docking tools are capable of reproducing the correct binding mode, they regularly 
fail to select this out of the produced pose list. 
In this thesis, the obstacles were tackled in a two step approach. Primarily, the model 
uncertainty was faced by an explorative step, where nine benzodiazepines were docked into 
an array of α1β2γ2 GABAA homology models, considering flexible sidechains and keeping 
the 100 best scored poses per ligand per model. Consequently in the selection step, exhaustive 
implementations of various validation sources in an orchestrated and integrative manner were 
necessary to filter the gigantic pose space. A key criterion in this filtering process was the 
common binding mode (CBM) hypothesis, which assumes that diazepam and its close 
structural analogues exhibit a common binding mode within the binding site. Therefore, 
ligand poses were clustered according to their common scaffold, which  led to three common 
binding mode geometries, CBM I–III. Then, the integrative qualities of CBM came into effect 
by incorporating experimental information from nine benzodiazepines for CBM I-III 
validation. The evaluation clearly demonstrated that CBM I is convincingly supported by a 
large variety of structural, computational and experimental evidence. The CBM I ligand-
receptor complex was then used in structure-based virtual screening runs and led to the 
successful discovery of  three novel, experimentally validated, benzodiazepine binding site 
ligand classes. The structural models were also used to investigate mechanistic receptor 
features and finally identified α1Y168 to be important for the mechanistic coupling from 
benzodiazepine binding to GABAA channel modulation.  
In a broader view, the gained structural models for α1β2γ2 GABAA receptors can be used for 
modelling other GABAA receptor subtypes that will ultimately improve our understanding of 
the structural determinants for subtype selectivity of GABAA receptors, leading to drugs 
excluding subtypes known to be responsible for addicting. Finally, the underlying 
computational workflow can stimulate other groups to integrate various information pieces in 
binding mode elucidation of structurally unresolved membrane proteins. 
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Die anxiolytische, antikonvulsive, muskelrelaxierende und sedative-hypnotische Wirkung von 
Benzodiazepinen wird durch allosterische Verstärkung der GABA Aktivität am GABAA 
Rezeptor ausgeübt. Nach 50 Jahren in klinischer Verwendung ist die molekulare Basis für 
diese Interaktion immer noch ungeklärt, da alle Maßnahmen zur strukturellen Aufklärung 
scheiterten. In Abwesenheit einer Kristallstruktur sind Homology Modeling und Molekulares 
Docking die einzigen Möglichkeiten zur Darstellung von Bindungshypothesen für 
Benzodiazepine. Zwei Tatsachen erschweren diesen Weg aber deutlich: Erstens sind die 
Homology Modelle ungenau da die Sequenzidentität zwischen Target und Template gering 
ist. Und zweites, obwohl Molekulares Docking den richtigen Bindungsmodus generieren 
kann, kann es ihn selten  aus der Menge an produzierten Posen selektieren. In dieser 
Dissertation wurden diese Probleme in zwei Schritten gelöst. Zuerst stellte man sich der 
Modellungenauigkeit in einem explorativem Schritt, indemneun Benzodiazepine in einen 
Array von α1β2γ2 GABAA Homologie Modellen gedockt wurden, unter Berücksichtigung 
von flexiblen Seitenketten und Einbeziehung der besten 100 Posen pro Ligand pro Modell. Im 
folgenden Selektionsschritt waren eine ausführliche Implementierung von verschiedenen 
Validierungsquellen in einem orchestrierten und integrativen Verfahren notwendig, um den 
sehr umfangreichen  Poseraum zu filtern. Ein Schlüsselkriterium in diesem Prozess war die 
common binding mode (CBM) Hypothese. Diese nimmt an, dass Diazepam und seine 
strukturellen Analoga einen gemeinsamen Bindungsmodus in der Bindetasche haben. 
Anschließendes Clustern der Posen führte zu drei common binding mode Cluster, CBM I-III. 
Die nachfolgende Validierung der drei CBMs erfolgte durch Inkorporation von 
experimentellen Informationen von neun Benzodiazepinen . Die Bewertung zeigte eindeutig, 
dass CBM I durch eine Reihe von strukturellen, energetisch-rechnerischen und 
experimentellen Befunden gestützt wird und somit als korrekter Bindungsmodus angesehen 
wird. Der CBM I Ligand-Rezeptor Komplex wurde dann für Virtuelles Screening verwendet 
und führte zur Entdeckung von drei neuen, experimentell bestätigten Substanzklassen, die an 
der Benzodiazepine Bindetasche binden. Die Strukturmodelle wurden auch für die 
Untersuchung von Rezeptor Mechanismen verwendet, die letztendlich die Bedeutung von 
α1Y168 in der Transduktion von Benzodiazepine Bindung zu GABAA Kanal Modulation 
zeigten. Die gewonnen Modelle für α1β2γ2 GABAA Rezeptoren können die Modellierung 
anderer Subtypen verbessern und damit die Entwicklung von Arzneistoffen vorantreiben 
welche nicht mehr mit Subtypen reagieren welche bekanntermaßen für die Abhängigkeit 
verantwortlich sind. Schließlich kann der Workflow von Gruppen mit ähnlichen 
Problemstellungen aufgegriffen werden.
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I. Motivation 
Benzodiazepines belong to the most widely prescribed drugs in current therapeutic use and 
exert their anxiolytic, anticonvulsant, muscle relaxant, and sedative hypnotic properties by 
allosterically enhancing the action of GABA at GABAA receptors1. In spite of being used 
clinically for 50 years, their exact mode of interaction with the benzodiazepine binding site of 
GABAA receptors still is not known.  
All experimental attempts to structurally resolve the GABAA receptor has failed so far. In 
particular the hydrophobic transmembrane domain of the protein aggravates the elsewhere 
quite successful X-ray crystallography.  
In the absence of the GABAA receptor structure, a bunch of experimental methodologies were 
applied to gain knowledge of the spatial arrangement of ligands within the benzodiazepine 
site of the GABAA-receptor. Over the years, methodologies like receptor mutation and ligand 
labelling have contributed a lot to this understanding2,3. But also affinity data from  ligand 
binding assays which become manifest in structure-activity relationships gave valuable hints 
about the orientation of ligands in the benzodiazepine binding site4. However, these findings 
gave only a vague schematic idea of the benzodiazepine binding mode.  
Suddenly new hope emerged in the year 2001 when a crystal structure from a functional and 
structural homologue of the extracellular ligand binding domain of the GABAA receptor, the 
ACh-binding protein (AChBP), became available5.  
Shortly after, the first homology models based on this crystal structure (AChBP) were 
generated and computational docking was used to generate structural hypotheses about the 
binding mode of benzodiazepines in the benzodiazepine binding site3,6-9. Overall, however, 
conclusions remained contradictory and unsatisfactory. Also after the resolution of other, 
more distant structural homologues, the quality of the hypotheses did not improve. The low 
success in the elucidation of the binding mode of 1,4-benzodiazepines with structure based 
approaches were based mainly on two shortcomings: 
 
1. High ambiguity in the GABAA receptor homology models due to the low sequence identity 
to the templates of around 18%.  Models that are built on such a low sequence identity are 
considered speculative at best for structure based studies10  ("ambiguity problem"). 
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2. Even if a correct model is available and molecular docking is able to generate the correct 
binding mode, docking scoring functions are not competent to identify this orientation out 
of other solutions11 ("evaluation problem"). 
The fact that 60% of today’s drug targets are membrane proteins12, make the described 
constellation of poor structural target models in line with intensive research and accumulation 
of experimental data, a quite frequent problem in the drug discovery field. 
The ambiguity in the models ("ambiguity problem") could be faced by broadly sampling 
protein and ligand flexibility during docking. This results in an enormous amount of possible 
ligand-receptor complexes, but with a high likelihood of generating the correct binding mode 
for benzodiazepines. 
However,  the great challenge of this thesis lies in the subsequent step, i.e.  the selection of the 
correctly generated binding mode out of an ocean of ligand-receptor complexes ("evaluation 
problem"). Here a protocol has to be established that supports docking scoring functions in 
the evaluation of ligand-receptor complexes. This protocol should implement various 
knowledge sources (mutagenesis data, labeling data, structure-activity relationships) in an 
orchestrated and integrative manner, leading to the selection of one single benzodiazepine 
binding mode. 
In a broader view the gained structural model of the benzodiazepine binding site will also 
improve our understanding of the molecular determinants for subtype selectivity of 
experimental ligands on GABAA receptors. This knowledge will aid the development of 
subtype selective benzodiazepine binding site ligands, avoiding interactions with subtypes 
known to be responsible for benzodiazepine addiction13. 
But these models and the established methodology should also stimulate structure based 
approaches beyond the GABAA receptor field. Together with the nicotinic acetylcholine 
receptors (nAChR), glycine, and serotonin type3 receptors, the GABAA receptors belong to 
the pharmacological important protein class of ligand gated ion channels. All members of this 
class share a sequence identity of at least 30% to each other14. So the findings of this study 
could be of interest for researches in this important field. After all, 10% of all currently 
approved drug targets belong to the class of ligand gated ion channels15, highlighting once 
again the pharmacological relevance of this protein class.  
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II. Biological Background 
 
 
 
Contribution of the thesis author to this review: 
The thesis author contributed to the computational section of this review (p. 2770 – 2774) 
with the aim of positioning the ligand based pharmacophore model into homology models of 
the benzodiazepine binding site of the α1β2γ2 GABAA receptor. The homology models were 
provided by M. Ernst and W. Sieghart. The molecular docking of diazepam into the homology 
models and the subsequent pose analysis was undertaken by the thesis author. Computational 
tools were programmed that aided the pose selection towards a diazepam pose that fit also the 
orientation and residue assignments of the ligand based pharmacophore model. 
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An Updated Unified Pharmacophore Model of the Benzodiazepine Binding Site on  
-Aminobutyric Acida Receptors: Correlation with Comparative Models 
T. Clayton1, J.L. Chen1, M. Ernst4, L. Richter4,5, B.A. Cromer2, C.J. Morton*,2, H. Ng2, C.C. Kaczorowski1,
F.J. Helmstetter2, R. Furtmüller4, G. Ecker5, M.W. Parker3, W. Sieghart4 and J.M. Cook*,1
1Departments of Chemistry & Biochemistry and 2Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI 53201; 3St. Vin-
cent’s Institute of Medical Research, Victoria 3065, Australia; 4Division of Biochemistry & Molecular Biology, Center for Brain Re-
search, Medical University Vienna, A-1090, Vienna, Austria; 5Department of Medicinal Chemistry, University Vienna, A-1090 Vi-
enna, Austria 
Abstract: A successful unified pharmacophore/receptor model which has guided the synthesis of subtype selective compounds is re-
viewed in light of recent developments both in ligand synthesis and structural studies of the binding site itself. The evaluation of experi-
mental data in combination with a comparative model of the ?? GABAA receptor leads to an orientation of the pharmacophore 
model within the Bz BS. Results not only are important for the rational design of selective ligands, but also for the identification and 
evaluation of possible roles which specific residues may have within the benzodiazepine binding pocket. 
Keywords: Aminobutyric acid(A) receptors, gated ion channels, GABA-A, computer-assisted analysis, benzodiazepine.
The GABAA receptor is the major inhibitory neurotransmitter 
receptor of the central nervous system (CNS) and the site of action 
of a variety of pharmacologically and clinically important drugs, 
such as benzodiazepines, barbiturates, neuroactive steroids, anes-
thetics and convulsants [1]. It is now clear that these receptors regu-
late the excitability of the brain, anxiety, muscle tone, circadian 
rhythms, sleep, vigilance, memory, and learning [1]. There are sev-
eral disease states associated with the improper functioning of this 
protein, including anxiety, epilepsy [2], insomnia [3], depression 
and bipolar disorder [4, 5], schizophrenia [6], as well as mild cogni-
tive impairment and Alzheimer's disease [7]. A role of GABAA
receptors in drug and alcohol abuse has also been reported [8-10].  
GABAA receptors are composed of 5 subunits that form a cen-
tral chloride channel and can belong to different subunit classes. A 
total of 19 subunits (??) of the GABAA
receptor have been cloned and sequenced from the mammalian 
nervous system [11, 12]. All these polypeptides possess an ap-
proximate molecular mass of ~ 50 kD and are structurally related. 
Each subunit consists of a large extracellular region, which contains 
several potential glycosylation sites and a characteristic “cys-loop” 
formed by a covalent bond between two conserved cysteines. This 
extracellular region is also important in contributing to the agonist 
GABA and modulatory benzodiazepine binding sites. The protein 
then traverses the lipid bilayer four times and has a large intracellu-
lar loop located between transmembrane regions 3 and 4 (M3 and 
M4). This intracellular region contains possible phosphorylation 
sites necessary for regulation of the receptor. The homology within 
each subunit class is about 60 – 80 %, while the homology between 
subunit classes is about 30 – 40 %. In Fig. (1) the proposed topol-
ogy of a single GABAA receptor subunit is shown. The pentameric 
structure of a ligand-gated ion channel is shown in Fig. (2) [13, 14].  
The existence of multiple GABAA receptor subunits can give 
rise to a large number of different GABAA receptor subtypes [15]. 
The majority of GABAA receptors, however, is composed of 1 and 
2? and 2? subunits. The presence of a  subunit within a GABAA
receptor is necessary for the formation of a benzodiazepine binding 
site that is located at the interface of an ? and  subunit. Whereas 
the classical benzodiazepines, such as diazepam or flunitrazepam, 
exhibit a high affinity for receptors composed of ?1?2, ?2?2, 
?3?2 or ?5?2 subunits (diazepam sensitive (DS) receptors), as 
well as for their less intensively investigated analogues containing 
the 3 subunit, other benzodiazepine binding site ligands are also  
*Address correspondence to this author at the Department of Chemistry, 3210 North 
Cramer Street, UW-Milwaukee, Chemistry Building Milwaukee, WI 53201, UW-
Milwaukee, Milwaukee, WI  53211, USA; Tel: 414-229-5856; Fax: 414-229-5530;  
E-mail: capncook@uwm.edu 
able to interact with ?4?2 or ?6?2 receptors (diazepam insensi-
tive (DI) receptors), or with receptors containing 1 subunits [1]. 
Receptors containing 1 or 3 subunits exhibit a quite low abun-
dance in the brain [16-18] and their contribution to the “in vivo”
effects of benzodiazepine binding site (BZ BS) ligands currently is 
unclear.  
Fig. (1). Proposed topology of a GABAA receptor subunit. The extracellular 
domain begins with the N-terminus and M1-M4 represent the four trans-
membrane domains. Figure reprinted with permission [13].  
The concept of receptor multiplicity has been extremely valu-
able, in that different receptor subtypes reside within anatomically 
distinct regions of the brain and are responsible for different 
physiological and pathological processes [15, 19, 20]. For example, 
the ?? receptor subtype has a prominent role in seizure suscep-
tibility and sedation [21-23], the ?2?2 and possibly also the ?3?2
subtypes are involved in anxiety, whereas the ?? subtype has a 
prominent role in memory and learning (Table 1) [15, 24-26]. 
These distinctions have thus become a motivation for the design of 
subtype selective ligands in order to elicit a single specific response 
[15, 27-34]. Differences observed in the action of such drugs may 
be due to subtype-selective affinity and absolute and/or relative 
subtype-selective efficacy [35].
Agonist binding to the receptor opens an intrinsic chloride ion 
channel, typically hyperpolarizing the cell membrane or at least 
opposing depolarization, thereby inhibiting neuronal transmission. 
Bz BS ligands are allosteric modulators, unable to induce channel 
openings themselves, but function to vary the frequency and not the 
channel opening times [37, 38]. Positive allosteric modulators at the 
benzodiazepine binding site (agonists) increase this frequency, 
- 13 -
2756    Current Medicinal Chemistry,  2007, Vol. 14, No. 26 Clayton et al. 
while negative allosteric modulators (inverse agonists) decrease the 
frequency. Currently it is not clear whether Bz BS ligands allosteri-
cally modulate GABA affinity or channel gating. Recent studies 
[39] support the view that high-affinity classical benzodiazepines 
modulate ? GABAA receptors via allosteric coupling to 
channel gating [40, 41]. Further studies are needed to determine 
whether the mechanism of modulation varies in different receptor 
subtypes.  
Table 1. Action of Benzodiazepines at GABAA ??   Receptor 
Subtypes [36] 
Subtype Associated Effect 
? Sedation, anterograde amnesia,  
Some anticonvulsant action, ataxia  
? Anxiolytic, hypnotic (EEG), some muscle relaxation 
? Some anxiolytic action, some anticonvulsant action,  
Maybe some muscle relaxation 
? Diazepam-insensitive site 
? Cognition, temporal and spatial memory  
(Maybe memory component of anxiety) 
? Diazepam-insensitive site 
In recent years a unified pharmacophore/receptor model for 
agonists, antagonists and inverse agonists at the Bz BS was devel-
oped, using the techniques of chemical synthesis, radioligand bind-
ing and receptor mapping [42, 43]. The overlap of these different 
modulators within the Bz BS has been supported by experimental 
data [44-46]. Using this ligand-based pharmacophore/receptor 
model and our ? GABAA receptor models [47, 48], the ex-
perimental data of recent and past years have been evaluated, and 
definite trends with regard to the orientation of the regions of the 
protein relative to the descriptors of the pharmacophore/receptor 
model have been identified and are presented in this work. The 
need to define such an orientation has been established [49], since it 
permits inspection of ligand docking studies and the identification 
of possible roles specific residues may have within the Bz BS. 
These roles may then be explored in future studies involving cova-
lent labeling, site-directed mutagenesis and structure-activity rela-
tionships, all of which contribute to the rational design of subtype-
specific modulators of the Bz BS of GABAA receptors. 
Fig. (3). Relative locations of the descriptors and regions of the unified 
pharmacophore/ receptor model. The pyrazolo[3,4-c] quinolin-3-one CGS-
9896 (dotted line), a diazadiindole (thin line), and diazepam (thick line) 
aligned within the unified pharmacophore/receptor model for the Bz BS. H1
and H2 represent hydrogen bond donor sites within the Bz BS while A2
represents a hydrogen bond acceptor site necessary for potent inverse ago-
nist activity in vivo. L1, L2, L3 and LDi are four lipophilic regions and S1, S2,
and S3 are regions of negative steric repulsion. LP = lone pair of electrons 
on the ligands. 
Fig. (2). Longitudinal (A) and cross-sectional (B) schematic representations of a ligand-gated ion channel. The numbers 1-4 refer to the M1-M4 segments. The 
M2 segment contributes to the majority of the pore lining within the membrane lipid bilayer. Figures reprinted with permission [14].
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THE UNIFIED PHARMACOPHORE/RECEPTOR MODEL 
More than 150 agonists, antagonists and inverse agonists at the 
Bz BS [42, 43] which encompassed 15 structural families were used 
for generating the unified pharmacophore/receptor model. Although 
the relative affinities, efficacies and functional effects displayed by 
various ligands from the same structural class at the diazepam-
sensitive and diazepam-insensitive benzodiazepine binding sites 
were taken into account, the approximate locations of descriptors 
(hydrogen bond donor sites, hydrogen bond acceptor sites, lipo-
philic regions, and regions of steric repulsion) were based primarily 
on in vitro binding affinities. Ligands from different structural 
classes were then superposed on each other to satisfy the same de-
scriptors, resulting in the unified pharmacophore model.  
Briefly, the pharmacophore/receptor model consists of two hy-
drogen bond donating descriptors (H1 and H2), one hydrogen bond 
accepting descriptor (A2) and one lipophilic descriptor (L1). In addi-
tion to these descriptors, there are lipophilic regions of interaction 
(L2, L3 and LDi) as well as regions of negative steric repulsion (S1,
S2 and S3). While occupation of L2 and/or L3 as well as interactions 
at H1, H2, and L1 are important for positive allosteric modulation, 
inverse agonists only require interactions with the H1, L1, and A2
descriptors of the pharmacophore/receptor model for potent activity 
in vivo. [42, 50-53] The LDi descriptor is a region of lipophilic inter-
action, for which the difference between the diazepam sensitive 
(DS) and the diazepam insensitive (DI) sub-pharmacophore models 
is most pronounced. Depicted in Fig. (3) are the relative locations of 
the different descriptors and regions of the model.  
The structures of ligands frequently referred to in this paper are 
shown in Fig. (4). 
The alignments of several Bz BS ligands within this model are 
shown in Fig. (5). 
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midazolam,  3
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Ro15-4513,  6
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CL-218, 872,  8
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XLi-093, 16
antagonist at ?5
Fig. (4). Structures of ligands and their modulation at the ? subtype.
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Ro 15-1788, 5 Ro 15-1788 rotated 90º 
Diazepam, 1 Diazepam rotated 90º 
DMCM, 10 DMCM rotated 90º 
zolpidem, 7 zolpidem rotated 90º 
CL-218,872, 8 CL-218, 872 rotated 90º 
Fig. (5). Alignments of several Bz BS ligands within the pharmacophore model.
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INCLUDED VOLUME ANALYSIS OF LIGANDS BINDING 
TO RECEPTORS CONTAINING DIFFERENT ALPHA 
SUBUNITS 
The benzodiazepine binding site of ??2 GABAA receptors is 
strongly influenced by the type of ? subunit present in these recep-
tors as indicated by the existence of ligands exhibiting certain selec-
tivity for receptors containing the respective ? subunits [1, 20, 54]. 
If subtype selective ligands are then aligned within the pharma-
cophore model according to the resulting alignment rules [55], their 
included volumes can be constructed and used to compare the to-
pologies of benzodiazepine binding pockets of different receptor 
subtypes [55, 56]. Ligands employed in the included volume for 
each receptor subtype exhibited potent affinity (Ki ? 20 nM) at the 
respective receptor subtype. CL-218,872 5 (Ki = 57 nM at ?) and 
zolpidem 4 (Ki = 26.7 nM at ?) were added to the included vol-
ume of the?? subtype since they are both ?-subtype selective 
ligands. The major differences with regard to volume and affinity 
are shown below and are important for interpreting experimental 
data.  
The included volume requirements show some trends that are 
useful to explain subtype preferences of ligands and that have al-
ready guided substance development: 
1. The included volumes of the ?? and ? subtypes are 
similar both in size and topology. This is consistent with the 
similar affinity profiles these subtypes displayed for classi-
cal benzodiazepine agonists, pyrazoloquinolinones and imi-
dazobenzodiazepines (i-BZDs) [57-59]. The included vol-
ume of the ?1 subtype is slightly different from that of ?2
and ?3 subtype as indicated by the selective affinities of 
zolpidem, CL-218,872, 6-substituted ?-carbolines (e.g. 6-
methylbenzyl amino betacarboline) and pyridodiindoles for 
this subtype and the space needed for accommodating these 
structures (Fig. 6a,b) [59]. Results from both the SAR stud-
ies and the included volume analysis imply that the ? and 
? subtypes are very similar in shape, polarity and lipophil-
icity.  
2. The included volumes of the ? and ?4 or ? subtypes are 
very different. Looking at Fig. (6d), it is evident that the in-
cluded volume of the ?6 subtype is significantly smaller 
Fig. (6). Overlap between pairs of included volumes derived from receptor subtype selective ligands: a) ? and ?, b) ? and ?, c) ? and ?,  d) ? and ?
e) ? and ?. Yellow color indicates overlapping regions and each grid measures 4 Å in width and height. In order to provide the connection between this 
figure and other figures, f) shows diazepam and the descriptors of the unified pharmacophore model depicted in the included volume requirement of the 
?subtype.
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than that of the ?1 subtype. Especially the LDi region is 
much larger in ?1 receptors. Contributions to the LDi region 
are derived in a large measure from 6-substituted ?-
carbolines and ring-A substituted pyrazoloquinolines, thus 
implying that occupation of the LDi region may be critical 
for ligand selectivity at the ? subtype. This is supported by 
the finding that the LDi region was also larger for the ?? subtype when compared with the ?? subtype 
(Fig. 6e).
3. L3 region is very small or non-existent for the ?  and ?
DI subtypes. Based on the inability to bind 1,4-
benzodiazepines, the lack of region L3 was believed to be 
responsible for the diazepam-insensitivity of these receptor 
subtypes (Fig. 6c, d) [42, 51]. With a few exceptions, ?-
carbolines also do not bind to the ?? receptor subtype, 
while i-BZDs and pyrazoloquinolinones (CGS series) rep-
resent the primary ligands that bind to this subtype.  
4. The L2 and LDi regions are slightly smaller for the ? ver-
sus the ? subtype. The sequence of the ? subunit is most 
homologous to the ? subunit and it was determined that 
the pharmacological profiles of these DI sites toward classi-
cal benzodiazepines are very similar [60]. Differences in the 
included volume of these DI sites are shown in Fig. (6c).  
5. The L2 region contributes to ? and ? selectivity. It has 
been observed that ligands with ? and/or ? selectivity are 
generally i-BZDs and have a lipophilic C(8)-substituent that 
occupies the L2 pocket. Based on ligands from various stud-
ies, examination of data in Fig. (6) illustrates that the L2 re-
gion is deeper and larger for the ? and ? subtypes, re-
spectively, than for the corresponding ? or ? subtypes 
[42, 43, 51, 61]. This L2 region seems to account for the se-
lective affinity of ligands at the ? subtype, as clearly illus-
trated in Fig. (6e), whereas the same region may account for 
the selective efficacy observed at the ? subtype. 
RECENT ALIGNMENT OF NON-CLASSICAL BZ BS 
LIGANDS SUPPORT THE UNIFIED PHARMA-
COPHORE/RECEPTOR MODEL 
Besides the major classes of Bz ligands used to define the 
model, several non-Bz ligands also fit within the pharma-
cophore/receptor model very well. Examples include zopiclone (17)
and its active enantiomer, the flavonoid 25 and the 8-
chloropyrazolo[5,1-c][1,2,4]-benzotriazine 5-oxide analog 38, as 
illustrated in (Figs. 7 and 8) and (Figs. 11 and 13).
Zopiclone and its Active Enantiomer 
Since the sedative-hypnotic zopiclone 17 was first reviewed in 
Drugs in 1986 [62], a much larger body of clinical data has become 
available to permit a more detailed comparison of the non-
benzodiazepine zopiclone with classical benzodiazepines. Results 
have shown that, regardless of the duration of action, zopiclone was 
Fig. (7). Structure of zopiclone 17, its alignment within the pharmacophore/receptor model and rotated 90 degrees.
Fig. (8). Alignment of zopiclone 17 (left) and its active enantiomer (right) in the included volume of the pharmacophore/receptor model for 
the ???32 subtype. 
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generally at least as effective as benzodiazepines in the treatment of 
insomnia, although comparisons between zopiclone and flurazepam 
have produced inconsistent results. It was observed that zopiclone 
had a relatively low propensity to elicit residual clinical effects, 
such as difficulty in waking or reduced morning concentration. 
While tolerance to the effects of zopiclone was not noticed in short 
term clinical trials (? 4 weeks), the results from longer term studies 
were conflicting and, therefore, the potential for tolerance during 
long term administration of zopiclone was unclear. Rebound in-
somnia to a level above that at baseline can occur after withdrawal 
of zopiclone. However, on the basis of data from short term studies, 
this does not appear to be common. Evaluation of prescriptions 
filled has indicated that zopiclone does not have a high dependence 
potential, at least in those who are not regular drug abusers/addicts. 
Zopiclone was well-tolerated in both the elderly and younger pa-
tients with insomnia. A bitter after-taste was usually the most com-
mon adverse event, but was relatively infrequent at 3.6 % in the 
largest available post-marketing study. Thus, zopiclone has now 
been firmly established as an effective and well-tolerated sleep 
agent [63].  
The structure and alignment of zopiclone within the unified 
pharmacophore/receptor model is shown in Fig. (7). The centroid of 
the pyridine moiety of zopiclone overlapped with region L1 of the 
receptor, while the lone pair of electrons of the carbonyl oxygen 
(O) atom interacted with H1 of the receptor to form a hydrogen 
bond between the ligand and the receptor. A second hydrogen bond 
was formed between the amide carbonyl oxygen atom (LP) and H2
of the receptor protein (Fig. 7).
However, a recent study by Sepracor [64] indicated that one of 
the enantiomers of zopiclone was much more active than zopiclone 
itself. This may be the result of receptor subtype-selective efficacy 
or simply a pharmacokinetic effect, but the pharmacophore/receptor 
model developed here revealed that the active enantiomer fits better 
into the included volume of the ?? subtype than zopiclone 17 
itself (Fig. 8). This enantiomer has just been approved by the FDA 
for treatment of insomnia. 
SH-053BZ Enantiomers 
In pursuing this approach using BZ enantiomers, the behavioral 
activity of three newly-synthesized compounds [65], functionally 
selective for ?2, ?3 and ?5-containing subtypes of GABAA recep-
tors (SH-053-S-CH3 and SH-053-S-CH3-2’F), or essentially selec-
tive for ?5 subtypes (SH-053-R-CH3) were examined. Motor influ-
ence was tested in the elevated plus maze, spontaneous locomotor 
activity and rotarod test, which are considered primarily predictive 
of the anxiolytic, sedative and ataxic influence of BZs, respectively. 
There was substantially diminished ataxic potential of BZ site ago-
nists devoid of ?1 subunit-mediated effects, with preserved anti-
anxiety effects at 30 mg/kg of SH-053-S-CH3 and SH-053-S-CH3-
2’F. However, all three ligands, dosed at 30 mg/kg, decreased spon-
taneous locomotor activity, suggesting that sedation may be partly 
dependent on activity mediated by ?5-containing GABAA receptors. 
Such an effect could not have been observed previously, because to 
date, all apparently non-sedating BZ receptor ligands, which are 
devoid of activity at ?1-containing GABAA receptors, engendered 
essentially antagonist [66] or only partial agonist efficacy at ?5-
containing GABAA receptors [67]. Therefore, it cannot be ruled out 
that substantial efficacy at ?5-containing GABAA receptors may 
contribute to sedative effects besides the effects on learning and 
memory processes [68, 69]. This is supported by two sets of data 
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Fig. (9). Structures and conformations of SH-053-S-CH3 (A1-A3) and SH-053-R-CH3 (B1-B3). The molecular modeling was carried out as described in 
Zhang et al. 1995 and He et al. 2000. SH-053-S-CH3 fits to the pharmacophore within the included volume of the ?2 subtype (A2); A3) is the same image 
rotated 90 degrees. It can be clearly seen that this conformer fits within the included volume. SH-053-R-CH3 fit to the pharmacophore in the included volume 
of the ?2 subtype (B2); B3) is the same image rotated 90 degrees. The R-CH3 at the prochiral center C4 changes the conformation of the molecule causing the 
pendant 6-phenyl to stick outside the included volume, consequently this ligand is not efficacious at the ?2 subtype. It simply does not interact strongly with 
?1, ?2 or ?3 subtypes.
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which indicate the possibility of substantial motor influence via ?5-
GABAA receptor modulation: In the spinal cord, somatic and 
preganglionic motoneurons (lamina IX and lateral cell column) 
exhibited a moderate to strong staining for the ?5 subunit, suggest-
ing a possible influence of receptors containing these subunits in 
motor behavior [70]. In addition, the knock-in mice harboring the 
?5 subunit insensitive to diazepam are refractory to development of 
tolerance to the sedative effect of diazepam dosed subchronically. 
Such a tolerance development might have been caused by a down-
regulation of receptors containing ?5 subunits in the appropriate 
brain regions of wild-type mice [71]. These two sets of evidence 
indicate that the motor influence of ?5-GABAA receptor modula-
tion is not necessarily an indirect consequence of the established 
effects on learning and memory processes [68, 69]. Hence, it has 
been hypothesized [65] that locomotor activity changes induced by 
ligands possessing a substantial ?5-efficacy may be, at least partly, 
contributed by modulation at GABAA receptors containing the ?5
subunit. It therefore could be of importance to avoid substantial 
agonist potentiation of ?5-subunits by candidate anxioselective 
anxiolytics, if clinical sedation is to be avoided. Nevertheless, as a 
caveat to all studies examining sedation, it should be remembered 
that a decrease in automatically measured locomotor activity can be 
due to a variety of causes other than sedation, including the occur-
rence of stereotyped behavior, motor impairments or pain [72]. To 
dissect these overlaps in activity und uncertainties, much is ex-
pected from screening of even more selective BZ site ligands in the 
future. 
Flavonoids 
Flavonoids represent a class of non-Bz ligands that fit ex-
tremely well within the unified pharmacophore/receptor model. 
These compounds are a class of natural products isolated from a 
variety of herbal plants and employed as tranquilizers in folk medi-
cine. They exhibit a wide range of biological activity, such as anti-
viral, anti-inflammatory, antithrombotic, antioxidant and estrogenic 
effects [73, 74]. Flavonoids also displayed potent anxiolytic effects 
and appeared devoid of myorelaxant, amnesic or sedative actions. 
Haberlein et al. has shown that the steric orientation of the substitu-
ents which lie coplanar to the aromatic ring was crucial for ligand 
affinity to the Bz BS [75]. This was especially true for the C(5) and 
C(6) positions. Furthermore, the recent work of Huang et al. indi-
cated that 6,3’-dinitroflavone 25 exhibited a Ki value of 12 nM at 
the Bz BS (Table 2) and was an extremely potent anxiolytic devoid 
of muscle relaxant effects. The 6-Br-3’-nitroflavone 26 also demon-
strated increased binding affinity, however, the anxiolytic effect 
was lower than the dinitroanalog 25 [76].  
Table 2. Affinities of a Series of Flavonoid Ligands for Benzodi-
azepine Receptors [76] 
O
O
R3'
R6 5
7
8
3
2
1'
4'
5'
6'
2'
Compound R6 R3’ Ki (nM) 
20 F NO2 182 
21 Cl NO2 8.0 
22 Br Cl 17.0 
23 Cl Br 23.0 
24 Br Br 19.1 
25 NO2 NO2 12.0 
26 Br NO2 1.0 
The flavonoids 21, 25 and 26 fit very well within the unified 
pharmacophore/receptor model. The alignment of 6,3’-
dinitroflavone 25 within the ?? subtype is shown in Fig. (11).
The centroid of the phenyl moiety overlapped with the L1 region 
Fig. (10). Concentration-effect curves for SH-053-S-CH3 and SH-053-R-CH3 on ?1?32, ?2?32, ?3?32, and ?5?32 GABAA receptors. Data points represent 
means  SEM from at least 4 oocytes from ? 2 batches.
Fig. (11). Alignment of 25 within the included volume of the 
?? subtype.
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and the 3’-nitro group occupied region L2, while the lone pair of 
electrons of the carbonyl oxygen (O) atom interacted with H1 to 
form a hydrogen bond between the ligand and the receptor. A sec-
ond hydrogen bond was formed between the oxygen lone pair and 
H2 of the receptor protein. This alignment essentially agrees with 
what has been discussed by Marder [77].  
Recently, some flavone-related analogs were prepared (Fig. 12)
[78] however, these flexible ligands with additional lipophilic 
groups did not bind to any GABAA receptor subtype. It is believed 
that more planar ligands are required for affinity to these subtypes, 
as the twist chair of the dihydropyran unit may have prevented the 
fit required for high affinity at the Bz BS. Together these data, 
combined with the work of others, indicate the phenyl ring, the 
carbonyl group and the double bond between C(2) and C(3) of the 
flavone are the key structural features that contribute to the binding 
affinity of flavonoids to the Bz BS.  
O
O
O
O
RR
R = H, Et, COCH3 or acetylene
Fig. (12). A series of flavone-related analogs that was inactive at 
the Bz BS. 
Analogs of 8-chloropyrazolo[5,1-c][1,2,4]-benzotriazine 5-oxide 
It has been recognized that small structural modifications in the 
same chemical family could lead to ligands which display different 
intrinsic activity. Costanzo et al. reported that small structural 
modifications in analogs of 8-chloropyrazolo[5,1-c][1,2,4]-
benzotriazine 5-oxide produced ligands that displayed different 
intrinsic activity (Table 3) [79]. When an aryl ester function occu-
pied position-3, this class of ligands exhibited high affinity at the 
Bz BS (Table 3, Ki = 11 – 35 nM). It was proposed the methoxy 
group of ligand 38, which bound with an affinity of 1.0 nM, acted 
as an electron donor group to enhance the ? stacking interactions 
between the phenyl ring of this ligand and the receptor protein. 
However, it may also be that the methoxy group enhanced lipo-
philic interactions within the L1 region. Costanzo et al. proposed 
that net inductive and resonance effects as well as the electron do-
nating properties ( = - 0.27) and suitable lipophilic features (- )
of the ligand facilitated this interaction.  
Alignment of 38 overlaid with diazepam is shown in Fig. (13),
wherein the N(1) and N(4) functions hydrogen bonded to the H2
and H1 donor receptor sites, respectively. It was felt that the 3-ester 
function fits into a limited dimension lipophilic pocket in the L1/ L2
region. Moreover, the orientation of the lone pair of electrons of the 
carbonyl oxygen atom of the ester function reinforced the receptor 
binding by means of a 3-centered hydrogen bond (N(4)/ CO/ H1). 
This hydrogen bond, which is similar to that described for the C(3) 
ester substituent in -carbolines, is also strengthened by the interac-
tion between the 5-oxide group and the nitrogen atom with H1.
Fig. (13). Alignment of ligand 38 (black) overlayed with diazepam (cyan) 
within the unified pharmacophore/ receptor model and rotated 90 degrees.  
Dimer Affinity for the Binding Site 
Some studies which involved monomeric i-BZDs indicated that 
there might be a limit on the size of 3’-imidazo substituents the 
receptor may accommodate [53]; However, studies that involved 
bivalent ligands suggested otherwise (Table 4) [80, 81]. It is thus 
possible that the spacer for i-BZDs dimers threaded the second 
portion of the bivalent ligand through and/or around the LDi/A2
region that presented steric hindrance for the monomers. 
Design of the bivalent ligand XLi-093 16 was based on the 
modeling of the ??selective monomer RY-80 52 in the ? phar-
macophore model. The ability of this ligand to bind (Table 4) and 
Table 3. Affinities of a Series of 8-Chloropyrazolo[5,1-c][1,2,4] 
benzotriazine 5-oxide Ligands at the Bz BS of GABAA
Receptors [79] 
N
N
N
N
CO2RCl
O
Ligand R Ki (nM) 
27 Ph 47.5  
28 4-F-Ph 146.0  
29 2-F-Ph 14.0  
30 4-Cl-Ph 49.2  
31 2-Cl-Ph 14.4  
32 4-Me-Ph 51.9  
33  2-Me-Ph 38.3  
34 4-NO2-Ph 41.8  
35 2-NO2-Ph 106.0  
36 4-MeO-Ph 11.6  
37 3-MeO-Ph 41.1  
38 2-MeO-Ph 1.0  
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Table 4. Structures and Affinities at the ?x?  Subtype [53]. NR = not reported; ANT = antagonist; IA = inverse agonist; ND = not determined 
yet. Activity is Defined for Receptor Subtype Listed in Bold 
N
N
N
CO2R
MeO
F NH
N
R CO2t-Bu
(R = H )
(R = TMS )
Ro15-1788, 5 (R = Et)
?-CCT,   13  (R = H)
WY-S-8, 39
WY-B-14, 40
NH
N
t-BuO2C
HN
N
CO2t-Bu
WY-S-2, 41
NH
N
t-BuO2C
HN
N
CO2t-Bu
WY-S-6, 42
N
N
N
H O
O
O
N
N
N
HO
O
O
MeMe
XLi-093, 16
N
H
N
H
N
N
bis(7)-THA, 43
N
N
N
H
O
O
N
N
N
H
O
O
O O
MeMe
XLi-210, 44
N
N
N
H
O
O
N
N
N
H
O
O
O
Ph Ph
DMH-III-96, 45
Ki (nM)
Ligand ? ? ? ? ? ? Activity
5, Ro15-1788 0.8 0.9 1.05 NR 0.6 148 ANT
13, ?-CCT 0.72 15 18.9 NR 110.8 5000 IA
39, WY-S-8 0.97 111 102 NR 208 1980 ND
40, WY-B-14 6.8 30 36 2000 108 1000 ND
41, WY-S-2 30 124 100 300 300 4000 ND
42, WY-S-6 120 1059 3942 NR 5000 5000 ND
16, XLi-093 1000 1000 858 1550 15 2000 ANT 
43, bis(7)-THA NR NR NR NR NR NR ANT 
44, XLi-210 231 661 2666 NR 5.4 54.2 ND
45, DMH-III-96 460 5000 NR NR 5000 5000 ND
- 22 -
Correlation with Comparative Models Current Medicinal Chemistry,  2007 Vol. 14, No. 26      2765
fit well within the pharmacophore (Fig. 14) requires the 3-carbon 
linker to be in a linear (versus folded) conformation. This linear 
conformation of XLi-093 has been confirmed both in the solid 
phase and in solution (Fig. 14) [82]. The J values calculated from 
the dihedral angles (J = 5.38) were in excellent agreement with 
those determined from the solution NMR spectrum (J = 6.39). Be-
cause this bivalent ligand is the most ?-selective ligand reported, 
the enriched selectivity of this dimer and those similar to it, was 
presumably entropic in nature, as the loss of affinity at the other 
subtypes was profound [81, 82].  
It has been shown via crystallographic and solution NMR stud-
ies that modification of the aliphatic spacer to a –CH2OCH2– or a -
(CH2)2O(CH2)2– group, provided the bivalent ligand with a folded 
conformation (Fig. 15) [82]. Modeling of this type of ligand (e.g.
DMH-III-96 45, Fig. 16) within the ? pharmacophore model illus-
trated the inability of bivalent ligands in the folded conformation to 
bind presumably because they are too hindered to access the Bz BS. 
Current data displaying these trends is shown in Table 5, while 
further studies are underway to evaluate the length the lipophilic 
spacers may contribute toward the selectivity of both the benzodi-
azepine and ?-carboline bivalent ligands (e.g. XLi-210 44 and WY-
S-6 42).
Success of XLi-093 and earlier in vitro data on WY-S-8 39 and
WY-B-14 40 (Table 4) indicated the C(6)-substituent of ?-
carbolines lies in the LDi region of the pharmacophore model or in 
the extracellular domain of Bz BS. For this reason, the ?-CCT di-
mer, WY-S-2 41 was designed and synthesized. Although the ?
subtype selectivity was not amplified with this particular ?-
carboline dimer, the ligand does bind. It was proposed that the two-
carbon linker was not long enough and that crowding between the 
second ?-CCT unit and the receptor protein decreased the binding 
affinity at ? subtype, thereby negating potential selectivity [80]. 
Further evaluation of the ?-CCT bivalent ligand with a bis-
acetylene linker (WY-S-6 42, Fig. 17) should shed light on this 
hypothesis. 
Similar to XLi-093, the dimer bis-(7)-THA 43 of Wang et al.
was determined to be a competitive antagonist at the Bz BS in both 
electrophysiological experiments and receptor binding assays (Ta-
ble 4) [73]. Although additional experimental data is needed, in-
spection of the alignment of XLi-093 (Fig. 14) and our receptor 
model (see below) indicated the aliphatic linker of these bivalent 
ligands would thread the second half of the dimer through the 
LDi/A2 regions and toward the solvent accessible space outside of 
the pocket.  
Beta-Carbolines 
The crystal structures and molecular mechanics simulations of 
several ?-carbolines has recently been reported [83]. In general, 
Fig. (14). Alignments of XLi-093 16 (white) and Ro15-1788 5 (cyan) within the included volume of the ?? subtype.
Fig. (15). Crystal structures of the linear XLi-093 16 (left) and the folded DMH-III-96 45 (right). Figures reprinted with permission [81, 82].
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substitution at C(3) and C(6) had the greatest effect on affinity. 
Consistent with the interaction with the H1 descriptor, high affinity 
ligands were always associated with groups able to interact as hy-
drogen bond acceptors at C(3). Furthermore, affinity was much 
lower for constrained ?-carbolines which contained the carbonyl 
group in the anti conformation, in agreement with the proposed 3-
centered hydrogen bond [42, 50, 52, 61] afforded by many ?-
carbolines in the stable syn conformation with the H1 descriptor. 
Table 5. The Molecular Composition and Stable Conformation of Various Bz BS Bivalent Ligands. ND = not determined yet 
N
N
N
O
O
O
A
Ligand Monounit 1 Monounit 2 Spacer Conformation in solution Crystal structure 
16, XLi-093 A A (CH2)3 linear  linear 
44, XLi -210 A A (CH2)5 linear ND 
46, XLi -347 A A (CH2)2O(CH2)2 folded ND 
47, XLi-374 A A  CH2OCH2 folded ND 
45, DMH-III-96 - - (CH2)2O(CH2)2 folded  folded 
Fig. (16). Alignment of a DMH-III-96 45 within the included volume of the ?? subtype. It is apparent that the folded conformation prevented it from 
binding to this GABAA subtype.  
Fig. (17). Alignment of WY-S-2 41 (left) and WY-S-6 42 (right) within the included volume of the ?? subtype.
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As previously stated, the C(6)-substituent of ?-carbolines lies in 
the LDi region of the unified pharmacophore/ receptor model for 
inverse agonists and antagonists. However, based on the CoMFA 
studies of Huang et al. [78] ?-carboline agonists have been pro-
posed to take on a vertical alignment with respect to the horizontal 
alignment of inverse agonists and antagonists. While only four ?-
carbolines have been reported to display agonistic activity, each of 
these compounds had a 4-methylmethoxy group that permitted 
interaction with the H2 descriptor and partial interaction with the 
region near the entrance to the L3 pocket (Table 6). It was postu-
lated that 6-PBC 12 should display agonistic activity, and indeed, 
since partial occupation of a lipophilic region near the C(6)-
substituent is probable (relative to ZK-93423 11), 6-PBC is a partial 
agonist [42, 84]. However, it is likely that the type of activity dis-
played by 6-PBC may be receptor subtype-dependent, because 
when evaluated in vivo, it inhibited PTZ-induced seizures in a dose-
dependent fashion and exhibited anxiolytic activity when evaluated 
in the elevated plus-maze paradigm. Yet, unlike typical 1,4-
benzodiazepines, 6-PBC 12 was devoid of muscle relaxant activity 
and even antagonized the muscle relaxant/ataxic activity of diaze-
pam [85, 86]. Further studies are needed to fully address this issue.  
LIGANDS THAT OCCUPY THE L2 REGION AND ARE SE-
LECTIVE FOR ?5 CONTAINING RECEPTORS  
RY-24 and Related Analogs 
Continued interest in the development of ? selective ligands 
goes forward in the CNS area for many reasons. One of these in-
volves the localization of these receptors and their presumed impor-
tance in developmental biology. Over 30 % of GABAA receptors in 
neonatal rat pups are comprised of ?? subtypes, whereas they 
only comprise about 5 % in adult rats [87]. In addition, these ?
subtypes are primarily found in the hippocampus [88], which 
prompted interest in memory and learning [25]. From the evalua-
tion of Ki values, it was found that many 8-substituted i-BZDs, such 
as RY-24 50 and RY-80 52 and their trimethylsilyl precursors 51
and 53 (Table 7), exhibited a significant degree of binding selectiv-
ity at the ? subtype in vitro. This observation was in agreement 
with the previous hypothesis that correct occupation of the L2 re-
gion can promote ? selectivity of a ligand [29, 51]. Therefore, the 
efficacy of the ?-subtype selective ligand RY-24 50 was evaluated 
in vitro. Recently, it was determined that this ligand was a potent 
inverse agonist at the ? subtype with a much weaker efficacy at 
the other subtypes (Fig. 18). These results confirmed previous bind-
ing data, which indicated that this ligand was ?-selective due to 
the lipophilic C(8)-substituent which fully occupied the L2 pocket 
[28, 29]. The data were also in agreement with previous studies in 
vivo, which indicated that some of these ligands enhanced cognition 
while other Bz BS ligands were not as effective [25, 89]. Further-
more, ligands devoid of a lipophilic substituent at the C(8) position 
showed no selectivity for the ? subtype (Table 7).  
Inspection of Table 7 revealed some observations worth noting. 
While the lipophilic substituent at R8 of RY-24 50 and RY-80 52
decreased the affinity for ?, ? and ?, it retained affinity for ?
and actually increased affinity for the ? subtype. Furthermore, 
selective affinity of i-BZDs at the ? subtype was independent of 
the occupation of the L3 pocket, as illustrated by the in vitro data of 
DM-I-81 55 (Table 7). This data again supports the importance of 
the occupation of the lipophilic pocket L2 for potent selectivity at ? subtype.  
June et al. recently reported the neurobehavioral results of RY-
23 and RY-24 in rats. In agreement with previous studies [28], 
these ? selective ligands were highly selective in suppressing 
ethanol-maintained responding (Fig. 19) [91]. As previously stated, 
the hippocampus contains the greatest concentration of ?-
containing receptors in the CNS [88, 92], and it is possible that 
these hippocampal ? receptors may regulate alcohol-motivated 
responding following systemic administration of an ?-selective 
agent. Furthermore, RY-24 also antagonized the motor-impairing 
and sedative effects of ethanol in Long-Evans rats. Combined with 
additional studies within the ventral pallidum (VP), it has been 
proposed that the GABAergic systems within the VP and hippo-
campal pathways may represent new extensions of the mesolimbic 
ethanol reward circuitry. Although these data do not strongly sup-
port a direct role for the modulatory influences of intrinsic efficacy 
in the behaviors examined, the synthesis of ? subtype selective 
ligands provides researchers a unique opportunity to explore the 
role of this subtype in the neurobehavioral effects of alcohol [28, 
93].
In studies involving the ? subtype, ?-CCT 13 and 3-PBC 14
were observed to selectively reduce alcohol-motivated behaviors 
for a variety of experiments [94, 95]. However, unlike the ? selec-
tive inverse agonist RY-23, both the ?-carboline antagonists ?-CCT 
and 3-PBC displayed mixed agonist-antagonist profiles in vivo in 
alcohol P and HAD rats. Therefore, in addition to being able to 
study the molecular basis of alcohol reinforcement, ? Bz BS 
ligands which display mixed agonist-antagonist pharmacology in 
alcohol P and HAD rats may be capable of reducing alcohol intake 
while eliminating or greatly reducing the anxiety associated with 
habitual alcohol, abstinence or detoxification. Thus, these types of 
ligands may be ideal clinical agents for the treatment of alcohol-
dependent individuals [94, 95].  
Additional behavioral studies of RY-24 were performed by 
Helmstetter et al. and provided further support for the role of the 
Table 6. Structures and Affinities at ?x? Recombinant Receptors and Modulation by ? -Carbolines. pAg = partial agonist; Ag = agonist [84] 
N
H
N
R4 R3R6
R5
 Ki (nM)  
Ligand R6 R5 R4 R3 ? ? ? ? ? ? Activity 
12, 6-PBC On-Pr H MOM CO2Et 0.49 1.21 2.2 NR 2.39 1343 pAg 
11, ZK-93423 OCH2Ph H MOM CO2Et 4.1 4.2 6 NR 4.5 1000 Ag 
48, ZK-91296 H OCH2Ph MOM CO2Et NR NR NR NR NR NR pAg 
49, Abecarnil OCH2Ph H MOM CO2-i-Pr 12.4 15.3 7.5 NR 6 1000 pAg 
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Table 7. Structures and Affinities of Some ??-Subtype Selective Ligands 
N
N
N
R8
O Me
CO2R3
N
N
N
R8
O
O
56
N
N
N
CO2Et
DM-I-81, 55
Ki (nM) 
Ligand R8 R3 ? ? ? ? ?
50, RY-24  H t-Bu 26.9 26.3 18.7 0.4 5.1 
51, RY-23  TMS t-Bu 197 143 255 2.61 58.6 
52, RY-80  H Et 28.4 21.4 25.8 0.49 28.8 
53, RY-79  TMS Et 121 142 198 5.0 114 
54 H  Et 1.2 2.0 1.1 0.4 > 300 
55, DM-I-81 Ph NA > 2000 > 2000 > 2000 176 > 2000 
56, PWZ-02990 Cl NA >300 >300 >300 38.8 >300 
Fig. (18). Subtype efficacy of RY-24 50. Dose response curves for RY-24 in oocytes expressing different subunit combinations of GABAA receptors. Subtype 
combinations are indicated in legends. cRNA–injected Xenopus oocytes were held at –60 mV under two-electrode voltage clamp. Increasing concentrations of 
RY-24 were superfused together with a GABA concentration eliciting ~ 20% of the maximal current amplitude. RY-24 was pre-applied for 30 sec before the 
addition of GABA, which was co-applied with the drugs until a peak response was observed. Data were normalized for each curve assuming 100% for the 
response in the absence of RY-24. RY-24 was made up and diluted as stock solution in DMSO. Final DMSO concentrations perfusing the oocyte were 0.1%. 
Values are presented as mean ± SD of at least 4 oocytes from at least 2 batches.
hippocampus in anxiety and learning [25]. Moreover, the data sug-
gested that Bz BSs within the hippocampus are important for the 
acquisition of fear conditioning. Although this subtype selective 
ligand has been shown to be an inverse agonist at the ? subtype 
[29, 96], this study suggested that RY-24 may act as an agonist at 
other alpha subtypes because larger doses of RY-24 were not as 
anxiogenic as the smaller doses and resulted in decreased learning. 
Consistent with the studies of Stephens et al. using ? knock-out 
mice [97] and the efficacy studies of Lüddens, June and Cook et al.
[98] these findings support the concept that the pharmacology ob-
served depends upon the dose, behavioral paradigm employed and 
subunit composition activated. Ligands such as RY-24 have proven 
to be valuable in the study of the biochemical and pharmacological 
properties of GABAA receptors and have permitted insight into the 
role this protein plays in anxiety and learning. 
QH-ii-066 
Due to the pharmacological profile RY-24 exhibited in vivo, the 
development of additional ? subtype selective ligands was pur-
sued. Thus, the 7-acetyleno analog of diazepam, QH-ii-066 57, was 
synthesized and was determined to also exhibit a binding and func-
tional selectivity at the ? subtype over the? subtype (Table 8)
[27]. This was due to the full occupation of the L2 pocket, relative 
to diazepam (Fig. 20). To our knowledge, this was the first agonist 
ligand to display some ? selectivity from the 1,4-benzodiazepine 
- 26 -
Correlation with Comparative Models Current Medicinal Chemistry,  2007 Vol. 14, No. 26      2769
family. Importantly, the 7-cyano congener 58 (Table 8) did not 
potently bind to recombinant receptors of the ?5 subtype, which is 
in agreement with earlier work of Haefely and Fryer et al. on the 
SAR of 1,4-benzodiazepines [99, 100]. This cyano ligand also did 
not exhibit any subtype selectivity, re-emphasizing that occupation 
of the L2 region with lipophilic groups is important for ?5 selectiv-
ity as well as for high affinity. The selective efficacy of this QH-ii-
066 ligand over the ?1 subtype was demonstrated by reversing the 
convulsant actions of RY-24 50, an ?5-selective inverse agonist, in 
NIH mice [87]. This ability was not observed at comparable doses 
for the ?1-selective agonist zolpidem 7.
Fig. (20). Comparison of non-selective diazepam (black) with the ?5-
selective QH-ii-066 (cyan) when aligned within the unified pharmacophore/ 
receptor model. The acetylene group of QH-ii-066 increased the occupation 
of the L2 region relative to that of diazepam.  
Furthermore, Lelas and Cook et al. have recently determined 
that although QH-ii-066 had similar affinity for the DS subtypes in 
rats, it displayed functional selectivity in vivo, with diazepam-like 
efficacy at the ?5 subtype and partial efficacy at the ?1 subtype 
[27]. The study also indicated that this 7-acetyleno substituted di-
azepam analog exhibited less potency in protection against ECS-
induced seizures relative to diazepam than against PTZ-induced 
seizures. Hence, the ?1 subtype may play a more prominent role in 
ECS-induced seizures than in PTZ-induced seizures [27].  
COMPARATIVE MODEL OF THE BENZODIAZEPINE 
BINDING SITE 
Crystallization of GABAA receptors thus far has not been ac-
complished, but the successful structure determination of the water-
soluble acetylcholine binding protein (AChBP) [101] has generated 
much interest in the GABAA receptor community. Although this 
protein shares only ~ 18 % sequence homology with the extracellu-
lar domain of the GABAA receptor [101], the structural resem-
blance has been estimated to be relatively high (60 – 75 %) [48]. 
Several comparative modeling studies have used the AChBP struc-
ture to derive models of the extracellular domain of GABAA recep-
tors [47, 48]. Following the cryo-EM determination of the extracel-
lular and transmembrane domain structure of the nACh receptors, 
these structures also were used as templates for modeling GABAA
receptors [102]. Sequence homology is so low however, that de-
tailed features of the models are highly uncertain, and the proposed 
dockings of Bz BS ligands [103-105] have a qualitative character 
and do not sufficiently explain the observed differential effects of 
Fig. (19). Suppression of alcohol-motivated responding by RY-24 50 and RY-23 51 [93, 96]. Left: Dose-response of IP RY-24 (0.0–3.5 mg/ kg) and vehicle 
on responding maintained by ethanol (10 % v/v) (top panel) and water (bottom panel) in male Long-Evans rats. Right: Dose-response of unilateral infusions of 
RY-23 (0.0-40 g) in the hippocampus on a concurrent fixed-ratio (FR4) schedule for ethanol (10 % v/v) (top panel) and saccharin-maintained (0.025 % v/v) 
(bottom panel). For both studies, *p ? 0.05 versus control condition values was determined using ANOVA and post hoc Newman-Keuls test. Each bar repre-
sents the mean (± SEM) (n = 15 for RY-24 and n = 7 for RY-23). Figures reprinted with permission of the authors [93, 96].
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ligands interacting with different receptor subtypes. The experimen-
tal structure of the nAChR [106] has provided first data on how 
much the fold can vary between members of a family [106]. From 
this data the extent to which GABAA receptor subunits differ from 
each other in structure can be qualitatively extrapolated, but not 
predicted in detail.  
As mentioned before, the majority of GABAA receptors are 
composed of , 2?and subunits. Each subunit has per conven-
tion a “plus” and a “minus” side (Fig. 21). The subunit interfaces 
consequently consist of the plus and minus sides of neighboring 
subunits. The modulatory Bz BS is located at the ?? subunit inter-
face and is larger than, but homologous to the two agonist (GABA) 
binding sites, which are located at the ?? subunit interfaces [49, 
107, 108]. The absolute subunit configuration for the ?
GABAA receptor appears to be ??, when viewed counter 
clockwise (from + to - , Fig. 21) [48, 109-111].  
Fig. (21). Absolute subunit arrangement of the ? GABAA receptor 
when viewed from the synaptic cleft. The GABA binding sites are located at 
the ?? subunit interfaces and the modulatory Bz binding site is located at 
the ?? subunit interface. The part of the schematically drawn subunits 
marked by the + indicates loop C of the respective subunits.  
While the 2 subunit is required for recognition and binding of 
benzodiazepines as well as many other substance classes that act 
via the Bz BS [112, 113], it is now clear that sequence variations 
between different ? and  subunits determine subtype selectivity 
and efficacy of Bz BS ligands [20, 112-114]. The Bz BS has been 
proposed to consist of three segments provided by the ? side, the 
so-called “loops A, B and C” and by three segments of the ? , the 
so-called “loops D, E and F” [112, 113]. These segments were 
then confirmed by X-ray crystallographic and EM-structures of 
AChBP [101] and the nAChR [106] to form a groove-like pocket at 
the interface boundary between subunits that appears to be con-
served in the entire superfamily.  
Even later than the nAChR structure, a series of AChBP crystal 
structures with co-crystallized ligands appeared [115]. These struc-
tures revealed how ligand binding can alter the local conformation 
of the binding site. Particularly loop C has been found to be a 
highly mobile subdomain, additional more subtle changes are seen 
along the entire subunit boundary [115]. These findings are consis-
tent with the hypothesis that many receptor conformations exist, 
that are separated by low energy barriers, and can be stabilized by 
different ligands. Unfortunately it cannot be decided a priori which 
of the experimental structures is the “best” template to model a 
particular receptor/ligand complex. Depending on template and 
alignment choice, model Bz pockets differ in total volume by as 
much as 40% and can vary by several Angstrom in the distances 
between key residues in the binding site loops.  
Although changes in protein conformation may be minor, it has 
been demonstrated that they can profoundly affect the efficacy of 
Bz BS ligands [116]. Furthermore, efficacy can vary for the same 
ligand at different GABAA receptor subtypes [27, 31, 35]. As pro-
teins are inherently dynamic and able to sample many conforma-
tions, and the stabilization of the active state relative to the inactive 
state has been calculated to be less than 1 kcal/mol [117], it is im-
possible to provide absolute assignments of specific side chains to 
specific descriptors for any particular conformation. This conforma-
tional flexibility may imply that residues which satisfy certain 
pharmacophoric descriptors can vary, resulting in a “soft” orienta-
tion of the pharmacophore in the receptor. Thus, a unified view of a 
pharmacophore model and a homology derived receptor model will 
assign large areas of lipophilic interaction to specific regions in the 
protein, but allow a flexible assignment of specific interactions such 
as H-bridges or ?- ? stacking.  
RELATIVE ORIENTATION OF THE PHARMACOPHORE 
WITHIN THE COMPARATIVE MODEL  
Prior to structure determination of the AChBP, we published a 
review which evaluated results of site-directed mutagenesis and 
provided insights as to where certain side chains in the Bz BS might 
be located relative to the pharmacophoric descriptors [118]. How-
ever, with the knowledge gained from recent experimental data and 
with the aid of our GABAA receptor models, built by homology to 
lymnea AChBP [47], aplysia AChBP and the nAChR [102] an up-
date of the orientation is provided here. We now propose an orien-
tation which is favored by experimental evidence, allows some 
degree of conformational flexibility which can lead to variable as-
Table 8. Structures and Affinities of 1,4-Benzodiazepines 
N
N
Me
O
R7
Ki (nM) 
Ligand R7 ? ? ? ? ?
1, diazepam Cl 14 20 15 11 > 3000 
57, QH-ii-066 H 76.3 42.1 47.4 6.8 > 3000 
58 C N 320 310 350 265 > 3000 
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signments for H-bridge interactions, but is based on specific areas 
of lipophilic interactions that are determined by binding site geome-
try. 
Evidence from Covalently Reactive Ligands Allows to Position 
the L2 Lipophilic Pocket 
Covalent labeling studies contributed significantly to the deter-
mination of residues that are located within the Bz BS [104, 119-
124].  
Table 9. Ligands Used for Affinity Labeling Studies [104, 121-124] 
N
N
N
C
S
Me O
N
N
N O
O
O
N
S
59 60
7-isothiocyano-1,4-benzodiazepine
Ligand Activity Site of Interaction 
2, [3H]flunitrazepam Agonist ?H102 
6, [3H]Ro15-4513 inverse agonist ?Y210 
59
60
Agonist 
part. Agonist 
?H101C (rat) 
?H101C, ?G157C 
?V202, ?V211C (rat) 
Photoincorporation studies with the agonist [3H]flunitrazepam 
identified ?H102 of the human sequence as the primary site of 
incorporation [123]. Although it is possible that flunitrazepam is 
coupling via the nitro group at the 7-position, the coupling group of 
flunitrazepam is currently not known. Studies with the inverse ago-
nist [3H]Ro15-4513 indicated ?Y210 as the primary site of incor-
poration [104]. Thus, the azido group at the 7-position of Ro15-
4513 should be in close apposition to?1Y210, assuming no rear-
rangement of the photo-activated intermediate. Further information 
comes from recent studies reporting the covalent coupling of 7-
isothiocyano- derivatives of a 1,4-benzodiazepine, (substance 59
[122]) and of Ro15-1788 (substance 60 [124]) to GABAA receptors 
in which individual amino acid residues had been mutated to cys-
teines. Primary site of reaction of both substances is the rat 
?1H101C mutant that is homologous to ?1H102 of the human 
subunit. Thus, the 7-substituent both of 1,4-benzodiazepines and of 
imidazodiazepines appears to be in apposition to ?H102. The 
imidazobenzodiazepine 60 reacts with additional cysteines in posi-
tions corresponding in the human sequence to positions ?1V203C 
and ?1V212C in the loop C stem, and with ?1G158C in loop B (see 
alignment in Fig. 22). Thus, the 7-substituent of this compound, in 
agreement with the data from photolabeling H102 with flunitraze-
pam and Y210 with Ro15-4513, is in apposition to loop A, the loop 
C base, and additionally loop B.  
Thus, all the findings from covalently incorporated ligands 
given above can be reconciled by placing the 7-substituent, and thus 
the L2 descriptor of the unified pharmacophore model, between the 
loop C base near ?1V203/?1V212/?1Y210 and loop A ?1H102. The 
homology models reveal that this is not only topologically possible, 
but also provides the additional apposition to loop B that is sug-
gested by the reaction of 60 with rat ?1G157C. Thus, the L2 lipo-
philic pocket is most likely formed by the base of loop C, together 
with parts of loop A.  
THE A2 DESCRIPTOR AND THE LDI REGION 
Experimental data yields some very convincing evidence for as-
signing the A2 descriptor and the LDI region of lipophilic interac-
tion next to A2 to protein segments close to residues ?A79 and 
?T81 at loop D. Certain imidazobenzodiazepines, which occupy 
the pharmacophore volume close to A2 (see Fig. 5), are more sensi-
tive to ? A79 mutations than classical benzodiazepines or benzodi-
azepines that lack a 3'-imidazo substituent. This was shown in a 
study where mutations of ?A79 and ?T81 had little effect on the 
binding of the agonists diazepam and flunitrazepam, but in a 
roughly size dependent fashion decreased the affinities of antago-
nist Ro15-1788 and inverse agonists Ro15-4513 [125, 126]. In 
agreement with other studies, midazolam, which lacks a 3’ substitu-
ent, behaved more closely to classical benzodiazepines than i-BZDs 
[44, 125, 127,128]. This trend is enhanced by rigid and bulky 3'-
imidazo substituents, altogether suggesting that ?A79 and ?T81
are located close to the region of the Bz BS surrounding the 3' sub-
stituent of i-BZDs [125]. The localization of the 3'-imidazo sub-
stituents in the unified pharmacophore model, see Fig. (5), thus 
positions the A2 and LDI descriptors near residues ?A79 and 
Fig. (22). Alignment and homology model depiction of the so called “loops A-F” and flanking regions of the human sequences of the Bz recognition site in 
different subunits. The homology model is as seen from “outside” of the channel mouth, the membrane would be parallel to the lower edge of the image. Key 
residues are shown in stick representation: Loop A His102, loop B Tyr 160 and loop D Phe77.
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?T81. Further support for this localization comes from the obser-
vation that DMCM also looses affinity upon mutagenesis in posi-
tions ?A79 and ?T81, [125, 126] consistent with the alignment of 
this substance in the pharmacophore. Fig. (5) shows that changes to 
the protein near the A2 descriptor would in all likelihood not be 
tolerated by DMCM.  
COMBINING HOMOLOGY MODEL AND EXPERIMEN-
TAL EVIDENCE  
If the two assignments discussed above are correct, they should 
be reflected in results of computational ligand docking to homology 
models of the binding site. Thus, computational docking of diaze-
pam and flumazenil was performed in multiple different models 
based on different templates [101, 106, 115] and the best 100 dock-
ing poses per model were collected in a database. A database query 
was then formulated to search among the (unrefined) docking poses 
for those with the following properties: The seven membered ring 
of diazepam or flumazenil is in the conformation that is assumed to 
be the active one; [99] the 7-substituents are near residues 
?H102/?V203/ and ?Y210/?V212 in order to be consistent 
with the covalent labeling data; the 3’ ester group of flumazenil is 
near residues ?A79 and ?T81. Such a query yields docking poses 
that are consistent with all covalent labeling studies on one hand, 
and with the steric requirements that were found for 3’ substituted 
imidazobenzodiazepines [125] on the other hand. Such poses were 
indeed present in our database, and one representative diazepam 
pose is shown in Fig. (23): To be consistent with the presentation of 
the pharmacophore and its descriptors so far, the orientation of the 
benzodiazepine binding pocket had to be turned upside down and 
slightly tilted. 
This and similar docking poses not only satisfy the two assign-
ments for L2 and A2 that are discussed in the sections above, but at 
the same time position the remaining descriptors as follows: H1 can 
be satisfied by appropriate side chains near the tip of loop C, the 
LDI region is near the subunit interface, essentially between ? loop 
B (Y160) and the ?  region spanned by the interface forming sheet 
involving M130, T142 and F77; A2 can be satisfied by H-bridge 
Fig. (23). The main figure shows a diazepam docking pose in an ?1?2 pocket matching the orientation proposed in the text. Diazepam is rendered space fill-
ing, (turquoise: carbon, white: hydrogen, green: halogen, red: oxygen, blue: nitrogen), the protein as ribbon, and key amino acids in stick representation. The 
insert figure shows the empty pocket in the “upright” position to facilitate orientation in the main figure, where the model has been turned and tilted to bring 
diazepam approximately into the orientation depicted in the unified pharmacophore model, Fig. (3). In this particular docking pose, His102 and Thr206 could 
satisfy H2 and H1, respectively, and His 102, Val 212 and Tyr 210 would be part of the L2 hydrophobic pocket. This positions 7-substituted reactive ana-
logues such as compound 59 into a position where the reactive groups find free access to His102, Tyr 210, Val 212, Val 203. It should be noted that due to
high uncertainties in model backbone position and side chain rotamers, high accuracy docking that correctly reflects all ligand-protein interactions is not feasi-
ble, this image is one representative of a big cluster of similar docking poses.
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accepting sites near ?Y160, A79, ?M130 and T142. 
If these proximity relations that are found in the docking poses are 
transferred to the unified pharmacophore model, the following pic-
ture emerges:  
Within the different poses that exhibit this orientation, there is 
still some degree of variation in structural details. There are several 
sources for this variability in the computationally derived struc-
tures: template and alignment choice, model construction and re-
finement, as well as docking algorithms contribute to the variability 
of the poses that are found.  
This orientation is also strongly supported by the observation 
that XLi-093, as aligned in Fig. (14) with the docked diazepam 
shown above, will be able to thread the portion of the molecule not 
inside the included volume towards the solvent accessible space 
through the subunit boundary.  
Fig. (24). Location of important Bz BS residues relative to the pharmacophoric descriptors in two views that correspond to a 90 rotation about L1, with A2 in 
front, as determined by evaluation of experimental data and the comparative model of the ? GABAA receptor. The ligand shown is diazepam. Since 
inverse agonists stabilize protein conformations that vary from the conformations preferred by agonists, it seems plausible that more than one side chain could 
satisfy the same descriptor.
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Agreement between this orientation of the pharmacophore 
model inside the structural model of the protein with single ligand 
dockings that have been proposed in the past [103-105] will have to 
be examined in detail. The overall picture appears to be pointing 
towards a satisfactory orientation of the pharmacophore model in 
the pocket, and for those instances where there could be a discrep-
ancy, further experiments will clarify.  
Refinement of the predicted protein-ligand complexes with the 
aid of the unified pharmacophore model appears to be a very prom-
ising approach to arrive at 3D structures that are of sufficient accu-
racy to be used for structure guided drug design. Studies that com-
bine advanced protein modeling techniques with the classical 
pharmacophore approach are currently underway.  
CONCLUSION 
A unified pharmacophore model incorporating many substance 
classes that act at the DS and DI benzodiazepine binding sites of 
GABAA receptors has been updated to include new substance 
classes. Compound development guided by this pharmacophore 
model has led to new agents with interesting pharmacological pro-
files, particularly enhanced preference for ? or ? containing 
GABAA receptor subtype. Based on the evaluation of experimental 
data and comparative models of the ?? GABAA receptor, the 
location of several residues relative to the descriptors of the phar-
macophore/receptor model has been proposed. Although no abso-
lute assignments were made regarding which amino acids satisfy 
the pharmacophoric descriptors, experimental data strongly indi-
cated definite trends with regard to how ligands of varying pharma-
cological activity are oriented within the receptor. Because the uni-
fied pharmacophore/receptor model accounts for the binding and 
activity profiles at the six GABAA receptor subtypes containing any 
one of the different alpha subunits, the proposed orientation should 
also be similar within the different models [110] of the various 
receptor subtypes. Information to be immediately gained from this 
proposed orientation can have far reaching benefits, not only for the 
rational design of selective ligands and the interpretation of ligand 
docking results, but also for the identification and evaluation of 
possible roles certain residues may have within the pocket. As 
structure determination of the GABAA receptor is eagerly awaited, 
it is hoped that this proposed orientation may be used by others to 
gain additional insight into the potential mechanisms underlying 
binding and modulation at the Bz site, all of which will lead to a 
better understanding of the structure and function of GABAA recep-
tors. 
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III. Computational Background 
1     Homology Modeling 
 
Introduction 
In the field of drug discovery, we aim to comprehend the three-dimensional structure of a 
protein binding site as it uncovers the proteins’ interaction properties in molecular detail. 
These detailed structural insights provide the basis for the rational design of future drugs. 
Experimental procedures like X-ray and NMR spectroscopy lead to the structural resolution 
of about 31000 non-homologous (<=95% sequence identity) protein structures until April 
2012 (Ref1). However, this number sounds small in comparison to the approximately 
15000000 protein sequences which are deposited in the UniProt knowledge database2. 
Based on this abundance of sequence information and on the general observation that proteins 
with similar sequence have similar structures the methodology of homology modeling 
evolved. Homology modeling generates three dimensional models of a protein necessitating 
only its amino-acid sequence3. In this process the target amino-acid sequence is first 
compared against sequences of known structures. If a similar sequence of a known structure 
(template) could have been found, the protein backbone of this template works as a structural 
frame for the target sequence. 
In the field of drug discovery, homology modeling for membrane proteins is of special 
interest because of two facts. First, membrane proteins account for around 60% of todays' 
approved drug targets4. And second, the structural resolution of membrane proteins is 
difficult, especially for human membrane proteins. Of the about 31000 resolved non-
homologous proteins in the RCSB PDB1, only around 2000 are membrane proteins (GO5 
ID:16020) and  approximately 500 are humane membrane proteins. 
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1.1     Homology modeling workflow 
In general the homology modeling procedure can be divided into four steps as described in the 
following6 (Fig. 1):  
 (i)  Identification of evolutionarily related proteins with experimentally determined structures 
(ii)  Sequence alignment between target and template sequence         
(iii) building the three dimensional model based on the alignment of template structure                          
(iv) validation/refinement/evaluation of the models 
 
Figure  1 – The four main steps of comparative protein structure modeling: template 
selection, target-template alignment, model building and model quality evaluation. Figure 
adapted from Ref6. 
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1.2     Homology modeling accuracy 
As the name already implies, models are, by definition, an abstraction and thus contain errors. 
It has been shown that there is a clear correlation between target-template sequence identity 
and homology model accuracy7. 
Table 1 - Correlation between target-template sequence identity and homology model 
accuracy. Data and Table from Ref7. 
 sequence 
identity 
 root mean square 
error for main-chain  
 frequent type of errors 
high-accuracy 
homology models 
> 50%  1Å  side-chain packing 
medium-accuracy 
homology models 
30 - 50 %  1.5Å 
(~90% of main-chain 
atoms) 
 frequently side-chain 
packing errors, 
mainchain distortions 
low-accuracy 
homology models 
< 30%  >1.5Å  alignment error, 
sidechain packing 
errors, mainchain 
distortions 
 
In the field of drug discovery, the following rule for homology model accuracy emerged: 
Models built with over 50% sequence identities are good enough for drug discovery purposes 
(elucidation of binding mode, hit discovery). In case the sequence identities are between 30 
and 50%, derived models can be used for estimation of target drugability, and for the design 
of mutagenesis experiments. Finally, models that are built with a sequence identity between 
15 and 30% are only suitable for the assignment of protein function and for compilation of 
mutagenesis experiments8. 
But next to the sequence identity also other features have to be considered in the estimation of 
model accuracy. For example in GPCRs, low sequence identity within the family is partly 
compensated by the common heptahelical transmembrane domain. This also holds true for the 
extracellular domain of Cys-loop pentameric ligand gated ion channels9 (LGIC). 
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2     Molecular Docking  
 
Introduction 
In the past decades the number of structurally determined protein structures has increased 
from one structure in 1972 to approximately 75 000 protein structures in 2012 (Ref1). This 
trend clearly promotes the application of computational methods that can exploit knowledge 
from structurally determined protein binding sites in hit identification and lead optimization10.  
 
Such a methodology, docking of small molecules into protein binding sites was introduced in 
1980 with the introduction of DOCK11. In principle, molecular docking aims to predict the 
binding mode and the affinity of the docked molecules against a target protein. The whole 
docking process can be subdivided into two steps, 1) posing and 2) scoring12. In the first step, 
the posing step, the program samples the ligands' translational, rotational and conformational 
degrees of freedom within the binding site. This results in a multitude of computationally 
generated "ligand-receptor complexes", called poses. Then, in the second step, the scoring 
step, the poses are evaluated by a "scoring function" which applies algorithms that 
approximate the underlying enthalpic and entropic contributions to binding free energy. 
Finally, the poses are ranked according to their scoring values, assuming the best ranked pose 
to be correct and its scoring value representing the ligands' binding affinity. 
 
Nowadays dozens of docking software are available (Fig. 2). They mainly differ in either 
their posing algorithms or in their evaluative scoring functions. The next paragraphs should 
give a structured overview about the most important algorithms and functions applied in 
docking. 
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 Figure 2 - Chart presentation for the most common docking software based on number of 
citations taken from ISI Web of Science (2005). Figure and data taken from Ref13. 
 
2.1     Posing  
As already mentioned, posing algorithms aim to sample the ligands' translational (Tx, Ty, Tz), 
rotational (Rx, Ry, Rz) and conformational (N) degrees of freedom within the constraints of 
the binding site. During this sampling process a coarse and fast evaluation function omits 
poses that show severe protein clashes.  
In general three groups of search methods are used for the sampling purpose and thus are 
implemented in docking software12: 
• Systematic search methods    2.1.1 
• Stochastic/ random search methods  2.1.2 
• Simulation methods     2.1.3 
These three methods are described in more detail in the following paragraphs. 
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2.1.1 Systematic search 
Systematic search algorithms aim to systematically sample all degrees of freedom during 
docking (Fig. 3). In dependence of the desired sampling resolution, sampling parameters like 
torsion angle increment (∆α = 10°, 30°, ... for sigma bonds) can be adjusted for ligand 
flexibility. As for larger molecules (high number of rotatable bonds) one will inevitably face 
the problem of combinatorial explosion14, certain adaptations have been developed. Here the 
most prominent approach is the incremental ligand growth within the active site. In this 
procedure the ligand is first separated into rigid (core fragment) and flexible parts (side 
chains). Once the rigid cores are docked, the flexible parts are incrementally added15,16. 
Incremental growth algorithms are implemented in popular software packages such as 
DOCK11, FlexX15, Glide17 and Hammerhead18.  
Next to incremental growth another popular method is the use of libraries of pre-generated 
ligand conformations. Here, the ligands' internal degrees of freedom are sampled once and 
then stored as a conformational library. In the subsequent step each conformation is then 
rigidly translated and rotated within the pocket.  
Figure 3 - Visual scheme for the systematic search approach. Here represented for ligand 
conformation sampling. In the scheme, the x-axis represents possible ligand conformations 
while the y-axis resemble the conformations' corresponding energy level. The aim of the 
search algorithms is the seek for the global minimum conformation. In the systematic 
algorithms the torsional angles of the ligand are systematically rotated by a pre-defined 
raster (∆α = 10°, 30°, ...) aiming to find one conformation near to the global energetic 
minimum. 
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2.1.2 Random search 
In total contrast to the systematic search algorithms, the stochastic search methods aim to 
discover the global minimum configuration of an intermolecular complex by randomly 
sampling the ligands' degrees of freedom within a binding site (Fig. 4). Monte Carlo19 and 
genetic algorithms20 are here the most popular among the random search methods. The 
advantageous progress of tabu search21 is that it takes into consideration already sampled 
degrees of freedom. Stochastic search algorithms are often combined with energy 
minimization algorithms that optimize the intermolecular complex towards the next 
minimum.  The very prominent docking programs, AutoDock22 and GOLD23 use stochastic 
algorithms as search algorithms. The genetic algorithm in GOLD represents a pose as a 
chromosome consisting of a set of genes. The genes correspond to the ligands' translational, 
rotational and conformational degrees of freedom and are altered randomly. In the very 
beginning the starting population is created by randomly generating thousands of 
chromosomes (poses). During the docking procedure a fitness function then represses 
improper genes during evolution. 
 
Figure 4 - Visual scheme of a stochastic search. The x-axis resemble the pose space while 
the y-axis correspond to the energy level. Stochastic search algorithms aim to detect the 
global minimum by implementation of random algorithms. Variations of rotational, 
translational and conformational states are introduced in a random manner. The generated 
poses are then frequently taken as starting point for energy minimization tools that optimize 
the intermolecular complex to the nearest minimum. 
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2.1.3 Simulation methods 
The most popular method among the simulation methods is molecular dynamics. The 
thorough sampling of the ligands' degrees of freedom is the key advantage of these 
algorithms. On the other hand the drawback of molecular dynamics simulations is that they 
often fail to rise above high-energy barriers24. So if the starting configuration is chosen 
unfavorably (as shown in Fig. 5), one ends up only in local minima of the energy surface. One 
approach to address this drawback is to start molecular dynamics calculations from different 
ligand positions.  
Another simulation method, energy minimization, is hardly used alone as a search algorithm 
due to its limitation to reach only the nearest local minima. But it is often combined with 
other search methods to optimize the geometry of an intermolecular complex. DOCK for 
example conducts a minimization after each fragment addition. Glide, DOCK and AutoDock 
all use simulation methods as a complementary tool in posing. 
 
Figure 5 - Visual scheme of a molecular simulation run. Molecular simulation methods 
enable a high-resolution sampling but lack to overcome high-energy barriers. The starting 
orientation plays a critical role in the simulation output. If the starting orientation is trapped by 
a high-energy barrier (conf. 2) the molecule cannot reach the targeted global minimum. In 
another constellation (conf. 1) it is capable. One can circumvent this problem by taking 
multiple starting orientations, but will have to accept an increase of computational resources 
needed. 
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2.1.4 Protein flexibility 
The importance of protein flexibility during ligand binding is demonstrated by the structural 
changes of holo and apo X-ray structures and between holo structures harboring different 
ligands. The mutual adaption of ligand and receptor is termed "induced fit" phenomenon. The 
necessity for sampling protein flexibility is even more important in case no experimental 
structure is available and thus ambiguous homology models are used in the docking 
procedure.  
However, considering protein flexibility also opens a new order of complexity for posing 
algorithms, as the proteins' degrees of freedom have to be additionally sampled. The search 
algorithms for protein flexibility are less advanced than those designed for ligand flexibility. 
Nonetheless one has to notify that great advances have been made in the recent years.  
Several methods have emerged that should account for protein flexibility in the docking 
process. In general, they can be grouped into four categories25 (a) soft docking, (b) rotamer 
exploration, (c) molecular relaxation and (d) docking into multiple protein structures. 
(a) Soft docking 
The earliest and simplest attempt to account for protein flexibility was rigid receptor docking 
with a softened scoring function. Softened scoring functions tolerate some clash between 
ligand and receptor atoms thus resembling some receptor plasticity26,27. The big advantage of 
soft docking is its computationally economy (only some parameters have to be lowered). But 
on the other hand soft docking can only consider small conformational changes from the 
receptor side.  
(b) Rotamer exploration 
In these methods, side-chain flexibility of the receptor is sampled during the docking 
procedure while keeping the backbone fixed. One easy implementation was pioneered by 
Leach et al.28 using a rotamer library resembling discrete site-chain flexibility. Newer more 
sophisticated algorithms like those implemented in the software package GOLD23, offer in 
addition  to rotamer libraries also continuous side-chain flexibility during docking. However, 
only ten amino acids at maximum can be treated flexible during docking with GOLD. 
Interestingly, also some minor variations in the backbone can be sampled within GOLD by 
enabling the "improper" option for a flexibilized amino acid. Next to these, further 
methodologies emerged29. 
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(c) Molecular relaxation 
This procedure can be divided into two steps. In the first step the ligand is docked into a rigid 
receptor using a softened potential. In the subsequent second step a relaxation of the binding 
site backbone and side-chain atoms is conducted. The relaxation or minimization is performed 
by Molecular Dynamics or other methods30. 
In comparison to rotamer exploration or soft docking, the molecular relaxation method is 
computationally more expensive because next to side-chain conformational changes also 
backbone flexibility has to be taken into account. 
One prominent docking tool that uses this molecular relaxation algorithm is "Induced-Fit 
Docking" within the Schrödinger Suite31. Here in a sophisticated manner GLIDE docking and 
minimization protocols are combined to thoroughly sample protein space and induced fit 
phenomena.  
(d) Docking into multiple protein structures 
The most frequent method for taking protein flexibility into account is to dock into an 
ensemble of conformationally different protein structures. Knetgel et al.32 was one of the 
pioneers in this field by constructing an averaged energy grid derived from experimentally-
determined protein structures using a weighting scheme. Claussen et al.33 implemented a fast 
and economic search algorithm that calculates protein flexibility based on an internal analysis 
of input structures. These input structures can consist of a set of molecular dynamics 
snapshots or are a series of holo X-ray structures. The detected variability between the input 
structures is then considered in the docking procedure in a combinatorial manner. 
As the additional degrees of freedom also enhance the chance to generate false positives, the 
knowledge of the user is decisive. Only those parts of the protein should be kept flexible that 
are justifiable. 
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2.2     Scoring 
The output of the posing process is a list of possible ligand orientations within the binding 
site, which is also referred to as pose list. In order to discriminate between artificially 
generated and the correct ligand orientation, scoring functions for pose evaluation are applied.  
These scoring functions are algorithmic approximations of the underlying biophysical and 
biochemical events that contribute to the free energy release which occurs upon ligand 
binding. While enthalpic contributions like H-bonding, van der Waals interactions, charge-
charge interactions, etc. can be modeled quite fast and accurate, entropic contributions like 
solvation and reduced conformational flexibility in the bound-state, still remain inaccurate 
and/or time-consuming.  
However, the scoring function is used to rank the pose list, assuming the best scored pose to 
be correct. Ideally, this pose represents the bioactive ligand orientation and its scoring value 
correlate with the ligands' affinity. 
In total, three different classes of scoring functions are implemented in todays' docking 
programs12: 
• Force-field based scoring functions    2.2.1 
• Empirical scoring functions     2.2.2 
• Knowledge-based scoring functions   2.2.3 
and will be described in more detail in the following: 
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2.2.1 Force-field-based-scoring 
In principal force-field-based scoring functions can be viewed as the sum of two energies, the 
1) ligand-receptor interaction energy (nonbonded energy) and the 2) internal ligand energy 
(bonded energy). The calculation of the ligand-receptor interactions, again can be subdivided 
into two terms, the van der Waals term represented by a Lennard-Jones potential and the 
electrostatic term represented by a Coulombic formulation. On the other hand, internal ligand 
energy sums up strain resulting from bond stretching/ bending/ torsional distortions. The 
force-field parameters for energy calculation derive from AMBER34  (AutoDock35), 
CHARMM36, or other packages  For the representation of Hydrogen-bonding different terms 
have evolved within different programs.   
Initially the force-field parameter sets were determined to model enthalpic gas-phase 
contributions  and thus do not inherently consider solvation and entropic effects. The most 
sophisticated method to account for solvents is to treat water molecules explicitly as 
implemented in Free Energy Perturbation (FEP) and Thermodynamic Integration (TI)37. 
However, these functions are computationally very expensive and would make virtual 
screening of large libraries nearly impossible. Thus methods like generalized-Born/surface 
area (GB/SA) models37 and the Poisson-Boltzmann/surface (PB/SA) models38 that have 
implicit solvent models, are normally preferred. Next to these, even faster methods exist that 
try to cover the entropic effects by the addition of a simple torsional entropy term as 
implemented in G-Score39.  
Well-known force-field-based scoring functions are: GOLD, AutoDock, DOCK, G-Score. 
 
2.2.2 Empirical scoring functions 
Empirical scoring functions are based on experimentally determined ligand binding energies 
and their structural X-ray information. These scoring functions are represented as a sum of 
parameterized functions as exemplified in the FlexX scoring function15 (Fig. 6). Each 
individual function covers a certain type of free energy contribution, such as an entropic term, 
an H-bond term, an ionic interaction term, a hydrophobic term and an aromatic interaction 
term. The coefficients for the individual functions derive from regression analysis using a 
database of experimentally determined binding energies in connection with the corresponding 
structural complexes. 
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 Figure 6 - Structure of the FlexX Scoring 
function as a sum of parameterized 
functions. Each function accounts for a 
certain type of binding free energy 
contribution. The parameters (∆R, ∆α) derive 
from regression analysis of experimental 
data sets. 
 
 
 
 
 
 
In the representation of hydrogen bonds a great diversity of algorithms exists among empirical 
scoring functions. For example, in LUDI40, two hydrogen bonds (a neutral hydrogen bond and 
an ionic hydrogen bond) are distinguished, whereas ChemScore41 does not have this 
differentiation. In a similar manner the calculation of hydrophobic terms is manifold. In 
LUDI, hydrophobic contributions are calculated on basis of the molecular surface area, 
whereas ChemScore considers distances between hydrophobic atom pairs. 
One disadvantage of empirical scoring functions is their great variability in their coefficients 
depending on which dataset of experimentally binding energies was used to parameterize the 
scoring function. 
Terms for entropy and desolvation have been introduced into several empirical scoring 
functions like ChemScore and FlexX Score. However,  these terms can only approximate this 
complex part  in protein-ligand binding. 
Well-known empirical scoring functions are: GlideScore17, PLP42, X-Score43, ChemScore41 
and LUDI40. 
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2.2.3 Knowledge-based scoring functions 
As opposed to the other scoring functions, knowledge-based scoring functions are developed 
to primarily reproduce experimentally determined ligand-receptor complexes rather than 
binding energies. The basis for knowledge-based scoring functions is described by the inverse 
Boltzmann relation (Fig.7).  
 
Figure 7 - Inverse Boltzmann relation, where kB is the Boltzmann constant, T stands for the 
absolute temperature, ρ(r) is the pair density between protein-ligand atoms at a distance of r 
in the training set, and ρ*(r) is the density of protein-ligand atom pairs in a reference state 
with no interatomic interactions. 
In analogy to empirical scoring functions, also knowledge-based scoring functions extract 
their parameters  from experimental structures. They use the interatomic distances in the 
ligand-recptor complexes and transform them into distance-dependent interaction free 
energies. 
In principle, the scoring value is the sum of pairs of ligand atom – receptor atom interactions 
which makes the calculation very fast- This is one of the big advantages of knowledge-based 
scoring functions and predispose them for virtual screening issues.  
Prominent representatives of these scoring functions are: POTENTIAL OF MEAN FORCE 
(PMF)44 and DrugScore45. 
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2.3     Molecular Docking Performance 
 
Pharmaceutical companies have a deep interest in an objective and thorough performance 
check for applications in drug discovery. This fact made the survey of Warren et al.46 
especially interesting as it was driven by GlaxoSmithKline Pharmaceuticals to rigorously 
evaluate molecular docking performance from a unbiased position. In their survey they 
evaluated the performance of not less than 10 widely used docking programs across seven 
different target types. More interestingly the ligand set for each target consisted of a large 
number of experimentally determined affinities with closely related structures (Table 2), 
mimicking corporate compound libraries.  
 
For this reason the findings of Warren et al. constitute the core in the next paragraphs that 
describe the docking performance in the light of three tasks in structure-based drug discovery 
• binding mode prediction 2.3.1 
• virtual screening  2.3.2 
• potency prediction  2.3.3 
 
In the study of Warren et al. for each of the 8 targets the corresponding ligand set was docked 
with the following docking pograms: Dock411, DockIt47, FlexX15, Glide17, GOLD23, Flo, Fred, 
LigFit, MOEdock and MVP. See Table 2 for the composition of the data set. 
 
Table 2 – Protein and ligand data set details used in the survey of Warren et al.46. 
protein No. of 
ligands 
No. of ligand 
classes 
No. of 
cocrystals 
Max affinity 
(nM) 
Min affinity 
(nM) 
Chk1 193 2 15 7 >10000 
factorXa 218 4 10 <1 5000 
Gyrase B 138 3 7 4 >10000 
HCV 
polymerase 
205 2 13 5.6 >10000 
Met tRNA 
synthetase 
144 2 31 1 >10000 
E. coli PDF 199 3 2 1 >10000 
Strep PDF 186 3 4 <2 >10000 
PPARd 206 5 54 0.3 >10000 
 
Finally the molecular docking performance against homology models will be reviewed 
(2.3.4). Here the focus was set on two studies: The study of Kairys et al.48 which was mainly 
concerned with the capability of molecular docking software packages to reproduce the 
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experimentally determined binding mode (2.3.4.a), and the study of Fan et al.49 that analyzed 
the virtual screening performance of docking into homology models (2.3.4.b). 
 
2.3.1 Binding Mode Prediction 
First, the capability of docking programs to reproduce the crystallographically determined 
ligand-receptor complex will be described. The test set for this evaluation contains 136 
ligands (representing 21 compound classes) for which cocrystals exist (Table 2). Ten docking 
programs were used to redock these ligands into its native X-ray structure and the similarity 
between the docking poses and the experimentally determined ligand bound orientations was 
assessed by calculating the Root-Means-Square-Deviation (RMSD) of the ligands' heavy 
atoms. Poses with a RMSD <= 2Å to the crystallographic orientation were considered as 
good. And poses with a RMSD <= 4Å are considered as fairly good, roughly representing the 
correct global orientation. Each docking program produced multiple docking poses for each of 
the 136 ligands and rmsd values for all generated poses were calculated. The performance of 
the 10 docking programs against the 8 targets is summarized in Figure 8.  
 
Figure 8 - Representation of docking performance in binding mode prediction from the study 
of Warren et al.46. Plot of docking poses with rmsd value of <= 4Å generated with all ten 
docking programs, against the 21 compound classes used in the binding mode prediction 
survey. Only for three compound classes no pose was generated that had a rmsd of <= 2Å to 
the crystal structure. Figure taken from Ref46. 
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The results of this study showed that in general docking programs are capable of correctly 
predicting the experimentally determined binding mode, but with the important limitation that 
scoring functions were less successful at identifying the pose which was closest to the crystal 
structure from the pose list. Finally it was stated that among the ten docking programs tested 
not a single one performed well against all protein targets. 
 
2.3.2 Virtual Screening 
In the field of drug discovery the virtual screening performance of molecular docking is of 
special interest. It evaluates the crucial ability of this methodology to select active 
chemotypes out of a pool of decoy molecules.  
For this purpose all ligand sets (Table 2), compromising 1303 ligands, were docked into its 
corresponding target keeping only the best scored pose for each ligand. The resulting eight 
docking libraries are then ranked according to their scoring value, resulting in eight score-
sorted libraries. For each of the libraries the enrichment factor for the top 10% of the score-
sorted library were calculated. This procedure was undertaken with all ten docking programs 
and the results are presented in Table 3. 
Table 3 – Enrichment Factor for actives (<= 1µM) found at 10% of the score-sorted library 
found in the study of Warren et al.46. 
program 
 
Chk1 FXa gyrase 
B 
HCVP MRS E. coli 
PDF 
Strep 
PDF 
PPARδ 
ideal 10.0 9.8 10.0 9.5 10.0 7.6 8.3 8.6 
Dock4 1.4 4.1 1.7 1.8 4.2 0.9 0.8 1.7 
DockIt 4.2 2.0 2.0 1.0 1.0 0.2 0.0 3.2 
FlexX 7.0 2.2 5.8 0.9 3.9 0.8 0.8 5.2 
Flo+ 5.6 2.7 2.3 3.4 1.7 1.5 0.8 3.6 
Fred 2.9 4.1 1.9 2.0 0.6 3.2 1.2 1.1 
Glide 6.3 3.4 1.0 1.0 5.3 0.6 0.4 4.8 
Gold 0.1 4.1 4.0 0.0 0.8 1.0 0.1 5.5 
LigandFit 3.3 1.9 2.8 1.8 2.9 2.9 1.7 1.2 
MOEDock 3.9 0.6 0.0 0.0 1.0 2.1 0.6 0.0 
MVP 7.2 5.8 5.3 3.6 6.4 6.7 6.9 3.9 
 
In essence the study of Warren et al. showed that virtual screening was capable in enriching 
actives out of a population of decoy molecules. But it has to be noted that the performance 
across diverse targets was inhomogeneous. 
Another important study in this field was undertaken by Huang et al.50 presenting for the first 
time the directory of useful decoys (DUD). The DUD is actually developed to test docking 
algorithms by providing challenging decoys together with a broad target set. In total it 
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contains 2950 known active ligands for 40 structurally determined targets. And for each 
active ligand, 36 “decoys” with dissimilar structural topology but similar physicochemical 
properties (e.g. number of H-bond donors, number of H-bond acceptors, molecular weight, 
calculated logP, …) were selected summing up to 95316 decoy compounds (Table 4). 
Ligands and decoys are then docked into their corresponding target using DOCK11 and 
enrichment factors for actives were calculated for the top 1% and top 20% of the score-sorted 
library, respectively (Table 4). The average enrichment for the top 1% and top 20% across all 
40 proteins was 17.3 and 2.6, respectively. 
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Table 4 - DUD benchmark set consisting of 40 targets, 2950 unique ligands and 95316 
decoys, described in Huang et al.50. Each set was docked into its corresponding target 
and EF1% and EF20% for actives was calculated.  
protein PDB-code resolution (A) no ligands no decoys EF 1% EF20% 
AR 1xq2 1.9 74 2630 33.5 3.8 
ERagonist 1l2i 1.9 67 2361 19.2 4.5 
ERantagonist 3ert 1.9 39 1399 12.7 1.3 
GR 1m2z 2.5 78 2804 8.9 1.4 
MR 2aa2 1.9 15 535 46.2 3.7 
PPARg 1fm9 2.1 81 2910 0 0 
PR 1sr7 1.9 27 967 0 2 
RXRa 1mvc 1.9 20 708 24.8 2.2 
CDK2 1ckp 2.1 50 1780 13.9 1.4 
EGFr 1m17 2.6 416 14914 2.1 2.4 
FGFr1 1agw 2.4 118 4216 0 0.2 
HSP90 1uy6 1.9 24 861 8.6 2 
P38 MAP 1kv2 2.8 234 8399 2.1 2.4 
PDGFrb model n/a 157 5625 0 0.6 
SRC 2src 1.5 162 5801 1.2 1.5 
TK 1kim 2.1 22 785 54 5 
VEGFr2 1vr2 2.4 74 2647 1.3 1.4 
FXa 1f0r 2.7 142 5102 14.6 3.8 
thrombin 1ba8 1.8 65 2294 13.7 2.9 
trypsin 1bju 1.8 43 1545 22.5 2.6 
ACE 1o86 2 49 1728 40.4 3.7 
ADA 1stw 2 23 822 12.9 2.4 
COMT 1h1d 2 12 430 0 3.3 
PDE5 1xp0 1.8 51 1810 11.8 2.3 
DHFR 3dfr 1.7 201 7150 21.7 3.5 
GART 1c2t 2.1 21 753 42.4 3.3 
AChE 1eve 2.5 105 3732 1.9 2 
ALR2 1ah3 2.3 26 920 38.1 2.3 
AmpC 1xgj 2 21 734 17.1 4.7 
COX-1 1p4g 2.1 25 850 4 1.6 
COX-2 1cx2 3 349 12491 20.1 3.3 
GPB 1a8i 1.8 52 1851 22.8 4.1 
HIVPR 1hpx 2 53 1888 3.7 2.2 
HIVRT 1rt1 2.6 40 1439 5 3 
HMGR 1hw8 2.1 35 1242 33.9 2.1 
InhA 1p44 2.7 85 3043 0 0.3 
NA 1a4g 2.2 49 1745 20.2 3.3 
PARP 1efy 2.2 33 1178 6 3.6 
PNP 1b8o 1.5 25 884 31.7 4.4 
SAHH 1a7a 2.8 33 1159 78 5 
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An overviewof successfully experimentally validated hits derived from docking-based virtual 
screening is presented in Kolb et al.51 for the time range 2007 to mid-2009 (see Table 5). 
These results are in line with the good screening performance reported in the survey of 
Warren et al.46 and Huang et al.50.    
 
 
 
 
 
 
 
 
Table 5 - Docking predictions subsequently confirmed by experiments: 2007 to mid-2009. 
Data and table taken from Ref51 
Target Docking program Lead inhibitor IC50 (μm) 
AdoMetDC Glide 12 
AHAS DOCK 4/AutoDock 15.2 
Aldose reductase N/A 0.53 
CDC25 phosphatase FRED/Surflex/LigandFit 13 
DNA gyrase DOCK 5 50 
EphB4 DAIM-SEED-FFLD 1.5 
FFAR Glide 3.6 
Histamine H4 FlexX 95.8 
Human pregnane X Surflex 0.049 
MCH-R1 ICM 7.5 
Pim-1 kinase Glide 0.091 
PNP GOLD 18.9 
PPAR-γ Glide/IFD 2.9 
Tm0936 DOCK 3.5 105 m−1 S−1 (Kcat/Km) 
TRH-R1/TRH-R2 FlexX 0.29 
β2-Adrenergic receptor DOCK 3.5.54 0.009 
β-Lactamase DOCK 3.5.54 140 
SHP2 DOCK 100 
Al-2 quorum sensing DOCK 5 35 
Anthrax edema factor HINT/AutoDock 1.7 
hPRMT1 GOLD 12 
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2.3.3 Affinity Prediction Tool 
Scoring functions try to estimate the free energy of binding and thus the assigned scoring 
values for docking poses should correlate with the ligands’ affinity.  
Warren et al. showed for their dataset (Table 2) that there was no strong correlation found for 
any scoring function-protein target pair. Table 6 presents the  correlation coefficients between 
compound affinity and docking score.  
Table 6 – Best Correlation Coefficient r between –log Affinity and Docking Score for all 
Programs across All Targets in the study of Warren et al.46. 
program Chk1 FXa gyrase 
B 
HCVP MRS E. coli PDF Strep 
PDF 
PPARδ 
Dock4 -0.33 -0.31 -0.39 0.00 -0.13 -0.38 -0.34 0.07 
DockIt -0.49 -0.19 -0.37 0.04 -0.28 -0.13 -0.30 -0.34 
FlexX -0.57 -0.31 -0.39 -0.12 -0.01 -0.42 -0.25 -0.36 
Flo+ -0.44 -0.38 -0.36 -0.09 0.05 -0.27 -0.39 -0.42 
Fred -0.14 0.01 -0.13 -0.07 0.13 0.07 -0.24 0.06 
Glide -0.47 -0.08 -0.21 -0.04 0.08 -0.13 -0.12 -0.35 
Gold -0.42 -0.05 -0.14 -0.09 0.04 -0.12 -0.11 -0.43 
LigandFit -0.45 -0.13 -0.39 -0.06 -0.15 -0.21 -0.49 -0.10 
MOEDock -0.29 0.00 0.07 -0.01 -0.13 0.08 0.20 0.17 
MVP -0.26 0.10 -0.33 -0.01 -0.18 -0.17 -0.16 -0.18 
 
2.3.4 Docking into Homology Models 
(a) Binding mode prediction 
Kairys et al.48 analyzed the capability of molecular docking into homology models in binding 
mode prediction. For this purpose, homology models for four experimentally determined 
protein structures (carboxypeptidase A, factor Xa, CDK2 and AChE) were generated, 
whereby the target-to-template sequence identity ranged from 30.9 to 66.6. These models 
were then used for molecular docking and the resulting poses were then compared to the 
experimentally observed ligand orientation, using RMSD as a similarity measure. 
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 Figure 9 – Representation of the findings of Kairys et al.48 in examining the performance of 
molecular docking into homology models in binding mode prediction. For the four 
experimentally determined ligand-target complexes (carboxypeptidase A, factor Xa, CDK2 
and AChE), a total of 16 homology models was created. These models were based on 16 
templates (Table 7) listed on the left hand side of the Figure. Bars show the percentage of 
ligand-target complexes with available crystal structures for which top scoring pose has a 
RMSD < 2Å (black) and < 4Å (black + gray). Figure edited from Ref48. 
 
Table 7 - Templates and associated template-to-target sequence identity for proteins 
analyzed in Kairys et al.48. 
target template sequence identity 
carboxypeptidase A Procarboxypeptidase A 30.9 
 Carboxypeptidase T 31.8 
 Procarboxypeptidase A2 66.6 
factor Xa Protein C 34.9 
 Factor VIIa 38.8 
 Thrombin 40.7 
 Factor Xa 100 
CDK2 c-Abl 28.6 
 PKA 31.2 
 ERK2 37.0 
 CDK6 48.2 
AChE para-nitrobenzyl esterase 31.4 
 Cholesterol Esterase 32.8 
 Triacylglycerol Lipase 32.8 
 Carboxylesterase 1 36.2 
 BuChE 53.3 
 
These findings clearly demonstrate that molecular docking into homology models is capable 
to regenerate the experimentally observed ligand-protein complex for proteins with a 
sequence identity greater than 30%. 
- 55 -
 (b) Virtual screening 
The first exhaustive virtual screening performance comparison between experimentally 
determined structures and homology models thereof was assessed by Fan et al.49. They used 
the widely applied docking benchmark set of the “directory of useful decoys” (DUD) for 
performance evaluation50.  
In the study of Fan et al. 38 of the 40 subsets described in DUD were used to compare the 
virtual screening performance using homology models or crystal structures. For each of the 38 
targets, template structures were selected (1-12 per target) with varying sequence identity 
(ranging from 20% to 99%), resulting in a total set of 222 templates and 222 homology 
models (5 models per target on average). Finally DUD ligands and decoys (38 of the 40 
subsets in Table 4) were docked with DOCK against the 38 X-ray structures and against the 
222 homology models. Subsequently, enrichment factors expressed as logAUC were 
calculated and the results were compared (Table 8). 
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Table 8 - Ligand enrichments found in Fan et al. for molecular docking into homology 
models and X-ray structures. Table taken from Fan et al.49. 
protein target 
most enriching model        best model by SI consensus 
enrichment 
holo X-ray 
enrichment SI enrichment SI enrichment 
ACE 44.1 50.2 54.8 37.9 48.9 40.6 
ADA 26.5 40.3 84.8 38.8 41.1 22.7 
COMT 20.1 0 20.1 0 0.0 27.6 
PDE5 30.4 22.1 95.5 20.5 18.6 12.1 
DHFR 27.9 34.6 37.3 13.1 20.3 18.9 
GART 40.4 27.5 41.5 0.6 27.4 35.3 
FXa 30.4 52.1 63.8 27.2 49.6 41.8 
thrombin 30 43.4 39.5 36.9 42.4 29.4 
Trypsin 78.8 38 78.8 38 32.3 29.3 
AChE 38 35.7 92.7 17.3 29.1 38.5 
ALR2 68.7 41.9 86.6 39.5 37.1 39.7 
AmpC 76.6 46.6 76.6 37.2 40.3 47.4 
COX-1 63.4 26.2 63.4 26.2 25.3 28.3 
COX-2 64.4 13.3 64.7 8.2 12.4 40.8 
GPB 41.8 8.9 80.7 6.5 6.8 17.1 
HIVPR 49 30.5 96.9 4.8 23.7 11.9 
HIVRT 97.7 12.9 98.9 0 12.9 25.8 
HMGR 100 43.2 100 43.2 41.5 40.9 
InhA 29 14.6 29 14.6 11.8 8.2 
NA 28.8 51.2 34.2 20.4 42.6 47.6 
PARP 46.4 9.2 86.8 6.4 6.3 8.2 
PNP 36.9 33.5 93.1 19.3 23.9 49.1 
SAHH 84.7 82.4 84.7 82.4 78.4 82.8 
CDK2 27.6 13.5 94.9 10.1 11.7 11.3 
EGFr 37.7 13.2 38.1 12.3 10.7 21.5 
FGFr1 41.3 12.3 51 6.2 11.9 6.7 
HSP90 62.4 18.7 70.4 14.5 11.5 24.6 
P38 MAP 29.4 31.4 62.2 21.2 15.6 12.5 
SRC 68.8 13.8 82 13.4 12.3 9.5 
TK 20.7 13.4 40.4 3 2.9 63.5 
AR 56 31.7 84.3 31.5 14.5 48.2 
ERagonist 93.1 41 93.1 41 19.6 55.4 
ERantagonist 21 19.2 93 9 14.7 23.2 
GR 27.4 18.8 56.6 15.2 16.7 20.5 
MR 56.8 30.5 56.8 30.5 29.5 57 
PPARg 20.2 13.2 65 9.2 8.8 4.4 
PR 53.5 35.9 53.5 35.9 11.8 23.2 
RXRa 87 26.9 88.8 2 11.2 37.9 
Enrichment, the ligand enrichment is represented by logAUC. SI, stands for the target to 
template sequence identity. 
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Taking only the most enriching model for each target, the averaged enrichment (logAUC) for 
the holo X-ray structures was 30.6 which was only slightly higher than the average 
enrichment (logAUC) of the most enriching homology models (28.7). However, this 
difference was not statistically significant. 
Subsequently they analyzed model properties (template resolution, binding-site sequence 
identity, overall sequence identity, N-DOPE score) which could correlate with enrichment 
performance, in the hope to identify parameters that can predict model performance. However 
none of the parameters showed a strong correlation with model enrichment performance.  
But on the other hand they noticed that homology models performed significantly better if 
models were left out which derive from orthologous templates and template-model pairs 
where the sequence identity is lower than 25%. This indicates  that models below a sequence 
identity of 25% show a significant weaker performance. 
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IV. Aim of the study 
 
1,4-benzodiazepines exert their anxiolytic, anticonvulsant, muscle relaxant, and sedative-
hypnotic properties by allosterically enhancing the action of GABA at GABAA receptors via 
their benzodiazepine binding site1. After 50 years of clinical use, the molecular basis of this 
interaction still is not known. The primary aim of this thesis is the elucidation of the binding 
mode of 1,4-benzodiazepines in the benzodiazepine binding site of α1β2γ2 GABAA-receptors 
with the computational means of homology modeling and molecular docking. The identified 
binding mode should be in accordance with existing experimental data, and ultimately the 
gained structural knowledge should predict novel ligand classes acting at the benzodiazepine 
binding site. Furthermore the derived structural models will also improve the current 
mechanistic understanding from modulator binding (at the benzodiazepine binding site) to 
alterations in channel gating. This can be achieved by the analysis of intra-molecular protein-
protein interactions in proximity to the benzodiazepine binding site that may mediate GABAA 
receptor modulation. 
But let’s face the facts: 
 No crystal structures for GABAA receptors available  
 Target to template sequence identities of around 18% at the time the thesis was conducted  
 A highly flexible loop shaping the benzodiazepine binding site  
 And finally, major difficulties of scoring functions to rank the correctly computed ligand 
orientation on the top position even in redocking experiments  
Honestly spoken the aim to uncover the binding mode of 1,4-benzodiazepines in the 
GABAA-receptor seems at least challenging. In principle there are two problems associated 
with the development of accurate models of ligand bound benzodiazepine binding sites.                 
First, the homology models that could be built at the time of the study are quite uncertain as 
the sequence identity between templates and target is only around 18%. Second, although 
standard docking tools are capable of reproducing the correct binding mode, they normally 
fail to rank these on top of the pose list. 
In the workflow of the thesis these problems will be tackled in a two step approach. In the 
first step, the explorative step, we want to face the high ambiguity in the input data by broadly 
sampling the pose space. This will inevitably result in an enormous amount of poses, but 
with a high likelihood of generating a plausible ligand-receptor complex. 
Consequently, the aim of the subsequent step, the selection step, will be the selection of 
the most plausible ligand-receptor complex(es) out of an ocean of poses. Exhaustive 
implementation of various sources of information (experimental, computational, structural) in 
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an orchestrated and integrative manner will be the key factor for this evaluative process that 
should finally narrow down the gigantic pose space to one single coherent solution.  
Once the plausible binding mode has been identified the predictive power of the identified 
ligand-receptor complex should be tested in the field of drug discovery by the conduction of 
structure-based virtual screening runs.   
In the following a short description of the steps is provided. 
Step 1, exploration step. In this step, homology modeling and molecular docking will be 
used in order to produce binding hypotheses for 1,4-benzodiazepines at the benzodiazepine 
binding site. The sampling during the docking has to be broad as the input data is highly 
ambiguous (low target-template sequence identity, flexible loop in binding site, low resolution 
of templates).  
In detail multiple homology models will be built deriving from different templates and 
varying sequence alignments. Additionally, flexible side-chains will be used during the 
docking procedure, once more adding degrees of freedom. And finally the first 100 poses per 
ligand per model will be kept for further evaluation. This all will result in an enormous 
amount of poses, but with a high likelihood of generating the correct ligand-receptor 
complex. 
Step 2, selection step. The aim of this step will be the selection of the most plausible 
binding mode out of the thousands of docking poses, generated in the exploration step. A 
large array of evaluation criteria (comparison with experimental data, docking scores, 
structure activity relationships and others) will be used in this sensible selection step.  
In this process the emphasis will be on the integration of existing experimental data as 
binding mode quality criteria. Plenty information about the spatial arrangement between 
ligand and binding site has already been accumulated in the last 50 years of research2,3. They 
are encoded as labeling data, mutagenesis data or can be found as structure-activity 
relationships. But as the experiments were compiled with various ligands we face a 
challenging situation: The plethora of information is dispersed through either i) different 
ligands within a compound class or ii) through ligands that belong to different classes. 
In this thesis the common binding mode (CBM) hypothesis will be applied as an 
adequate integrative platform that connects these seemingly dispersed informative pieces. The 
CBM provides an assumption about the ligand alignment of ligands acting at the same 
binding site. Hence the CBM can be used to incorporate information from ligands that derive 
from a common ligand class (narrow definition) or beyond that, also implements information 
that derive from other ligands  classes (extended definition). 
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In the narrow definition, the CBM hypothesis is based on the general assumption that  the 
scaffold of ligands belonging to the same class (here: 1,4-benzodiazepines, Fig. 10a) bind in 
the same mode in the binding site, thus providing a hypothesis for the mutual spatial 
alignment of these ligands. 
In the more extended view of the CBM hypothesis, which will be used as supplementary 
validation, information from further ligand classes (e.g. imidazobenzodiazepines, Fig. 10b) 
will be used in validating the binding mode of 1,4-benzodiazepines (Fig. 10a). 
 
Figure 10 - Representation of the structures of 1,4-benzodiazepines (a), 
imidazobenzodiazepines (b) and their mutual alignment in a widely accepted pharmacophore 
model (c). (a) The common scaffold of 1,4-benzodiazepines is depicted in black colour. For 
the most prominent representative of this ligand class (diazepam) additional structural 
elements are shown in grey colour. (b) The common scaffold of imidazobenzodiazepines is 
depicted in black colour. For the most prominent representative of this ligand class 
(flumazenil) additional structural elements are shown in grey colour. (c) Representation of 
the mutual spatial alignment of diazepam (grey stick representation) and flumazenil (violet 
stick representation) in the ligand based pharmacophore model of Cook et al.4 These aligned 
ligands share one common hydrophobic feature (L1, white meshed sphere) and two H-bond 
acceptor features (H1 and H2, red meshed spheres). 
 
The spatial link from 1,4-benzodiazepines to accessory ligand classes (e.g. imidazo-
benzodiazepines) will be taken from the ligand alignment described in a widely accepted 
pharmacophore model4 (Fig. 10c). This alignment will be the connective platform that 
facilitates cross evaluation among various compound classes. Consequently a diazepam (Fig. 
10a) pose can then be additionally validated by experimental evidence deriving from other 
ligand classes, for example by a flumazenil (Fig. 10b) docking pose that is found to spatially 
align (according to the pharmacophore model alignment, Fig. 10c) with the mentioned 
diazepam pose. So the pharmacophore model should enable the combination of information 
deriving from different ligand classes. 
Once the binding mode of 1,4-benzodiazepines has been identified, the ligand-receptor 
complex will be used in structure-based virtual screening runs taking the information encoded 
in the ligand-receptor complex to identify novel benzodiazepine binding site ligands.  
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B. Results and Discussion 
 
I. Diazepam-bound GABAA receptor models  
Identify  new benzodiazepine site ligands…………  66 
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I. Diazepam-bound GABAA receptor models identify 
new benzodiazepine binding-site ligands 
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GABAA receptors (GABAARs) are the major inhibitory trans-mitter receptors in the brain and the site of action of a variety of pharmacologically and clinically important drugs, such 
as benzodiazepines, barbiturates, neuroactive steroids, anesthetics 
and convulsants1. These receptors are chloride ion channels com-
posed of five subunits that can belong to different subunit classes. 
A total of 19 GABAA receptor subunits (A1–6, B1–3, G1–3, D, E, 
P, Q, R1–3) have been identified in mammalian brain. The majority 
of GABAARs are composed of one G-, two B- and two A-subunits. 
The two GABA-binding sites of these receptors are located extra-
cellularly at B-A interfaces (Fig. 1a). Classical benzodiazepines, 
such as diazepam, predominantly exert their action via GABAARs 
composed of A1BG2, A2BG2, A3BG2 and A5BG2 subunits and are 
known to bind at the extracellular A-G interface2 (Fig. 1b). Owing 
to the lack of high-resolution structural data for this important 
drug-binding site, however, a consensus binding-mode hypothesis 
explaining all of the experimental data is still lacking.
GABAARs, together with nicotinic acetylcholine receptors 
(nAChRs), glycine receptors and serotonin type 3 receptors, are 
members of the cysteine-loop receptor superfamily. Although so far 
no crystal structure of a GABAAR is available, a variety of crystal 
structures from a functional and structural homolog of the ligand-
binding domain of cysteine-loop receptors, the acetylcholine-
binding protein (AChBP), and more recently from the nAChR and 
bacterial homologs thereof, is available3 and demonstrates a high 
structural conservation within this receptor superfamily. Some of 
these structures have served as templates for protein homology 
models and docking studies that have yielded controversial bind-
ing-mode hypotheses for various benzodiazepines4–8. However, 
because of their low sequence identity of <20%, different members 
of the superfamily have appreciable variability in local interface and 
pocket structure3. To overcome this problem, we constructed mul-
tiple homology models of the GABAAR from a variety of structural 
templates to broadly sample the benzodiazepine-pocket  geometry. 
We then developed a workflow that, in contrast to automated 
ligand-supported modeling approaches9, did not rely on energetic 
scoring functions. This workflow allowed unbiased selection and 
refinement of those models best suited to describe a diazepam-
bound state as well as evaluation of several thousand docking poses 
of diazepam and its close structural analogs. The procedure yielded 
a binding mode for diazepam and analogs that is convincingly sup-
ported by experimental evidence. Using this binding hypothesis in 
a virtual screening of a large compound library, we identified new 
allosteric modulators of GABAARs acting via the benzo diazepine 
site, thus confirming their suitability for drug discovery and 
structure-based drug design.
RESULTS
Computational modeling and docking
To account for the substantial variability in local interface and 
pocket structures10 of cysteine-loop receptor family members, 
we constructed a total of 37 homology models of the GABAAR 
derived from eight distinct structural templates (Supplementary 
Methods, Supplementary Table 1), multiple sequence alignments 
(Supplementary Fig. 1) and variations in degrees of protein flexibil-
ity (Supplementary Schemes 1 and 2). We then docked diazepam in 
its bioactive conformation (M conformation; Supplementary Fig. 2 
and Supplementary Table 2) into all initial models (Supplementary 
Results, Supplementary Tables 3 and 4 and Supplementary Fig. 3) 
using the software package FlexX11. FlexX and other docking algo-
rithms are able to explore the conformational space sufficiently well 
to generate correctly docked poses, but they often fail in ranking the 
correct poses on top. Furthermore, the binding-mode prediction 
accuracy of scoring functions is target dependent12. We therefore 
evaluated the 100 top-scoring poses (FlexX score), thus ensuring that 
correct poses were retained. We then eliminated homology models 
that predominantly provided poses with poor lipophilic interac-
tion for ligand features L1 and L3 (Fig. 1c) of the diazepam struc-
ture or featured no simultaneous ligand contacts with A1 and G2 
subunits. For the remaining 14 models, we extended docking to 
multiple ligands (1, 3–5, 8, 9; in M conformation in Fig. 1c) and 
used the docking protocol FlexE13 to enable the  flexibility of those 
1Department of Medicinal Chemistry, University of Vienna, Vienna, Austria. 2Leiden–Amsterdam Center for Drug Research, Division of Medicinal 
Chemistry, Faculty of Sciences, VU University Amsterdam, Amsterdam, The Netherlands. 3Department of Biochemistry and Molecular Biology, Center for 
Brain Research, Medical University of Vienna, Vienna, Austria. *e-mail: margot.ernst@meduniwien.ac.at
Diazepam-bound GABAA receptor models identify 
new benzodiazepine binding-site ligands
Lars Richter1, Chris de Graaf2, Werner Sieghart3, Zdravko Varagic3, Martina Mörzinger3, Iwan J P de Esch2, 
Gerhard F Ecker1 & Margot Ernst3*
Benzodiazepines exert their anxiolytic, anticonvulsant, muscle-relaxant and sedative-hypnotic properties by allosterically 
enhancing the action of GABA at GABAA receptors via their benzodiazepine-binding site. Although these drugs have been used 
clinically since 1960, the molecular basis of this interaction is still not known. By using multiple homology models and an un biased 
docking protocol, we identified a binding hypothesis for the diazepam-bound structure of the benzodiazepine site, which was 
confirmed by experimental evidence. Moreover, two independent virtual screening approaches based on this structure identified 
known  benzodiazepine-site ligands from different structural classes and predicted potential new ligands for this site. Receptor-
binding assays and electrophysiological studies on recombinant receptors confirmed these predictions and thus identified 
new chemotypes for the benzodiazepine-binding site. Our results support the validity of the diazepam-bound structure of the 
 benzodiazepine-binding pocket, demonstrate its suitability for drug discovery and pave the way for structure-based drug design. 
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amino acid side chains that have been shown to be important for 
ligand recognition2 and/or constitute the main steric determinants 
of the binding site. By applying the above-mentioned criteria for 
each ligand docked, we further reduced the number of homology 
models. The three best-performing models were based on Protein 
Data Bank (PDB) entries 2BYQ3 (Aplysia californica AChBP, epi-
batidine bound), 1UW6 (ref. 3) (Lymnea  stagnalis AChBP, nico-
tine bound) and 2QC1 (ref. 3) (mouse nAChR, A1 subunit, 
A-bungarotoxin bound). To improve conformational sampling, we 
further increased the flexibility of these three models by consider-
ing additional rotamers of amino acid side chains in direct contact 
with pocket-defining residues, especially at the crowded subunit 
interface between loops A and B. This resulted in three additional 
models (Supplementary Scheme 2).
Subsequently, we docked ligands 1–9 (Fig. 1c) into the six final 
models (Supplementary Table 3) using the FlexE protocol. We then 
performed an energy minimization of all poses and calculated the L1 
and L3 interaction strengths. Of the 4,997 energy-minimized poses, 
we retained 1,463 with L1 and L3 interaction strengths above the 
median value. These poses still sampled a wide variety of putative 
binding geometries for smaller ligands such as diazepam and fluni-
trazepam. Ligands with bulky substituents (Fig. 1c; 4–9) assumed 
more restricted poses. Thus, by using only lipophilic interaction 
strength as our selection criterion, we retrieved a set of poses in 
which all of the binding modes compatible with the sampled pocket 
topologies were still present.
Binding-mode search
To compare binding modes in different templates, we three-
 dimensionally aligned the ligand-protein complexes on the basis 
of the conserved domains of the A- and G-subunits of their benzo-
diazepine-binding pocket. Then, we identified similar binding 
modes through cluster analysis (Supplementary Scheme 3) after 
computing the r.m.s. deviation values of the ligands’ common atom 
positions14 between each pair of poses and storing them as a matrix. 
Cluster analysis then produced groups of poses with small differ-
ences in r.m.s. deviation. By allowing 2-Å scatter around each cen-
troid pose, thirty clusters, each comprising a group of similar binding 
modes, emerged (Supplementary Figs. 4 and 5).
Common binding-mode screen
To define candidate geometries representing a common binding mode 
(CBM), we split the docked ligands (Fig. 1c and Supplementary 
Table 5) into mandatory ‘core ligands’ (Fig. 1c; 1–5), and ‘accessory 
ligands’ (Fig. 1c; 6–9). Core ligands have very similar chemical struc-
tures, affinities, efficacies and patterns in their response to mutation, 
suggesting tightly overlapping bound-state geometries. Although this 
assumption is not necessarily true in each case, it is the basis of all 
rational hit-optimization efforts and (quantitative) structure-activity 
studies. Additionally, we also considered compound 5 ‘core’, not as a 
ligand but as affinity chromatography bait (Supplementary Fig. 6). 
Accessory ligands should also bind in a similar binding mode as the 
core ligands, but they either do not share all pharmacophore features 
with diazepam or, because of steric requirements, may induce some-
what different conformations of the binding site. Only three of the 
clusters contained all of the mandatory core ligands and were thus 
further considered as CBMs (Supplementary Scheme 3).
For these three clusters, we extended the measure of ‘binding-
mode similarity’ to include not only the orientation of the ligand’s 
common substructure but also the pocket atoms interacting with 
this substructure. The resulting ‘bound-complex r.m.s. deviation’ 
value describes the similarity of ligand-pocket interaction patterns. 
By clustering the bound-complex r.m.s. deviation values, we finally 
extracted the most homogenous subsets of poses from each parent 
cluster, resulting in CBM candidates CBM I, CBM II and CBM III 
(Fig. 2 and Supplementary Tables 6–8).
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Figure 1 | Structure of diazepam-sensitive GABAARs and of benzodiazepine 
ligands. (a) Top view of the extracellular domain of the pentameric 
A1B2G2 GABAAR in ribbon mode. The benzodiazepine-binding site (BZ) 
and the two GABA-binding sites are indicated by arrows. Diazepam in the 
benzodiazepine-binding site is depicted in space-filling mode. (b) View from 
a perspective nearly parallel with the lipid bilayer of the A1G2 extracellular 
interface in ribbon mode with a diazepam-bound pose of CBM I in space-
filling mode. The dashed window indicates the section shown in Figures 2–5. 
Segments (loops) A, B, C, D, E, F and G are labeled, and the corresponding 
protein segment is rendered in a darker shade. In both panels the plus (+) 
and minus (−) sides of the subunits are indicated. (c) Chemical structures 
of compounds used in this study. 1–9 were used for docking and 10–14 were 
used for validation. The pharmacophoric features L1, L3, H1 and H2 (ref. 48) 
are superimposed on two-dimensional structures of diazepam and flumazenil 
(11). As an additional feature we introduce H1? to denote the interaction with 
the second lone pair of the carbonyl oxygen. More detailed information on 
the compounds can be found in Supplementary Table 5.
- 68 -
©
20
12
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
NATURE CHEMICAL BIOLOGY | ADVANCE ONLINE PUBLICATION | www.nature.com/naturechemicalbiology 3
ARTICLENATURE CHEMICAL BIOLOGY DOI: 10.1038/NCHEMBIO.917
Evaluation of the CBM candidates
CBM I (Figs. 2 and 3 and Supplementary Fig. 7) contains the 
highest number of poses of core and accessory ligands and is more 
homogeneous in terms of ligand overlap (small average r.m.s. devia-
tion distance to centroid) than the other putative binding modes 
(Fig. 2 and Supplementary Table 9).
Analysis of all types of ligand interactions with pocket residues 
indicated that not all of the poses of a given CBM feature all inter-
actions. Whereas in particular the highly rotamer-sensitive hydro-
gen bonds fluctuate considerably, major lipophilic interactions are 
present in most poses and are CBM defining. CBM I is the only 
pose pool in which both of the lipophilic L-features (Fig. 1c) and 
hydrogen bonds of all of the core ligands are matched. CBM II fails 
to provide a consensus H1 hydrogen bond (Fig. 1c), and CBM 
III has a very heterogeneous L-feature pattern (Supplementary 
Tables 6 and 9).
A comparison of the crystal structures of ligand-bound mem-
bers of the cysteine-loop receptor family indicated that the positions 
of large side chains within the binding pocket seem to be well con-
served. Notably, the positions of CBM I A1 Tyr159 and A1 Tyr209, 
the key residues defining its L1 pocket (Fig. 2), are similar to those 
of homologous residues of the ligand-bound complexes of both 
AChBP and nAChR, even though we kept all large side chains in 
the pocket flexible during docking (Supplementary Fig. 8).
Subjecting all poses from the five core ligands used for the CBM 
screen to two scoring functions15,16 indicated that 13 of the 50 top ten 
scoring poses were located in CBM I, none were in CBM II and one 
was in CBM III. The remaining top-scoring poses were distributed 
randomly across the other 27 clusters (Supplementary Table 9).
Validation of binding modes by experimental evidence
The correct binding mode must be supported by experimental evi-
dence. When flunitrazepam was used as a photolabel for the ben-
zodiazepine-binding pocket, covalent modification of A1 His101 
(loop A) was observed17. Similarly, when covalent labeling of various 
cysteines engineered into the benzodiazepine pocket was investi-
gated with compound 10 (Fig. 1c), which carries a cysteine-reactive 
isothio cyanate at a position equivalent to that of the nitro group in 
flunitrazepam, irreversible labeling and permanent modulation of 
receptors containing the A1 H101C mutation was reported, suggest-
ing that the active state was captured18. CBM I (Fig. 4) and CBM II 
allow such covalent labeling, whereas CBM III does not (Table 1).
Receptors that contain the A1 H101R mutation have a drastically 
reduced affinity for classical benzodiazepines such as flunitrazepam. 
Compounds lacking the pendant phenyl ring, such as flumazenil, 
tolerate this mutation19, possibly suggesting an interaction of A1 
His101 with the pendant phenyl ring. Alternatively, the loss of fluni-
trazepam binding in the A1 H101R mutant could reflect an unfa-
vorable steric interaction with arginine7. However, having a cysteine 
in this position20 results in a loss of affinity for flunitrazepam by 
a factor of 200, whereas glutamine leads to a loss of affinity by a 
 factor of only 15. These findings were interpreted as evidence for 
a strong aromatic or hydrophobic interaction between the pendant 
phenyl ring (L3) of flunitrazepam and A1 His101 (ref. 20). Such an 
interaction is present in CBM I (Figs. 2 and 3), in which A1 His101 
is an essential part of the pocket accommodating L3, and to a lesser 
degree in CBM III but not in CBM II.
The loop C mutation A1 Y209A, though producing a near wild-
type GABA response, leads to a decrease in binding affinity both 
for diazepam (by a factor of 40) and the imidazobenzodiazepine 
flumazenil (by a factor of 41) (Fig. 1c; 11)21. This suggests that A1 
Tyr209, in contrast to A1 His101, provides an essential interaction 
with a structure common to diazepam and flumazenil. In CBM I, 
the L1 pharmacophoric feature common to both compounds forms 
a strong aromatic interaction with A1 Tyr209 (Fig. 4a,b). Notably, 
the imidazobenzodiazepine Ro15-4513 (Fig. 1c; 12), which is 
structurally similar to flumazenil, photolabels A1 Tyr209 (ref. 22) 
(Fig. 4b). More recently, a derivative of Ro15-4513, in which the 
azido group has been replaced by an isothiocyanate group (Fig. 1c; 
13), has also been shown to react with several engineered cysteines 
in the A-subunit23. Only CBM I is fully consistent with the reac-
tion patterns of both studies (Fig. 4b) and with the additional 
reaction of compound 13 with the A1 H101C mutant, which was 
interpreted as strong evidence for an overlapping binding mode of 
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Thr206Val202
Val211
Tyr209
His101 Tyr159 Phe77
Ala79
Thr142
Figure 3 | Representation of a CBM I pose of diazepam. The L1 
hydrophobic feature (Fig. 1c) shows strong interactions with A1 Tyr159  
and A1 Tyr209 (ref. 26). The L3 hydrophobic feature (Fig. 1c) shows  
strong interactions with A1 His101 and G2 Phe77. The asterisk on G2 Phe77  
indicates the position of the hydroxyl group in the ligand-bound F77Y 
mutants24 (Supplementary Fig. 9a). The arrow indicates rotational 
freedom of the pendant phenyl ring. The imine nitrogen forms a hydrogen 
bond with A1 Ser204. The carboxyl oxygen of diazepam with its two lone 
pairs interacts with G2 Thr142 and A1 Thr206. The A1 subunit is in yellow, 
and the G2 subunit is in blue.
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Figure 2 | CBM candidates. View of the benzodiazepine-binding pockets 
of the CBM pose pools as depicted in the dashed window of Figure 1b. 
(a–f) In all panels, the L1-forming annealed benzene group is depicted  
in orange and the L3-forming pendant phenyl group in purple.  
The A-subunits are shown in yellow fine-line representation, and the 
G-subunits are shown in blue. Color codes used for the seven-membered 
ring and the side chains: gray for carbon, blue for nitrogen and red for 
oxygen. All labels are color-matched to the interaction partner. All side 
chains providing major interactions (H1, H1?, H2, L1 and L3 as defined in 
Fig. 1c) in a given CBM are indicated in panels a–c to show the variability. 
The scatter of core ligand poses (Supplementary Table 9) is depicted for 
each CBM in panels d–f.
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 diazepam and flumazenil23. Together, these results suggest that only 
CBM I can provide a single structural hypothesis for all of these 
covalently incorporated derivatives of diazepam, flunitrazepam 
and flumazenil.
Compounds with a pendant phenyl ring suffer an affinity loss 
in the loop D G2 F77Y mutant, which is relatively less pronounced 
(by a factor of 250) for diazepam but is much stronger in diaze-
pam  analogs with chlorine substituents (monochlorodiazepam, by 
a  factor of 530; dichlorodiazepam (Fig. 1c), by a factor of 700 
(ref. 24)) that decrease the flexibility of the pendant phenyl ring. 
Thus, G2 Phe77 has been proposed to interact with the pendant 
 phenyl ring of diazepam and its analogs24. CBM I features precisely 
this interaction and has a sufficiently narrow L3 pocket, defined 
mostly by G2 Phe77 and A1 His101, to possibly cause steric pro-
blems when phenylalanine is replaced by tyrosine. Diazepam might 
be able to accommodate to the loss of space by its pendant phenyl 
ring adapting another rotational state (Fig. 3) that is probably not 
possible for its more rigid analogs. Neither CBM II nor CBM III 
offer interactions consistent with these findings.
Other mutations in G2 Phe77 have subtle effects on the affinities 
of diazepam and flumazenil. The point mutation G2 F77L is toler-
ated well by both ligands, whereas G2 F77I leads to a loss of affin-
ity for flumazenil by a factor of 2,000 but to a loss of affinity for 
diazepam25 or Ro15-8670 by a factor of only 4–5 (Supplementary 
Fig. 9a,b). Docking of flumazenil into the final models indicated 
that flumazenil, much like Ro15-8670, can be accommodated in 
all three CBM geometries, thus supporting the postulated CBM 
between diazepam and flumazenil23 by direct docking. The CBM I 
pose (Fig. 4b) features a strong hydrophobic interaction between 
G2 Phe77 and flumazenil. After replacement of phenylalanine with 
leucine in our flumazenil-bound wild-type CBM I structures, both 
the hydrophobic interaction and local ligand burial of flumazenil 
are reduced, although the pocket structure tolerates the point 
 mutation without detectable unfavorable interactions. When isoleu-
cine replaces phenylalanine, the loss of hydrophobic interaction and 
ligand burial are much more pronounced. In addition, steric clashes 
are observed and thus suggest that this mutation would induce 
local rearrangements in the pocket involving both subunits. CBM I 
structures are thus fully compatible with experimental data on the 
F77X mutants.
Several other experimental findings, such as the importance of 
A1 Tyr159 (loop B) for the action of diazepam, flunitrazepam and 
flumazenil23,26 or of subtle effects of the A1 T206V substitution in 
loop C for the potency of diazepam and Ro15-8670 (ref. 24), together 
can only be explained by CBM I and suggest a close approximation 
between the ester group of Ro15-8670 (8) and A1 Thr206 (Table 1 
and Supplementary Fig. 9a,c). This conclusion is supported by the 
effects of A1 S205N substitutions on compounds with or without 
this ester group27 as well as by covalent labeling of A1 S205C and A1 
T206C mutants by a nitrazepam derivative carrying a reactive iso-
thiocyanate in the seven-membered ring’s 3C position28 (Fig. 1c; 14; 
also Fig. 4b). Finally, other experiments indicated that the ester 
group of 3?-ester–substituted imidazobenzodiazepines must be 
located close to G2 Ala79 (ref. 29) (Fig. 4b and Supplementary 
Fig. 9c). All of these results are consistent with CBM I poses of these 
ligands (Table 1) and thus again support an overlapping orientation 
of benzodiazepines and imidazobenzodiazepines within the benzo-
diazepine binding pocket.
Alternative workflow leads to the same binding mode
To avoid the assumption of a common binding mode, we also sub-
jected the initial pool of 30 pose clusters to an alternative workflow 
(Supplementary Scheme 3) and evaluated all poses by geometric 
restraints (distance between a pocket residue and a ligand atom) 
derived from experiments 2, 3, 7, 8, 10 and 11 cited in Table 1. 
Only two clusters met all criteria at different cutoff levels for the 
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Figure 4 | CBM I reference binding modes of diazepam and flumazenil compared to docking poses of virtual screening hits 19 and 20,  
selected by IFP scoring. Representation shows the A-subunit (yellow) and G-subunit (blue). Ligand and key residues are rendered in stick 
representation, and hydrogen-bond interactions are indicated by cyan dotted lines. (a) Two-dimensional scheme shows diazepam 1 and  
analogs 3, 10 and 14 in CBM I. Position of covalent incorporation of 7-NCS18 is indicated by ($), and the sites of 3-NCS28 reactivity are indicated 
by (#). (b) Two-dimensional scheme shows flumazenil (11) and analogs 12 and 13 in CBM I. Residues whose respective cysteine mutants react 
with the imid 13 (ref. 23) are marked (*), and the A1 Tyr209 whose bovine homolog is photolabeled by 12 (ref. 22) is marked (§). The ester 
group is localized between loops C and D. (c,d) 19 (c) and 20 (d) place their phenyl and thiazol groups in the same tight aromatic binding pocket 
between A1 His101, A1 Tyr159 and A1 Tyr209 as that occupied by the L1 ring of 1 in a and 11 in b, and they stack with the same G2 Phe77 as the 
reference ligands.
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selected distances. These two clusters are the parent clusters of CBM 
I and CBM II. When all poses were scored by two scoring functions 
as above, the group of poses containing CBM I once again emerged 
as a strong candidate.
Neither of the two approaches led to a single bound-state model. 
The bound-state hypotheses derived in this work represent groups 
of poses with some uncertainty associated with atomic positions 
and protein-ligand interactions. The pose groups derived from the 
CBM analysis are smaller and more homogeneous, as we used their 
interaction pattern in defining the binding mode (Supplementary 
Tables 6–8).
Retrospective validation of CBM I by virtual screening
If CBM I structures are indeed binding competent, they should 
be suitable for enriching other benzodiazepine-site ligands from 
different structural classes out of a library of decoy molecules. 
To investigate this possibility, we generated a ‘validation’ library 
in analogy to the directory of useful decoys (DUD) database30 
(Supplementary Scheme 4) by extracting 41 benzodiazepine-
 binding-site ligands from different structural classes from the lit-
erature (Supplementary Table 10). We property-matched decoys 
on the basis of the five terms used to construct the DUD database, 
plus net formal charge31. Thus, for each of the 41 ligands, we gener-
ated all protonation states near pH 7.0, resulting in 48 unique ligand 
protomers. For each of them, we created 50 decoy molecules that 
are physically similar but topologically distinct and thus should not 
bind the benzodiazepine site, resulting in a library of 2,400 decoys. 
After seeding the 48 unique ligand protomers into the decoy library, 
the resulting validation library was used for virtual screening using 
structure-based pharmacophore models. These we generated using 
the software program LigandScout32 using bound-state complexes 
from all three CBM pools as our basis (Supplementary Fig. 10). 
We sorted the compounds in the validation library for those that 
best matched these pharmacophore models . In the sorted libraries, 
we computed33 the enrichment of known binders in the top 0.5%, 
1%, 2%, 5% and 10% for each CBM. CBM I performed much  better 
than CBM II and CBM III (Supplementary Table 9), resulting in an 
enrichment over random selection of 24.8 when the top 0.5% was 
analyzed. With the exception of purely two-dimensional similarity 
searching, this screen outperforms those conducted with a ligand-
based pharmacophore model and shape-based similarity search 
(Supplementary Table 11). Such enrichment factors are comparable 
to the average enrichment factors obtained for the 40 crystal struc-
tures of the original DUD database30, clearly indicating that CBM I 
complexes are sufficiently binding competent to identify known 
benzodiazepine-site ligands from different structural classes.
CBM I binding hypotheses predict new ligands
We then investigated whether CBM I–derived pharmacophore 
 models (Supplementary Fig. 10) can be used for the discovery of 
new ligands (Supplementary Scheme 5). As a screening library we 
used the large DUD databank30, which contains 95,357 compounds 
and covers a large chemical space. After the screening run, we 
grouped the top 0.5% of compounds in the DUD screen accord-
ing to their chemical scaffolds. Some of the compound classes in 
the top 0.5% were found to have anticonvulsive activity in animal 
models but were never investigated for a possible interaction with 
GABAARs. Representatives from four of these compound classes 
were commercially available and were tested for displacement of 
[3H]flunitrazepam binding from mouse cerebellum membrane 
preparations (Table 2).
In contrast to compounds 16–18, the 3-hydroxyoxindole 15 at a 
10-MM concentration was able to inhibit [3H]flunitrazepam binding 
to 18 ? 7% of the control values, indicating that it interacts with 
the benzodiazepine-binding site of GABAARs. This compound 
at 1-MM and 10-MM concentrations also significantly (P < 0.001) 
stimulated GABA-induced currents in recombinant A1B3G2 
receptors expressed in Xenopus laevis oocytes (Table 2). Notably, 
the ligand-based screening approaches would have missed this new 
hit compound (Supplementary Table 12).
A subsequent similarity search revealed that other 3-hydroxy-
oxindoles were also present in the top 0.5%, four of which (15a–15d) 
were commercially available. To further increase the number of com-
pounds for the follow-up study, we bought five additional analogs 
Table 1 | CBM candidates in light of experimental data
Ligandsa CBM I CBM II CBM III
A1 His101
(1) Flunitrazepam photolabeling17 3 All ++ All ++ None −
(2) 7-NCS covalent labeling18 10 All ++ All ++ None −
(3) A1 His101 interacts with L3 (ref. 20)b 3 13/16c ++ None − 3/6c +
A1 Tyr209
(4) A1 Tyr209 interacts with L1 (ref. 21) 1 All ++ None − All ++
(5) Ro15-4513 photolabeling22 12 All ++ None − All ++
A1 His101, A1 Gly157, A1 Val202 and A1 Val211
(6) ‘Imid-NCS’ compound covalent labeling23 13 All ++ None − None −
G2 Phe77
(7) G2 Phe77 interacts with L3 (ref. 24)b 1–3 All ++ 3/8c + 7/12c +
A1 Thr206
(8) A1 Thr206 hydrogen bonding24 1,3 34/37c ++ 3/7c + None −
(9) A1 Thr206 contacts ester24 8 All ++ 1/3c + None −
A1 Ser205 and A1 Thr206
(10) 3-NCS covalent labeling28 14 All ++ All ++ None −
G2 Ala79
(11) G2 Ala79 near ester29 8 All ++ All ++ None −
aOnly poses of the defined ligands (Fig. 1c) were used for evaluation. bInteractions were calculated using SCORING.SVL. cNumber of poses fulfilling the respective criterion in relation to number of total 
poses in a CBM (Supplementary Table 7 lists the total number of poses per ligand within a CBM).
- 71 -
©
20
12
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
6  NATURE CHEMICAL BIOLOGY | ADVANCE ONLINE PUBLICATION | www.nature.com/naturechemicalbiology
ARTICLE NATURE CHEMICAL BIOLOGY DOI: 10.1038/NCHEMBIO.917
Table 2 | Effects of top 0.5% compounds on [3H]flunitrazepam binding to cerebellar membranes and on GABA-stimulated currents 
in recombinant a1b3g2 receptors
Cmpd. 15, 15a–15i
N
R3
O
O
R2 OH
R1
Percentage of 
ﬂunitrazepam 
binding left at 10 mM
Percentage of GABA EC3 
stimulation at a1b3g2 
receptors
Cmpd. ZINC code R1 R2 R3 1 mM 10 mM
15 ZINC00657218a,b H Ethyl p-Bromophenyl 18 ? 7 130 ? 4 300 ? 28
15a ZINC00106837b H Methyl
S
69 ? 7 124 ? 9 140 ? 5
15b ZINC01320283b H Methyl
S
34 ? 5 118 ? 3 168 ? 9
15c ZINC02854078b H Bromo
O
77 ? 6 134 ? 9 165 ? 16
15d ZINC01108532b 2-Ethinyl Bromo 4-Pyridyl Inactive n.d. n.d.
15e ZINC17744128c H H Methyl Inactive n.d. n.d.
15f ZINC00037760c Methyl H Phenyl Inactive n.d. n.d.
15g ZINC00299974c Isopropyl H Phenyl Inactive n.d. n.d.
15h ZINC00089290c O
NH2
H Phenyl Inactive n.d. n.d.
15i ZINC00299984c O
O
H Phenyl Inactive n.d. n.d.
16 ZINC00421595a
N
N
NH
S
N
N
H
Inactive n.d. n.d.
17 ZINC00627050a
N
N
S HN
OO
F
Inactive n.d. n.d.
18 ZINC00099714a
F NH
O
N N
N
O
H2N Inactive n.d. n.d.
19 IOTA0004d
N
N
N
H
25.6 ? 9.6 MMe
20 IOTA0431d
N
S
N
O
34.7 ? 2.6 MMe
aCompounds ranked within the top 0.5% in score-sorted DUD decoys database that belong to a compound class in which anticonvulsive activity was shown in literature. bCompounds ranked within top 
0.5% in score-sorted DUD decoys database that belong to the 3-hydroxyoxindole class. c3-hydroxyoxindoles not contained in DUD decoys database. dCompounds ranked within the top 30 of the IFP 
score–sorted fragment library capable of displacing [3H]flunitrazepam in radioligand assays. eIC50 values were measured by the competition for [3H]flunitrazepam binding to mouse brain membranes.  
Data are means ? s.d. from three independent [3H]flunitrazepam binding assays performed in triplicate. n.d., not determined.
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(15e–15i) not present in the DUD database. We then tested all nine 
additional 3-hydroxyoxindoles, as shown in Table 2. Displacement 
of [3H]flunitrazepam binding at 10-MM compound concentrations 
revealed that, in addition to compound 15, the compound 15b at 
10 MM was able to inhibit [3H]flunitrazepam binding to about 34 ? 
5% of control binding (P <0.001), whereas compounds 15a and 15c 
inhibited this binding to approximately 70% (P < 0.01). The other 
3-hydroxyoxindoles investigated did not significantly (P < 0.5) 
inhibit [3H]flunitrazepam binding at this concentration. All four 
compounds able to displace [3H]flunitrazepam binding were also 
able to significantly (P < 0.001) enhance GABA-elicited currents 
in A1B3G2 recombinant receptors expressed in X. laevis oocytes at 
10-MM concentration (Table 2). We then characterized compounds 
15b and 15, which had the highest potency for inhibition of [3H]
flunitrazepam binding (half-maximum inhibitory concentration 
(IC50) values of 4.9 ? 1.5 MM and 3.8 ? 0.8 MM, respectively; Fig. 5 
and Supplementary Fig. 11). Both compounds showed a dose-
dependent stimulation of GABA-induced currents and shifted 
the GABA dose-response curve to the left. In addition, the effect 
of these compounds could be reduced by coapplication of 100 nM 
of the benzodiazepine-site antagonist flumazenil, indicating that 
the effect was at least partially generated by interaction with the 
benzodiazepine-binding site of these receptors. Flumazenil inhib-
ited the effects of 15b more strongly than those of 15. The additional 
effect of these compounds in the presence of flumazenil might have 
been caused by their interaction with additional binding sites at 
these receptors34.
These data clearly indicate that 3-hydroxyoxindoles are unique 
modulators of GABAARs via the benzodiazepine-binding site. 
The structural novelty of this compound class is also reflected by 
the fact that the most similar known benzodiazepine-site ligand 
(Supplementary Table 12) has a Tanimoto similarity of 0.56 (based 
on molecular access system (MACCS) keys).
Results obtained for this small data set indicate that an aromatic 
ring at R3 in combination with an unsubstituted nitrogen atom 
seems to be beneficial for biological activity. This idea is also sup-
ported by the orientation of compound 15b in the pharmacophore 
model, which shows a considerable overlap of substituent R3 with 
the pendant phenyl ring of diazepam and a hydrogen bond of the 
NH group to the backbone carbonyl of A1 Tyr159 (Fig. 5). However, 
systematic studies have to be performed to get deeper insights into 
the structure-activity relationship and binding mode of this unique 
ligand class. Finally, whether this activity accounts for some of the 
previously reported anticonvulsive activity of this compound class35 
has to be clarified in future experiments.
In an alternative approach, we performed docking-based virtual 
screening studies (Supplementary Scheme 5) against the diazepam-
bound (Fig. 4a) and flumazenil-bound (Fig. 4b) GABAAR models 
(CBM I) used for generating the protein-based pharmacophore 
model (Supplementary Fig. 10)36. To assess the robustness of the 
benzodiazepine-binding-site models, we used a docking method 
(protein-ligand ANT system (PLANTS)37) different from that used 
to derive ligand binding modes (FlexX) for virtual screening studies. 
To consider protein flexibility, we performed two independent 
docking simulations for each of the two benzodiazepine-pocket 
models: a ‘rigid’ docking run considering no side chain flexibility 
and a ‘flexible’ docking run allowing flexibility of the side chains of 
G2 Thr142 (ref. 38) and A1 Thr206 (ref. 24) (important hydrogen 
bond–donating residues involved in ligand binding and activation). 
We used the original ligand poses of diazepam and flumazenil in 
the respective benzodiazepine-binding-site models to define refer-
ence interaction fingerprints (IFPs) for scoring the docking poses 
of an in-house library of 1,010 chemically diverse fragment-like 
molecules, as described previously39. The IFP scoring method 
determines ligand binding mode similarity to experimentally sup-
ported ligand binding poses (Fig. 4a,b). IFPs have been used as an 
efficient alternative postprocessing method of docking poses36,39 
to overcome target-dependent scoring problems12. We used seven 
different interaction types (negatively charged, positively charged, 
hydrogen bond–accepting, hydrogen bond–donating, aromatic 
face-to-edge, aromatic-face-to-face and hydrophobic) to define 
the IFP (Supplementary Table 13). We used the Tanimoto coeffi-
cient measuring IFP similarity with the reference ligand pose in 
the benzodiazepine-binding-site receptor model to score the dock-
ing poses of known actives and decoys. Normalized IFP scores 
(Z values) of the docking poses in the diazepam and flumazenil 
binding pocket receptor models were merged and ranked with 
respect to the normalized IFP score. We successfully used this 
docking-based virtual screening procedure to identify two new ben-
zodiazepine-binding-site ligands from the 1,010 chemically diverse 
fragment-like molecules (Supplementary Scheme 5)40. From the 
top-ranked 30 fragment-like compounds, we selected 10 fragments, 
chemically dissimilar from known benzodiazepine-binding-site 
ligands, for radioligand binding assays. Two of these in silico hits, 19 
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Figure 5 | 3-hydroxyoxindoles as a new class of benzodiazepine-binding-site ligands of GABAARs. (a) The CBM I–derived pharmacophore model 
(Supplementary Fig. 10a) based on the diazepam-bound structure and its match with 15b is depicted. Both dark blue aromatic features match, as do the 
red hydrogen bond and the yellow lipophilic feature. The steric exclusion volumes are depicted in an overlay with a ribbon structure to provide orientation 
in the model. (b) Two-dimensional structure of 15b. (c) Inhibition of 2 nM [3H]flunitrazepam binding to mouse cerebellar membranes by 15b. Data 
represent means ? s.d. from three experiments performed in triplicate. nH, Hill coefficient. (d) Electrophysiological traces and dose-response curve  
of 15b on GABA EC3 (3% of maximum GABA current) currents in the absence (squares) or presence of 100 nM flumazenil (asterisks), obtained from  
X. laevis oocytes expressing recombinant GABAARs composed of A1B3G2 subunits. Data represent means ? s.d. from three separate experiments 
performed in different oocytes from two different batches. (e) GABA dose-response curves in A1B3G2 receptors expressed in X. laevis oocytes with  
(open squares) and without (filled squares) 30 MM 15b. Data represent means ? s.d. from three separate experiments performed in different oocytes  
from two different batches. In c, d and e, x-axis scale is logarithmic.
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and 20, inhibited [3H]flunitrazepam binding (IC50 values of 25.6 ?  
9.6 MM and 34.7 ? 2.6 MM, respectively; Table 2). Remarkably, the 
new ligands are proposed to make the same interactions with the 
 benzodiazepine-binding-site as diazepam and flumazenil 11, but 
most of the functional groups (hydrogen bond acceptors and aro-
matic ring systems) mediating these conserved interactions are 
located at positions different than those of the corresponding func-
tional groups in the reference ligands (Fig. 4). The newly identified 
chemical scaffolds (the MACCS Tanimoto similarity of 0.58 was 
the closest to any of the 41 benzodiazepine-binding-site ligands; 
Supplementary Table 12) illustrate the suitability of this molecular 
IFP approach for scaffold-hopping purposes41.
CBM I models are similar to the GluCl structure
After submission of this study, a nematode glutamate-gated chloride 
channel (GluCl) structure was reported (PDB code 3RIF)42. This 
cysteine-loop receptor features 28%, 35% and 29% sequence iden-
tity in the extracellular domain with A1, B2 and G2 subunits, respec-
tively, and thus it is clearly the template of choice for future studies. 
Careful analysis of this structure and homology models derived 
from it (Supplementary Table 4) indicated that our CBM I models 
indeed are more similar to the structure with PDB code 3RIF than 
the AChBP structures used in modeling and, more importantly, 
much more so than the models that we rejected through our work-
flow. This again highlights the validity of our approach.
DISCUSSION
In the absence of a crystal structure of the ligand-bound benzo-
diazepine-binding-site of GABAARs, protein homology modeling 
and computational ligand dockings are the only bases on which 
structure-based hypotheses for the interaction of benzodiazepines 
with their binding site can be formed. However, accurate predic-
tion of membrane-protein structures and ligand interactions 
remains a challenge43 and requires accurate modeling of structurally 
divergent regions and extensive use of experimental evidence, as 
shown recently in a community-wide G protein–coupled receptor 
structure-prediction assessment. Here we compensated for the local 
uncertainty resulting from structurally divergent regions of related 
cysteine-loop receptor family members by constructing a variety of 
homology models from different templates. We then exploited the 
given structure of diazepam and its derivatives to select those models 
best accommodating these compounds. To do so, we developed 
a workflow that allowed handling of multiple models and  several 
thousand diazepam docking poses. The only selection criteria 
used were a reasonable lipophilic interaction with the hydrophobic 
parts of the diazepam structure as well as simultaneous contacts of 
diazepam with the A1 and the G2 subunit of GABAARs. With the 
assumption that diazepam and its close structural analogs have a 
CBM within the benzodiazepine-binding pocket and by clustering 
of ligand poses according to a similar orientation of their common 
structure and according to similar interactions with pocket residues, 
we were finally led to three CBM geometries, CBMs I–III.
CBM I binding geometry and interactions are supported by 
a large variety of structural, computational and experimental 
evidence. Furthermore, CBM I can provide a single structural 
hypothesis for seemingly discrepant results obtained with various 
covalently incorporated compounds and supports the hypoth-
esis that diazepam and the imidazobenzodiazepines Ro15-4513 or 
fluma zenil show a  similar binding mode within the benzodiazepine 
pocket. Finally, CBM I can also explain subtle changes in affinity of 
various ligands for various amino acid substitutions. Taken together, 
this abundance of evidence indicates that CBM I is the correct 
 binding mode of diazepam in the benzodiazepine-binding pocket.
Previous studies also featured docking poses of diazepam or its 
analogs. Overall, however, the conclusions remained contradictory. 
In one study5, a flunitrazepam orientation similar to the CBM III 
poses was reported. Another study6 identified a diazepam pose 
vaguely similar to the CBM I pose, but apparently it had a very 
different interaction pattern owing to a different pocket topology. 
A pharmacophore-derived diazepam pose4 is in a position inter-
mediate between that of CBM II and CBM I. Most recently, bind-
ing modes vaguely resembling our CBM II were proposed based 
on modeling structures from a single template and covalently 
incorporated ligands7. In a study more concerned with zolpidem8, 
flunitrazepam poses featured the P conformation, which has been 
demonstrated to be inactive at the benzodiazepine-binding site 
(Supplementary Table 2).
A correct structure, however, should also be able to accommodate 
other ligands of this site from different structural classes. Thus, by 
using structure-based pharmacophore models derived from CBM I, 
we identified 5 out of 41 benzodiazepine-site ligands from different 
structural classes within the top 0.5% of hits of a benzodiazepine-
 focused set of decoy molecules (validation library), and we found 
five additional compounds within the top 2% and eight more in the 
top 10% of compounds (Supplementary Tables 9 and 10). Such 
enrichment factors, as well as the remaining false negatives (bind-
ers that are not ranked in the top range) are comparable to those 
obtained from docking into ligand-bound crystal structures30.
Virtual screening with the DUD database30 identified not only 
additional known benzodiazepine-site ligands present in this 
database but also a variety of other anticonvulsive compounds 
that so far have not been associated with GABAARs. By investi-
gating a commercially available subset for a possible interaction 
with the benzodiazepine-binding site of GABAARs, we identified 
several 3-hydroxyoxindole derivatives that were able to modu-
late GABA-induced currents in recombinant receptors via the 
 benzodiazepine-binding site. Furthermore, in a complementary 
approach, docking-based virtual screening studies using a mole-
cular protein-ligand IFP scoring method identified two additional 
new chemical scaffolds, which were proven active in [3H]flunitraze-
pam displacement assays. These data further support the validity of 
our  diazepam-bound structure of the benzodiazepine-binding site 
and demonstrate its suitability for structure-based drug discovery.
Further exploration of our in silico screening results presum-
ably will identify additional new ligand classes for the benzodiaz-
epine-binding site. Information from docking studies with other 
benzodiazepine-site ligands as well as molecular dynamics studies 
will identify the flexible and rigid parts of the pocket and define 
their ligand-pocket interactions as well as the mechanism of allo-
steric modulation of positive, negative and neutral interactors. The 
present structural models can also be used for modeling of the 
 benzodiazepine-binding sites of other GABAAR subtypes, and dock-
ing of unselective and subtype-selective ligands into their binding 
sites will ultimately lead to appropriate structural hypotheses that 
allow lead optimization and fragment-based drug design. Finally, 
our structures can be used for the modeling of similar extra cellular 
pockets of GABAARs34, again enabling lead optimization and 
drug discovery.
METHODS
Template characterization and preparation. Six AChBP structures (PDB  
codes 1I9B, 1UW6, 2BYN, 2BYQ, 2BYR and 2BYS)3 and two nAChR structures  
(PDB codes 2BG9 and 2QC1)3 were used as GABAA modeling templates 
(Supplementary Table 1) and structurally aligned with ProFit (http://www.bioinf.
org.uk/software/profit/). Only the extracellular domains of the structures with  
PDB codes 2BG9 and 2QC1 were considered, and both complete pentamers and  
individual subunits, reassembled into multitemplates, were used.
Alignment and model building. A multiple-sequence alignment with all templates’ 
extracellular domains and the GABAAR A1, G2 and B2 extracellular domains’ 
sequences was constructed with clustalX44 (Supplementary Scheme 1 and 
Supplementary Fig. 1). All templates were structurally aligned with secondary-
structure matching10. Individual pairwise sequence-to-structure alignments 
between the GABAAR subunits and all template subunits were obtained from the 
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Fugue server45. From these data, alignment variants of variable segments were con-
structed46, and homology models were built using Modeller. For the two subunits 
that contribute to the benzodiazepine-binding site, multiple template combinations 
were used to sample the structural variations in the templates.
Creation of input ligands. Seven 1,4-benzodiazepines and three 1,4-imidazo-
benzodiazepines were built in Molecular Operating Environment (MOE)  
version 2007.09 (http://www.chemcomp.com), using the M conformation of the 
seven-membered ring that is supported by experimental studies (Supplementary 
Table 2 and Supplementary Fig. 2).
FlexX docking. Diazepam was docked into all models using FlexX v2.0.3 (ref. 11). 
RING_MODE was set to 0 (constraining the ring conformation), and all other 
parameters were left in their default values. The pose output limit was set to 100 for 
each run for extensive conformational sampling.
FlexE docking. FlexE13 allows protein flexibility through an ensemble of super-
posed protein structures where similar parts of the structures are merged and  
dissimilar areas are treated as separate alternatives. To prepare such ensembles,  
we explored the rotameric states of A1 His101, A1 Tyr159, A1 Val202, A1 Ser204, 
A1 Ser205, A1 Thr206, A1 Tyr209, G2 Tyr58, G2 Phe77 and G2 Thr142 with the 
MOE tool Rotamer Explorer. In cases in which more than ten rotamers were 
obtained for a certain side chain, the ten most diverse rotamers were retained. Each 
benzodiazepine-binding-site ligand was docked into the ensemble structures of 
the corresponding homology models, generating 100 poses for each ligand. Finally, 
each ligand-receptor complex of the final pose pool was refined using the MOE 
tool LigX energy minimize. Lipophilic interactions of L1 and L3 both in docked 
and energy-minimized poses were calculated with the Scientific Vector Language 
(SVL)-exchange tool SCORING.SVL (http://svl.chemcomp.com).
CBM candidate selection. We defined the CBM of a molecular scaffold to  
require common orientation of the scaffold and common binding-site topology 
surrounding the common scaffold. Poses were superposed on the backbone atoms 
of the conserved protein segments using MOE to determine ligands’ common  
scaffold r.m.s. deviation. The SVL-exchange script MOL_RMSD.SVL (http://svl.
chemcomp.com) was used for the r.m.s. deviation computation of the common  
ligand scaffolds. Then, the Microsoft Excel add-in XLSTAT (http://www.xlstat.
com) was used for hierarchical clustering of the r.m.s. deviation dissimilarity 
matrix using the WARD method.
All protein heavy atoms within 4 Å of any heavy atom of the molecular scaffold 
in more than 90% of all poses of the cluster were considered part of the binding site 
of the common scaffold. The identified atoms and the common scaffold were used 
for the calculation of the bound-complex r.m.s. deviation, which was used to  
cluster the poses to candidate binding modes within their parent cluster.
Evaluating covalent incorporation and mutagenesis data. Poses were considered 
to fit experimental data if the smallest distance between the atoms in any of the 
following combinations was <6 Å: (i) any atom of the nitro group (flunitrazepam) 
and any atom of A1 His101 (ref. 17), (ii) the photoreactive nitrogen of the arylazido 
group (Ro15-4513) and A1 Tyr209 (ref. 22), (iii) any atom of the ester moiety 
(Ro15-8670) and side chain atoms of A1 Thr206 or the CB of G2 Ala79 (ref. 29) or 
(iv) the carbon of isothiocyanate (NCS)-substituted ligands and the sulfur of the 
respective cysteine mutant.
Generation and validation of pharmacophore models. Two structure-based  
pharmacophore models were created for each CBM, one derived from the  
top-scoring diazepam pose (pharmacophore D) and the other from the flumazenil  
pose, which showed the lowest bound-complex r.m.s. deviation from the 
diazepam-selected pose (pharmacophore F). Pharmacophore models were  
created using LigandScout 3.0 (ref. 32) (Supplementary Methods).
Validation library. For each of the 41 known benzodiazepine-binding-site ligands 
(Supplementary Table 10), protonation states near pH 7.0 were generated,  
resulting in 48 unique ligand protomers. For each of them, we created 50 decoy 
molecules that are physically similar but topologically distinct and thus should not 
bind the benzodiazepine site, resulting in a library of 2,400 decoys (Supplementary 
Methods). A conformational database was created with OMEGA v2.3.3 (http://
www.eyesopen.com/omega) and screened against pharmacophore D and  
pharmacophore F using LigandScout 3.0. Hits of each pharmacophore model  
were sorted according to scoring value, and enrichment factors33 were determined 
for the top 0.5%, 1%, 2%, 5% and 10% for each CBM.
Discovery library. To test the ability of the CBM I–derived pharmacophore model 
to identify new ligands, we generated three-dimensional conformations for the 
DUD30 databank (using OMEGA v2.4.1 (http://www.eyesopen.com/omega) and 
screened the resulting database of 93,597 compounds against pharmacophore D 
and pharmacophore F using LigandScout 3.0 (ref. 32). Compounds 15, 15a–15i 
and 18 were bought from Ambinter, and compounds 16 and 17 were bought  
from Asinex.
PLANTS docking and IFP scoring. PLANTS37 speedup settings were used twice 
to generate 15 poses for each compound in two independent docking runs: one 
run considering no side chain flexibility and another run allowing flexibility of the 
G2 Thr142 and A1 Thr206 side chains. The original ligand poses in the respective 
GABAA models were used to define reference IFPs, as described previously36,39. 
The cavity used for the IFP analysis consisted of all of the residues within 5 Å of 
the reference ligand. Standard IFP scoring parameters36 and a Tanimoto coefficient 
measuring IFP similarity with the reference ligand pose were used to rank the 
docking poses.
Experimental section: Recombinant GABAARs were expressed in X. laevis oocytes, 
and HEK cells and compound modulatory effects were investigated using the  
two-electrode voltage-clamp technique at a GABA concentration eliciting 3% of the 
maximum current34. Binding of compounds was investigated by [3H]flunitrazepam 
displacement studies47 in mouse cerebellar membrane preparations.
Accession codes. PDB: the previously determined crystal structures for  
A. californica AChBP, L. stagnalis AChBP, mouse nAChR, a nematode glutamate-
gated chloride channel, an nAChR structure and four AChBP structures are  
deposited under accession codes 2BYQ, 1UW6, 2QC1, 3RIF, 2BG9, 1I9B, 2BYN, 
2BYR and 2BYS, respectively. 
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Supplementary Methods - Supplementary Schemes 
 
* In an initial step, the GABAA receptor sequences are aligned against each template structure 
with a sequence-to-structure alignment algorithm such as TCoffee49 or FUGUE50 yielding 
seed alignments. 
** In the seed alignments, gap positions in variable regions are varied according to the User’s 
Manual of Modeller51, thus generating a variety of input alignments. 
*** The standard homology modelling script supplied with the program is combined with 
one or more template structures and input alignments to generate the homology models. 
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34 initial (in) models
FlexX, docking of diazepam 
against 34 rigid models
good L1L3.
a1 and g2 
contact
3 final models (f)
6 models (f + fv)
(M1-M6)
+3 final model variants  (fv)
14 intermediate (im) models
good L1L3.
a1 and g2 
contact
-20 models
-11 models
FlexE, docking of 6 ligands 
against 14 flexible models
Flexibilize tight regions
+3
-20
FlexE, docking of 9 ligands 
against 6 flexible models.
Energy minimization and L1L3 
calculation.
L1 and L3 above
median
4997 poses
-3534 
poses
L1 & L3 pool
(1463 poses)
1463 poses
-11
no
yes
no yes
yes
no
Supplementary Scheme 2 – Model selection workflow
(see also Supplementary Table 3)
(see also Supplementary Table 3)
(see also Supplementary Table 3)
(see Supplementary Table 7)
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(1463 poses)
Clustering
(„ligands comon scaffold RMSD“)
30 
parent
clusters
Analysis of clusters alternative workflow
cluster contain
all 5 „core- 
ligands“ cluster fit 
experimental
data*
-1128 
poses
CBM I
1463 poses
Clustering based on
- similar orientation of common scaffold      
   in pocket structure
yes
no yes
no
parent
cluster III
parent
cluster I
parent 
cluster II
Clustering 
(„bound complex RMSD“)
-1224 
poses
146 poses 96 poses
CBM III CBM II
Evaluation of CBM candidates 
(Table 1 and Supplementary Table 9)
CBM I
93 poses
96 poses39 poses 49 poses
Clustering based on
- similar orientation of common scaffold in
   pocket structure
- similar binding pocket topology around scaffold
*All poses were evaluated by geometric restraints (distance 
between a pocket amino acid residue and a ligand atom) derived 
from experimental findings (2), (3), (7), (8), (10) and (11), cited in 
Table 1 in main text. Only two clusters met all criteria at different 
levels of cutoff for the selected distances.
3 clusters
2 clusters
-184 
poses
-88 poses
Supplementary Scheme 3 -
Binding mode search
(see Supplementary Figs. 4 and 5)
(see Supplementary Table 7 and 8)
(see Supplementary Table 7 and 8)
(see Supplementary Scheme 2)
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CBM I, II, III
Pharmacophore D Pharmacophore F
Virtual screening of validation library 
against pharmacophore models and 
subsequent ranking according to 
pharmacophore fit score.
Generation of structure based 
pharmacophore models based on:
Diazepam pose Flumazenil pose
Decoy set.
2400 decoys
48 protomers 
of 41 actives
decoy setCBM I, II, III
Generation of a decoy set in analogy to DUD52. 41 benzodiazepine binding site 
ligands (48 unique ligand protomers*) were seeded in ZINC53 database. For each 
ligand protomer, 50 physically similar but topologically distinct decoys were 
selected, resulting in 2400 (48x50) decoy molecules.
Validation library: The 41 benzodiazepine binding site ligands (48 unique ligand 
protomers*) were spiked into 2400 molecules comprising decoy set.
1. physically similar
2. topologically distinct
Validation library: 
48 protomers of 41 actives + 
2400 decoys
ZINC53 
database
Enrichment of actives in the top 
0.5%, 1%, 2%, 5% and 10% was
computed for each CBM. 
(Supplementary Table 9)
CBM I CBM II CBM III
Top %
Score-sorted validation libraries
*As decoys were also property matched against net formal charge, for each of the 41 
ligands all protonation states near pH 7.0 were generated, resulting in 48 unique ligand 
protomers. These 48 ligand protomers were seeded into the ZINC-database as well as 
into the validation library.
Supplementary Scheme 4 – Retrospective validation of CBMs by virtual screening
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Pharmacophore D
(Suppl. Fig. 10a)
Pharmacophore F
(Suppl. Fig. 10b)
Virtual screening of DUD library (95 357 
cpds.) against pharmacophore models 
and subsequent ranking according to 
pharmacophore fit score.
Generation of structure based 
pharmacophore models based on:
Diazepam pose Flumazenil pose
Top 0.5% of score-sorted library
4 cpds. tested in assay
normalized IFP 
(diazepam) score
normalized IFP 
(flumazenil) score
Molecular docking based virtual 
screening of 1010 fragments and ranking 
of library according to normalized IFP 
score.
Calculate Interaction Fingerprints 
(IFPs) for : 
Diazepam pose Flumazenil pose
Top 30 hits of score-sorted library
10  cpds. tested in assay
DUD library 
(95 357 cpds.)
In-house db of 1010 
fragment-like cpds.
1 novel 
benzodiazepine 
binding site ligand 
identified
2 novel 
benzodiazepine 
binding site ligands 
identified
Diazepam pose Flumazenil pose
CBM I
Flumazenil pose
Supplementary Scheme 5 – CBM I binding hypotheses predict novel ligands
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Supplementary Table 1– Templates used in model construction 
PDB ID protein ligand 
1I9B54 Lymnea AChBP HEPES bound 
1UW655 Lymnea AChBP nicotine bound 
2BG956 Torpedo nAChR apo/ undefined 
2BYN57 Aplysia AChBP apo 
2BYQ57 Aplysia AChBP epibatidine bound 
2BYR57 Aplysia AChBP methyllycaconitine bound 
2BYS57 Aplysia AChBP lobeline bound 
2QC158 mouse nAChR alpha1 
extracellular domain 
alpha-bungarotoxin bound 
3RIF59 Nematode glutamate gated 
chloride channel 
glutamate 
Templates up to and including 2QC158 were considered in the original study. The 
selection criteria were conformational diversity and resolution of the structures. 
Bacterial homologs released after 2QC1 were examined as the study progressed, 
and it was felt that models based on these would not alter the overall outcome. Upon 
revision, 3RIF59and related structures were also integrated in retrospect and found to 
be in good agreement with our model. 
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Supplementary Table 2 - Affinities of the two atropisomers/ enantiomers of 1,4-
benzodiazepines at the BZ- binding site. 
reference: conformation M conformation P 
Salvadori et al. 
199760 
annotation in ref: cpd. 7a  annotation in ref: cpd. 7b  
affinity: 93 nM affinity: 1750 nM 
  
Gilman et al. 199061 annotation in ref: cpd. 11 annotation in ref: cpd. 12 
affinity: 420 nM affinity: > 1000 nM 
  
Gilman et al. 199362 annotation in ref: cpd. 31a annotaton in ref: cpd. 31b 
affinity: 26.5 nM affinity: 540 nM 
  
Gilman et al. 199362 annotation in ref: cpd. 25a annotation in ref: cpd. 25b 
affinity: 7 nM affinity: 220 nM 
  
Lee at al. 200863 
 
 
 
 
 
annotation in ref: 1a-R annotation in ref: 1a-S 
affinity: 46 nM affinity: 2320 nM 
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reference: conformation M conformation P 
Blount et al. 198364 annotation in ref: 5 annotation in ref: 6 
affinity: 6.4 nM affinity: 2320 nM 
  
In principle two 1,4-diazepine ring conformations are energetically plausible for 1,4-
benzodiazepines (conformation M and conformation P, see also Supplementary 
Fig. 2) and are hence present in small molecule crystal structures (CSD reference 
code:  ANIXAX, FLDAZP).A literature search provides strong and coherent evidence 
that conformation M of the 7-ring is present in the high affinity bound-state complex 
of 1,4-benzodiazepines in the benzodiazepine binding site of GABAAreceptors. 
Gilman et al.61,62 and Salvadori et al.60 applied a selective synthetic procedure that 
leads to stable 1,4-benzodiazepines in either conformation M or conformation P. 
The interconversion of the synthesized molecules into the other 7-ring conformation 
was hindered by a bulky tert-butyl group either at N1 (1,4-benzodiazepines) or C1’ 
(imidazobenzodiazepines). Lee et al.63 used a different approach to isolate 
atropisomers of 1,4-benzodiazepines. They first synthesized pyrimido[1,2-a][1,4]-
benzodiazepines that have a high interconversion energy. After synthesis, the 
racemat of pyrimido[1,2-a][1,4]-benzodiazepines (containing both, conformation M 
and conformation P) was then separated on a chiral column. Blount et al.64 
synthesized pyrroloimidazobenzodiazepines that were constrained to conformation 
M (S enantiomer) or conformation P (R enantiomer) by ring annelation. The 
isolated atropisomers/enantiomers deriving from either synthesis or chiral 
separation, were then tested in radio-ligand binding assays. The experiments clearly 
demonstrate that compounds in the conformation M exhibit a much higher affinity 
for the GABAA receptor benzodiazepine site than compounds in conformation P. 
Furthermore, studies based on 3-substituted 1,4-benzodiazepines came to the same 
conclusion that conformation M is the 1,4-diazepine conformation 64-66 in the high 
affinity bound-state complex. 
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Supplementary Fig. 1 – Variable alignment portions of the alignments used for 
M1-6. The alignment is based on a multi sequence alignment as presented 
previously67. The different templates were aligned using the SSM server68, and the 
sequence alignment adjusted to the 3D alignment where needed. The sequence to 
structure alignments in the variable regions were initially made by Fugue50, and 
additional variants were made as suggested in51. The relevant variable segments are 
shown here for those models, from which the final pose pool was derived. For the 
pre-loop E region, that has an indirect influence on pocket volume, the final 
alignments to 2BYQ and 2QC1 are indicated. For loop F all variants that were used 
in the final models are also shown. Only one loop C variant entered the final model 
pool. It should be noted that the alignment based restraints do not restrain the pocket 
geometry beyond the initial model building step, and thus do not strongly enter the 
final conformations seen in the energy minimized poses. M1 and M2 are based on 
the same choice of templates and alignment, so are M3 and M4, as well as M5 and 
M6. 
Gamma subunit, minus side variable segments: pre-loop E and loop F: 
 
Full alignment for the gamma subunit, M1-6:  
PDB_2byq_A     DDDD-KLHSQAN---LMRLKSDLFNR------SPMY-PGP----T--KDDPLTVTLGFTL 
gamma-2        QKSDD-DYEDYASNKTWVLTPKVPEGDVTVILNNLLEGYDNKLRPDIGVKPTLIHTDMYV 
PDB_2qc1_B     -KSE---HET-------RLEAKLFED----YSS-VVRPVEDH-----RE-IVQVTVGLQL 
 
 
PDB_2byq_A     QDIVKADSSTNEVDLVYYEQQRWKLNSLMWDPNEYGNITDFRTSAADIWTPDITAYSSTR 
gamma-2        NSIGPVNAINMEYTIDIFFAQTWYDRRLKFNSTI-KVLRLNSNMVGKIWIPDTFFRNSKK 
PDB_2qc1_B     IQLINVDEVNQIVTTNVRLKQQWVDYNLKWNPDDYGGVKKIHIPSEKIWRPDVVLYNNAD 
 
 
PDB_2byq_A      --PVQVL-SPQIAVVTHDGSVMFIPAQRLSFMCD---PTGVDSEEGATCAVKFGSWVYSG 
gamma-2         ADAHWITTPNRMLRIWNDGRVLYTLRLTIDAECQLQLHN--FPMDEHSCPLEFSSYGYPR 
PDB_2qc1_B      GDFAIVKFT--KVLLDYTGHITWTPPAIFKSYCE-IIVTH-FPFDEQNCSMKLGTRTYDG 
 
 
PDB_2byq_A      FEIDLKTD--TDQV-DLSSYYASSKYEILSATQTRQVQHYSCCP-EPYIDVNLVVKFRER 
gamma-2         EEIVYQWKRSSVEVGDTRSWR-LYQFSFVGLRNTTEVVKTTSG---DYVVMSVYFDLSRR 
PDB_2qc1_B      SAVAINPE--SDQP-DLSNFMESGEWVIKEARGWKHWVFYSCCPTTPYLDITYHFVMQRL 
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Alpha subunit, plus side variable segment: loop C: 
 
Full alignment for the alpha subunit, M1-6:  
PDB_2byq_A     ------DDDD--KLHSQANLMRLKSDLFNR-SPMY-PGPT--KDDPLTVTLGFTLQDIVK 
PDB_1uw6_A     ----EFDRAD--ILYNIRQ--TSRPDVIP----------TQRDR-PVAVSVSLKFINILE 
alpha-1        QPSQ-DELKDNTTVFTR-----ILDRLLDGYDNRLR---PGLGERVTEVKTDIFVTSFGP 
 
 
PDB_2byq_A     ADSSTNEVDLVYYEQQRWKLNSLMWDPNEYGNITDFRTSAADIWTPDITAYSSTR--PVQ 
PDB_1uw6_A     VNEITNEVDVVFWQQTTWSDRTLAWNSS--HSPDQVSVPISSLWVPDLAAYNAIS--KPE 
alpha-1        VSDHDMEYTIDVFFRQSWKDERLKFKGPM-TVLRLNNLMASKIWTPDTFFHNGKKSVAHN 
 
 
PDB_2byq_A     VL-SPQIAVVTHDGSVMFIPAQRLSFMCDPTG--VDSEEGATCAVKFGSWVYSGFEIDLK 
PDB_1uw6_A     VL-TPQLARVVSDGEVLYMPSIRQRFSCDVSG--VDTESGATCRIKIGSWTHHSREISVD 
alpha-1        MTMPNKLLRITEDGTLLYTMRLTVRAECPMHLED-FPMDAHACPLKFGSYAYTRAEVVYE 
 
 
PDB_2byq_A     TD---TDQV--DLSSYYASSKYEILSATQTRQVQHYSCCPEPYIDVNLVVKFRERR-- 
PDB_1uw6_A     PT---T-ENSDDSEYFSQYSRFEILDVTQKKNSVTYSCCPEAYEDVEVSLNFRKKGRS 
alpha-1        WTREPARSVVVAE-DGSRLNQYDLLGQTVDSGIVQSS-TG-EYVVMTTHFHLKRKIG- 
 
Below is a more up to date full alignment. The alignments used in this study can be 
derived by simply repositioning the gaps in the variable segments as indicated in the 
figure above. The full alignment is based on structural 3D alignment of the newest 
crystal structure59 (PDB_3rif_A) with the templates used for this study, and the 
GABAA receptor subunits then aligned against the structural alignment data. Future 
modeling studies should consider the 3RIF and related structures when modeling 
GABAA receptors.   
 
CLUSTAL X (1.83) multiple sequence alignment 
 
 
PDB_2byq_A      -DDDD-KLHSQAN-----LMR---------LKSDLFNRSPMY--PGPTK---D-D--PLT 
PDB_1uw6_A      ----------EFD-----RAD---------ILYNIRQ--TSRPDVIPTQ---R-DR-PVA 
PDB_2qc1_B      ---------KSEH-----ETR---------LEAKLFED-Y-SSVVRPVE---DHRE-IVQ 
PDB_3rif_A      ------------S-----DSK---------ILAHLFTSGY-DFRVRPPTD--N-GG-PVV 
1uw6_A          ----------EFD-----RAD---------ILYNIRQ--TSRPDVIP----TQRDR-PVA 
2byq_A          -DDDD-KLHSQAN-----LMR---------LKSDLFNR-SPMY-PGPT------KDDPLT 
alpha-1         -QPSQDELKDNTT-----VFTR--------ILDRLLDG--YDNRLR-----PGLGERVTE 
minu2byq_A      -DDDD-KLHSQAN-----LMR---------LKSDLFNR-SPMY-PGP----T--KDDPLT 
minu2qc1_B      ---------KSE------HET--------RLEAKLFED-YSS-VVRPVEDH---RE-IVQ 
gamma-2         QKSDD-DYEDYASNKTWVLTPKVPEGDVTVILNNLLEG--YDNKLR-----PDIGVKPTL 
                                              :   :                          
 
PDB_2byq_A      VTLGFTLQDIVKADSSTNEVDLVYYEQQRWKLNSLMWD--PNEYGNITDFRTS---AADI 
PDB_1uw6_A      VSVSLKFINILEVNEITNEVDVVFWQQTTWSDRTLAWN--SS--HSPDQVSVP---ISSL 
PDB_2qc1_B      VTVGLQLIQLINVDEVNQIVTTNVRLKQQWVDYNLKWN--PDDYGGVKKIHIP---SEKI 
PDB_3rif_A      VSVNMLLRTISKIDVVNMEYSAQLTLRESWIDKRLSYGVKGD--GQPDFVILTVGHQ--I 
1uw6_A          VSVSLKFINILEVNEITNEVDVVFWQQTTWSDRTLAWN--SS--HSPDQVSVP---ISSL 
2byq_A          VTLGFTLQDIVKADSSTNEVDLVYYEQQRWKLNSLMWD--PNEYGNITDFRTS---AADI 
alpha-1         VKTDIFVTSFGPVSDHDMEYTIDVFFRQSWKDERLKFKGPM-TVLRLNNLMAS-----KI 
minu2byq_A      VTLGFTLQDIVKADSSTNEVDLVYYEQQRWKLNSLMWD--PNEYGNITDFRTS---AADI 
minu2qc1_B      VTVGLQLIQLINVDEVNQIVTTNVRLKQQWVDYNLKWN--PDDYGGVKKIHIP---SEKI 
gamma-2         IHTDMYVNSIGPVNAINMEYTIDIFFAQTWYDRRLKFNSTI-KVLRLNSNMVG-----KI 
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                :  .: .  :   .               *    * :                      : 
 
PDB_2byq_A      WTPDITAYSSTR--PVQVL-----SPQIAVVTHDGSVMFIPAQRLSFMCDPT------GV 
PDB_1uw6_A      WVPDLAAYNAIS--KPEVL-----TPQLARVVSDGEVLYMPSIRQRFSCDVS------GV 
PDB_2qc1_B      WRPDVVLYNNADGDFAIVK-----F-TKVLLDYTGHITWTPPAIFKSYCEIIVTHFPFD- 
PDB_3rif_A      WMPDTFFPNEKQ--A-YKHTIDKPN-VLIRIHNDGTVLYSVRISLVLSCPMYLQYYPMD- 
1uw6_A          WVPDLAAYNAIS--KPEVL-----TPQLARVVSDGEVLYMPSIRQRFSCDVSG------V 
2byq_A          WTPDITAYSSTR--PVQVL-----SPQIAVVTHDGSVMFIPAQRLSFMCDPTG------V 
alpha-1         WTPDTFFHNGKKSVAHNMT----MPNKLLRITEDGTLLYTMRLTVRAECPMHLED----- 
minu2byq_A      WTPDITAYSSTR--PVQVL-----SPQIAVVTHDGSVMFIPAQRLSFMCDPTG------V 
minu2qc1_B      WRPDVVLYNNADGDFAIVKFT------KVLLDYTGHITWTPPAIFKSYCEIIVTH----- 
gamma-2         WIPDTFFRNSKKADAHWIT----TPNRMLRIWNDGRVLYTLRLTIDAECQLQLHN----- 
                * **    .                     :   * : :         *            
 
PDB_2byq_A      DSEEGATCAVKFGSWVYSGFEIDLKTD---TDQ--VDLSSYY-ASSK--YEILSATQTR- 
PDB_1uw6_A      DTESGATCRIKIGSWTHHSREISVDPT---TENS-DDSEYFS-QYSR--FEILDVTQKK- 
PDB_2qc1_B      ----EQNCSMKLGTRTYDGSAVAINPE---SDQ--PDLSNFM-ESGE--WVIKEARGWK- 
PDB_3rif_A      ----VQQCSIDLASYAYTTKDIEYLWK---EHSP-LQL-KVGLSSSLPSFQLTNTSTTYC 
1uw6_A          DTESGATCRIKIGSWTHHSREISVDPT--T-ENS-DDSEYFS-QYSR--FEILDVTQKK- 
2byq_A          DSEEGATCAVKFGSWVYSGFEIDLKTD---TDQV--DLSSYY-ASSK--YEILSATQTR- 
alpha-1         FPMDAHACPLKFGSYAYTRAEVVYEWT---REPARSVVVAE-DGSRLNQYDLLGQTVDS- 
minu2byq_A      DSEEGATCAVKFGSWVYSGFEIDLKTD---TDQV--DLSSYY-ASSK--YEILSATQTR- 
minu2qc1_B      FPFDEQNCSMKLGTRTYDGSAVAINPE---SDQP--DLSNFM-ESGE--WVIKEARGWK- 
gamma-2         FPMDEHSCPLEFSSYGYPREEIVYQWKRS------SVEVG-DTRSWR-LYQFSFVGLRNT 
                       * :.:.:  :    :                           : :         
 
PDB_2byq_A      QVQHYSCC-P-EPYIDVNLVVKFRER-R-------------------------------- 
PDB_1uw6_A      NSVTYSCC-P-EAYEDVEVSLNFRKK-GRS------------------------------ 
PDB_2qc1_B      HWVFYSCCPT-TPYLDITYHFVMQRL-P-------------------------------- 
PDB_3rif_A      T-SVTNT----GIYSCLRTTIQLKREFSFYLLQLYIPSCMLVIVSWVSFWFDRTAIPARV 
1uw6_A          NSVTYSCC-P-EAYEDVEVSLNFRKK-GRS------------------------------ 
2byq_A          QVQHYSCC-P-EPYIDVNLVVKFRER-R-------------------------------- 
alpha-1         -GIVQSS-TG--EYVVMTTHFHLKRKIG-------------------------------- 
minu2byq_A      QVQHYS-CCP-EPYIDVNLVVKFRER-R-------------------------------- 
minu2qc1_B      HWVFYS-CCPTTPYLDITYHFVMQRLP--------------------------------- 
gamma-2         TEVVKTT-SG--DYVVMSVYFDLSRRMG-------------------------------- 
                     .       *  :   . : .      
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Supplementary Fig. 2  - Depiction of the two possible 1,4-diazepine 
conformations in 5-aryl-1,4-benzodiazepines. The two conformations can be 
distinguished by the dihedral angle of the atoms C2-C3-N4-C5. Conformation M 
(Minus) has a negative dihedral angle while conformation P (Positive) has a positive 
angle. A plethora of evidence summarized in Supplementary Table 2 showed that 
conformation M of the 7-ring is present in the high affinity bound-state complex of 
1,4-benzodiazepines in the benzodiazepine binding site of GABAA receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Natta projection was used for illustrative issues and does not indicate stereochemistry. Solid or 
dashed wedged bonds represent bonds pointing above-the-plane or below-the-plane of the fused 
benzene ring of 1,4-benzodiazepines, respectively 
conformation P 
conformation M 
conformation M conformationP 
* 
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Supplementary Methods - Supplementary Text 
 
Generation of the validation library (Bz-focused decoy set). The selection of 
decoys was accomplished with an automated decoy generator (M.M.Mysinger and 
John J. Irwin, unpublished results) in an analogous manner to the DUD52. First, 41 
benzodiazepine binding site ligands (Supplementary Table 10) were seeded into 
the ZINC database53. Then ZINC compounds with Tanimoto coefficient (Tc) less 
than 0.5 (Daylight fingerprint) to any of the 41 ligands were selected, thus resulting in 
a subset of ZINC compounds that are topologically dissimilar to the ligands.  
Next, for each of the 41 seed compounds, all protonation states near pH 7.0 were 
generated, resulting in 48 unique ligand protomers. For each of them, 50 decoy 
molecules that property-match with the ligand protomer were selected from the 
subset of the ZINC library. The following six physicochemical descriptors were used 
for property-matching: molecular weight, number of hydrogen bond acceptors, 
number of hydrogen bond donors, number of rotatable bonds, logP, and the net 
formal charge69. 
Thus for all 41 benzodiazepine binding site ligands, compromising 48 unique ligand 
protomers, 2400 (48x50) decoys that are physically similar but topologically distinct 
to the ligands, were generated. To generate finally the validation library, the 48 
ligand protomers were added to the 2400 decoys (Supplementary Scheme 4). 
 
 
Structure-based pharmacophore models.  Pharmacophore models were created 
using LigandScout 3.070. Feature specific feature ranges were 2.2 – 4.2 Angstrom for 
H Bond Donor and H Bond Acceptor, respectively. Detected pharmacophoric 
features which are also represented in Fig. 1c were set to obligatory features. 
Exclusion volumes coats were added, using an Alpha C distance of 2-7 A and an 
Alpha C exclusion tolerance of 1.75 A. In case a hydrophobic and an aromatic 
feature were detected, only the more specific (aromatic) was kept. For the remaining 
parameters default values were used. 
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Ligand-based pharmacophore models. The structure of diazepam was taken and 
the following features were assigned using LigandScout 3.070: hydrophobic to the 
fused benzene ring (L1), hydrophobic to the pendant phenyl ring (L3), H-bond 
acceptor to the carbonyl oxygen atom (H1), and H-bond acceptor to the imino 
nitrogen atom (H2) (see also Fig. 1c, main text and below). For flumazenil, the 
pharmacophore feature assignment was as follows: hydrophobic to the fused 
benzene ring (L1), H-bond acceptor to the imidazo-nitrogen (H1) and H-bond 
acceptor to the carbonyl-oxygen (H2) (see also Fig. 1c, main text and below). 
 
Depiction of assigned features (green = hydrophobic, red = H-bond acceptor) to the 
structures of diazepam (left) and flumazenil (right), respectively.  
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Compound characterization data 
 
Characterization data for [3H]-Flunitrazepam: 
[3H]-Flunitrazepam was purchased from PerkinElmer with a purity of greater than 
97% as described by the vendor. 
Characterization data for cpd. 8 (Ro15-8670): 
High field 1H NMR was performed for cpd. 8 (see p. 19), demonstrating high purity     
(>98%) and identity of cpd. 8. HRMS C20H16ClN3O2: [M+1]calc: 366.8189 
[M+1]found: 366.8191.  
Characterization data for cpds. 15, 15a-c (active compounds): 
Compounds 15 and 15a-c were ordered from Ambinter. High field 1H NMR and      
13C NMR were performed for compounds 15 and 15a-c (see p. 20-27), demonstrating 
high purity (>98%) and identity of the active compounds.                      
Characterization data for cpds. 15d-i, 16-18 (inactive compounds): 
Compounds 15d-i and 18 were ordered from Ambinter, compounds 16 and 17 from 
Asinex. The inactive compounds 15d-i and 16-18 had a purity of greater than 90% as 
described by the vendors. 
Characterization data for cpds. 19 and 20 (active compounds): 
High field 1H NMR and 13C NMR was performed for cpd. 19 (p. 28 and 29). HRMS 
C14H14N3: [M+1]calc: 224.1187  [M+1]found: 224.1153. The purity of this compound 
was then verified in LCMS (see p. 30) analysis. 
High field 1H NMR and 13C NMR was performed for cpd. 20 (p. 31 and 32). HRMS 
C14H15N2OS: [M+1]calc: 259.0905  [M+1]found: 259.0866. The purity of this 
compound was then verified in LCMS (see p. 33) analysis. 
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Supplementary Results - Supplementary Tables 
 
 
Supplementary Table 3 – modeling parameters 
Main 
template(s) 
Screening 
stagesa 
Templates for the individual subunits 
and the interface geometryb Varied 
parameters 
in im f fv alpha gamma interface 
1I9B 4 3   1I9B 1I9B 1I9B Alignmentc 
2BYN 2 1   2BYN 2BYN 2BYN Alignmentc 
2BYS 3 2   2BYS 2BYS 2BYS Alignmentc 
2BYQ 
3 2 2d  
2e 
2BYQ 
2BYQ/1UW6 
2BYQ 
2BYQ 
2BYQ 
2BYQ 
Alignmentc 
Loop Cf 
2BG9 1    2BG9_C 2BG9_B 2BG9_CB  
2BYQ/2BG9 5 4   2BYQ 2BYQ 2BG9_CB Alignmentc 
2BYQ/2BG9 5    2BYQ 2BYQ 2BG9_BA Alignmentc 
2BYQ/2QC1 
1 1 1g  
1h 
2BYQ 
2BYQ/1UW6 
2QC1 
2QC1 
2BYQ 
2BYQ 
 
Loop Cf 
2BYN/2BG9 1    2BYN 2BYN 2BG9_CB  
2BYR/2BG9 5 1   2BYR 2BYR 2BG9_CB Alignmentc 
2BYR/2BG9 4    2BYR 2BYR 2BG9_BA Alignmentc 
a  From each set of main template(s), one or more model variants were derived by varying 
additional modeling parameters. Models used in the initial screen are denoted “in” (rigid 
docking of diazepam with FlexX71), “im” those that were retained for the intermediate 
screening (flexible docking of cpds. 1,3,4,5,8,9 with FlexE72, see text), “f” are the final 
models of the original set, and fv are the variants of the final models that were obtained by 
enhanced rotamer exploration and additional conformational sampling thus increasing the 
sampling density of the most promising pocket geometries (see also Supplementary 
Scheme 2). 
b  Subunit templates were 3D-aligned with the indicated template for the interface geometry, 
in order to sample the relative orientation of the two subunits. This was necessary for 
including the monomeric structure 2QC1 as template, and for investigating the interface 
geometries seen in the 2BG9 heteropentameric structure. The chain IDs used for the 
interface are indicated as 2BG9_C, etc. 
c  Alignment variants in the unconserved segments that contain “loops” C, E and F were 
constructed as recommended51 (see Supplementary Fig. 1) with standard 
procedures49,50,67,73 to generate a wide variety of initial geometries. 
d corresponds to models M1 and M3 in Supplementary Table 8. 
ecorresponds to models M2 and M4 in Supplementary Table 8. 
f  In order to improve the sampling of the flexible C-loop tip, the alpha subunit was also 
modeled by local multi-template restraints based on two templates51. 
g corresponds to model M5 in Supplementary Table 8. 
h corresponds to model M6 in Supplementary Table 8. 
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Models were constructed from a broad variety of templates and parameters to 
identify those best suited for the bound state complex of diazepam and analogues 
(see also Supplementary Schemes 1 and 2). Some models were eliminated prior 
to docking due to poor stereochemistry and are not included in the table. The full 
breadth of structural variety in the pocket was then investigated with the initial model 
pool, (in). Based on exploratory docking, models that were largely incapable of 
providing promising poses of diazepam with sufficient hydrophobic interaction with 
L1 and L3 and pocket forming residues were eliminated. To those that remained, 
docking was extended to multiple ligands and parameters were added to consider 
conformational and side chain flexibility (intermediate pool, im). Upon evaluation of 
the intermediate pool using criteria as mentioned above for each of the investigated 
ligands, three best performing final (f) models were selected. From those three 
models, additional final variants (fv) were built to increase the sampling density of 
the models of interest. This resulted in a total of six models providing the final pool of 
docking poses, the three best performing of the intermediate pool, and one variant of 
each of those. In the variants, a more extensive rotamer exploration at the subunit 
interface (see Methods, main text) and a more detailed exploration of loop C 
conformations were performed as indicated by RMSD analysis and visual inspection 
of “empty” patches in the sampling of pocket geometries. 
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Supplementary Table 4 – Model variability in pocket forming segments 
 total final compared to 3RIF-model 
 37 models 6 models 37 models 6 models 
Segment ave.(max) ave. (max) ave.(max) ave. (max)  
A-Loop (α1F99 – α1N102) 1.9 (3.6) 0.3 (0.4) 1.5 (2.1) 1.3 (1.7) 
B-Loop (α1Y159 – α1Y161) 1.4 (2.5) 0.3 (0.5) 0.9 (3.0) 0.5 (0.8) 
C-Loop (α1V202 – α1V211) 3.1 (5.4) 0.5 (0.6) 2.6 (4.9) 1.1 (1.2) 
G-Loop (γ2D56 – γ2N60) 1.9 (3.8) 0.7 (1.0) 2.0 (3.5) 0.7 (0.7) 
D-Loop (γ2F77 – γ2A79) 1.6 (3.4) 0.6 (0.8) 1.5 (2.9) 0.8 (0.8) 
E-Loop (γ2M130 –γ2 I133 
&γ2L140–γ2T142)   1.5 (2.5)  0.5 (0.7) 1.8 (2.3) 
 
1.8 (1.8) 
F-Loop (γ2185 - γ2194) 4.3 (11.9) 4.2 (6.1) 4.9 (8.8) 4.3 (6.1) 
Loops (A-E & G) 2.2 (3.3) 0.5 (0.8) 2.1 (3.3) 1.2 (1.3) 
Loops (A-F & G) 2.8 (6.0) 2.1 (3.0)   
 
Average and maximum backbone RMSD values of pocket forming segments. The 
entire model pool has much higher variability than the final pool, which has 
converged to optimally accommodate the ligands. Loop F is not engaged in any 
obvious interactions with the ligands investigated, and thus remains variable. Since 
loop F suffers from template uncertainty and undefined alignments, total pocket 
RMSD is computed with and without loop F contribution. The value without loop F 
contribution is a good measure for the variability obtained in the structurally 
conserved pocket portions. The loop C value is a measure for the observed flexibility 
(Supplementary Fig. 3).The total maximal RMSD for the final models is a measure 
for combined overall protein variability that cannot be reduced with the workflow 
used here. It contains uncertainty, possibly induced fit contributions and lack of 
information to narrow down further. After submission of this work, a new structure 
(PDB ID 3RIF) of a glutamate gated Cl- channel, which shares ~30% PID with 
GABAA receptor subunits, was released. The “hindsight” validation against the 
models based on the new 3RIF glutamate bound structure (last columns) shows that 
our final models are more similar to this new structure than to some of the initial 
models. 
Thus, our workflow successfully identified models, that are “better” in the light of this 
new X-ray structure over alternative models, that were equally valid in the light of the 
older structural data.    
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Supplementary Table 5 – Compound information 
type cpd. Name affinity 
(α1β2γ2) nM 
modulation 
corea 1 Diazepam74 12 positive modulator 
core 2 Ro07-522074 2 (not known) 
core 3 Flunitrazepam74 3 positive modulator 
core 4 Flurazepam75 62 positive modulator 
core 5 Ro 7-1986/176 --b (not known) 
accessoryc 6 8,9-benzofused77 55 positive modulator 
accessory 7 7,8-benzofused77 120 (not known) 
accessory 8 Ro15-867074 34 positive modulator 
accessory 9 CNS705678 29  positive modulator 
not used for 
dockingd 
10 7-NCS79 3170 positive modulator 
docked only in f 
and fv modelse 
11 Flumazenil74 0.61 null modulator 
not used for 
dockingd 
12 Ro15-451380 3.9 negative modulator 
not used for 
dockingd 
13 „Imid compound“81 10 null modulator 
not used for 
dockingd 
14 3-NCS82 340 --f 
a core ligands were those for which a more strict definition of common binding mode was used: 
At the level of clustering by ligand RMSD, all core ligands were mandatory for a cluster of poses 
to be considered CBM-parent candidate. At the level of clustering with bound complex RMSD a 
tighter overlap (2 Å) was requested of those. 
b This compound is coupled to chromatography beads as affinity bait. 
c accessory ligands were those that were not considered mandatory in the first cluster analysis, 
and permitted larger bound complex RMSD in the second analysis (2.5 Å). If a CBM contained 
them, they were also used for CBM evaluation by experimental evidence, see Table 1 in the 
main text. 
d those ligands were aligned by the common atoms’ coordinates with docked ligands to evaluate 
the resulting position in the light of experimental evidence, see Table 1 in the main text. 
eFlumazenil was only docked into the final models (f) of the original set, and into the fv, the 
variants of the final models (see Supplementary Table 3) 
fdata for wildtype α1β2γ2 receptor not shown, positive allosteric modulator in α1S205Cβ2γ2 and 
α1T206Cβ2γ2. 
 
 
Core ligands: In the workflow shown in Supplementary Scheme 3, only those 
clusters were retained that contained all core ligands. Core ligands are assumed to 
share common binding and interaction patterns due to similar structure and 
biological profile 
Accessory ligands: were used additionally and less tight similarity was required in 
the Supplementary Scheme 3 workflow to further restrict the possible binding 
geometries by bulkier ligands.   
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Supplementary Table 6 – bound complex defining and major interaction forming 
residues 
 alpha1 gamma2 
Parent  
clusteraI 
H101, Y159, S204, T206, Y209 Y58, N60, F77, T142 
Parent  
cluster II 
H101, S158, Y159, S204, S205, T206, Y209 Y58, N60, F77, T142 
Parent  
cluster III 
F99, H101, K155, G157, Y159, V202, Q203, 
S204, T206, Y209, V211 
Y58, F77, T142 
 
 L1 L3 H1 H1’ H2 L1 L3 H1 
CBM I Y159  
100% 
Y209  
100% 
H101   66% γ2 T206 S204 α1 F77 100% 
Y58   19% 
T142 
CBM II γ2 Y159  100% 
Y209  100% 
- S205 T206 Y58 100% 
F77 100% 
α1 - 
CBM III Y209    
94% 
F99      88% 
H101   48% 
Y159    74% 
Y209  100% 
H101 - H101 Y58   59% 
F77 100% 
α1 - 
a Parent cluster was selected by ”ligands common scaffold RMSD” clustering (see 
Supplementary Scheme 3). 
 
 
For each putative common binding geometry (parent cluster), that was identified 
based on the clustering by ligand overlap RMSD (“ligands common scaffold RMSD”), 
the major bound complex forming atoms were determined. The upper three lines list 
those amino acid residues that were selected, based on average distance to the 
ligands’ common scaffold in the respective cluster, to compute the cluster’s individual 
“bound complex RMSD” values. Many, but not all of those residues are found in the 
final CBM poses as major interaction partners. The last three lines list the residues 
that were subsequently found to provide major interactions in the final CBM poses, 
for the lipophilic L interactions the percentage of core poses featuring the respective 
interaction is also indicated. This shows the heterogeneity that is present in the 
individual CBM pose pools.  Please note: Our structural hypotheses do feature 
well defined geometries and interaction pattern, but also some residual 
scatter. Thus, no single pose can be considered “best” or “correct”, the final 
poses define a conformational space in which the “true structure” is assumed  
to be contained. 
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Supplementary Table 8 – distribution of poses in the final 
models 
  Model identifiera 
model: total M1 M2 M3 M4 M5 M6 
rawposepool 4997 886 827 843 790 856 795 
L1 & L3pool 1463 114 239 237 389 236 248 
Parent cluster I 146 4 23 5 48 12 54 
Parent cluster II 96 8 4 8 24 48 4 
Parent cluster III 93 20 14 13 3 12 31 
CBM I 96 0b 23 0 28 0 45 
CBM II 49 1 0 2 1 44 1 
CBM III 39 4 7 2 0 4 22 
aSeeSupplementary Table 3 and Supplementary Fig. 1 for the 
modeling parameters used in these six models.  
b It is worth noting that the final binding mode CBM I occurs only in the 
models M2, M4 and M6 which were obtained by extending the rotamer 
flexibility (see Methods), and were thus able to assume an 
energetically more favorable loop B conformation. This table thus 
illustrates that a binding mode can be missed by insufficient sampling 
of model flexibility. 
 
The Supplementary Tables 7 and 8 illustrate the effects of the different work steps 
on the poses obtained with a given ligand (Supplementary Table 7) or a given 
model (Supplementary Table 8).  See also Supplementary Scheme 3. 
 
 
 
 
 
 
Supplementary Table 7 – poses for each compound tracked through the 
workflow from pose pool to CBM 
  Compound number 
 total 1 2 3 4 5 6 7 8 9 
rawposepoola 4997 600 444 600 537 588 595 510 538 585 
L1 & L3poolb 1463 257 156 183 210 156 181 164 123 33 
Parent cluster I 146 34 13 21 11 9 21 18 16 3 
Parent cluster II 96 20 12 9 17 22 4 5 4 3 
Parent cluster III 93 15 4 11 13 13 9 13 15 0 
CBM I 96 21 5 16 11 9 14 6 12 2 
CBM II 49 5 1 2 11 22 3 1 3 1 
CBM III 39 4 2 6 6 13 5 1 2 0 
a The raw pose pool refers to the number of poses obtained with FlexE flexible docking and 
retaining up to 100 poses. 
b  L1& L3 pool denotes the pool of models that satisfies the lipophilic saturation requirements. 
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Supplementary Table 9 – Characterization and computational evaluation 
of CBM candidates 
    ligandsa CBM I  CBM II  CBM III 
Homogeneity of poses 
 number of core poses 1-5 62   41   31  
 average distance to centroid Å 
 
1-5 1.2 
 
  1.24 
 
  1.45 
 
 
 number of acc. ligands 6-9 all   all   3/4  
 number of acc. poses 6-9 34   8   8  
 average distance to centroid Å 6-9 1.55   1.81   1.14  
Major interactionsb (see Fig. 2) 
 L1 – hydrophobic feature 1-5 α1Y159,α1Y209  γ2Y58,γ2F77  α1Y209,γ2Y58, 
  L3 – hydrophobic feature 1-5 α1H101,γ2F77, 
γ2Y58 
 α1Y159,α1Y209  α1F99,α1H101, 
α1Y159,α1Y209 
 H1 – H-bond donor feature 1-5 γ2T142  none  α1H101 
 H1’ – H-bond donor feature 1-5 α1T206  α1S205  none 
 H2 – H-bond donor feature 1-5 α1S204  α1T206  α1H101 
Poses exhibiting side chain positions conserved in superfamily (see Supplementary Fig. 8) 
 Conserved α1Y159 1-5 all ++  none -  none - 
 Conserved α1Y209 1-5 all ++  28/41
c +  28/31c ++ 
Scoring performance 
 Top10 X-Score83 1-5 13 ++  none -  1 - 
 Top10 London dG84 1-5 13 ++  none -  1 - 
Enrichment factors85 in Retrospective virtual screening (Number of actives in database 
fraction) (see Supplementary Scheme 4) 
 EF    0.5%  24.8 (5) ++  14.9 (3) +  9.9 (2) + 
 EF    1.0%  14.9 (6) ++  7.4 (3) +  5.0 (2) + 
 EF    2.0%  12.2 (10) ++  3.7 (3) -  2.5 (2) - 
 EF    5.0%  6.9 (14) ++  3.0 (6) -  2.0 (4) - 
 EF  10.0%  4.5 (18) ++  1.7 (7) -  1.7 (7) - 
a only poses of the defined ligand(s) (Fig. 1c) are used for evaluation. 
b interactions were calculated using SCORING.SVL (http://svl.chemcomp.com). 
c number of poses fulfilling the respective criterion in relation to number of total poses in a CBM 
(see Supplementary Table 7 for total number of poses per ligand within a CBM). 
 
The slightly smaller average distance to centroid for CBM III results from the fact that 
this binding mode accommodates only three of the four accessory ligands. 
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Supplementary Table 10 – 41 known binders used in enrichment computation 
cpd. 2D structure annotation in 
reference 
 
Screening
CBMIa 
affinity 
(nM) 
11 
 
Flumazenil86 Top 0.5% 
 
0.8 
1 
 
Diazepam86 Top 0.5% 14 
21 
 
U-9777587 Top 0.5% 1.2 
22 
 
Clobazam88 Top 0.5% 170 
23 
 
Triazolam86 Top 0.5% 0.8 
24 
 
2b89 Top 1% 0.55 
25 
 
MRK-01690 - 0.92 
26 
 
Panadiplon91 - 1.56 
27 
 
3892 Top 10% 2.0 
28 
 
Eszopiclone93 Top 5% 50.1 
29 
 
1094 Top 5% 0.1 
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cpd. 2D structure annotation in 
reference 
Screening
CBMIa 
affinity 
(nM) 
30 
 
7195 Top 2% 0.14 
31 
 
1k96 Top 2% 13 
32 
 
RWJ-5120497 - 0.37 
33 
 
2b98 - 2.36 
34 
 
U-8557587 Top 2% 0.3 
35 
 
4aR99 Top 10% 7.5 
36 
 
1a100 Top 10% 21 
37 
 
23101 - 0.26 
38 
 
4k102 - 0.5 
39 
 
 
 
 
 
 
 
 
CL218,87286 - 57 
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cpd. 2D structure annotation in 
reference 
Screening
CBMIa 
affinity 
(nM) 
40 
 
Pyridodiindole86 - 1.1 
41 
 
CGS-821686 Top 10% 0.05 
42 
 
2i103 Top 2% 3.9 
43 
 
45104 - 2.8 
44 
 
41105 - 0.9 
45 
 
1e106 - 5.4 
46 
 
DU43028107 - 0.07 
47 
 
Ocinaplon108 Top 5% 1200 
48 
 
 
 
 
 
 
 
 
 
RU32698109 - 114 
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cpd. 2D structure annotation in 
reference 
Screening
CBMIa 
affinity 
(nM) 
49 
 
74110 - 5.5 
50 
 
21111 - 2.3 
51 
 
Zolpidem86 - 156 
52 
 
35112 Top 5% 0.51 
53 
 
14113 - 4.3 
54 
 
SL-651498114 - 6.8 
55 
 
2b115 - 0.2 
56 
 
GBLD-345116 - 0.9 
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cpd. 2D structure annotation in 
reference 
Screening
CBMIa 
affinity 
(nM) 
57 
 
Ro19-8022117 - 0.38 
58 
 
TPA023118 - 0.92 
59 
 
Pazinaclone119 - 0.7 
aRanking of benzodiazepine binding site ligands in the top 0.5%, 1%, 2%, 5% or 
10% of the score-sorted validation library. Rankings derive from virtual screening 
of the validation library (see Supplementary Methods) against the CBM I derived 
pharmacophore models (Supplementary Fig. 10). 
 
 
These 41 known benzodiazepine binding site ligands from different chemical classes 
were extracted from the literature. These ligands together with property-matched 
decoys (validation library, Supplementary Methods) were used in virtual screening 
against structure-based pharmacophore models of CBM I-III (Supplementary 
Scheme 4). For CBM I, data indicate that flumazenil, diazepam and benzodiazepine 
binding site ligands from 8 additional compound classes were ranked within the top 
2% of the score-sorted validation library by the structure based pharmacophores. 
The enrichment obtained (see also Supplementary Table 11) is comparable to the 
average enrichment obtained by docking of the DUD database into the 40 crystal 
structures52. 
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Supplementary Table 11 - Retrospective virtual screening results of the 
validation library (Bz-focused decoy set) using different methodologies 
EFa 
(%) 
pharmacophore models 2D fingerprint (FP) search shape-similarity 
searchf structure-
basedb 
(CBM I) 
ligand-
basedc 
pharmacophore 
FP  
(GpiDAPH3)d 
substructural 
FP  
(MACCS)e 
0.5% 24.8 (24.4) 14.9 (14.6) 24.9 (29.3) 29.8 (29.3) 19.8 (19.5) 
1% 14.9 (17.1) 7.5 (7.5) 17.4 (17.1) 14.9 (14.6) 12.4 (12.2) 
2% 12.2 (12.2) 5.0 (5.0) 11.2 (12.2) 8.5 (8.5) 6.1 (6.1) 
5% 6.9 (6.8) 2.0 (2.0) 6.5 (6.8) 4.0 (3.9) 2.5 (2.4) 
10% 4.5 (4.4) 1.7 (1.7) 4.0 (3.9) 3.0 (2.9) 2.2 (2.2) 
aEnrichment factors were calculated as described in Wei et al.85. Values in brackets represent 
enrichment factors calculated according to guideline of Nicholls et al.120. 
bStructure-based pharmacophore models were created using LigandScout 3.070 (see 
Supplementary Methods) based on CBM I diazepam (pharmacophore D, see Supplementary 
Fig. 10a) and flumazenil (pharmacophore F, Supplementary Fig. 10b) poses. Conformational 
database was created using default values within OMEGA toolkit release 2.3.3 
(http://www.openeye.com/omega). Virtual screening was performed within LigandScout 3.070. 
cLigand-based pharmacophore models were generated based on the structures of diazepam 
and flumazenil (Supplementary Methods) using LigandScout 3.070. Conformational database 
was created using default values within OMEGA toolkit release 2.3.3 
(http://www.openeye.com/omega). Virtual screening was performed within LigandScout 3.070. 
d2D-similarity search was performed with MOE (http://www.chemcomp.com) against diazepam 
and flumazenil, respectively, using the pharmacophore graph triangle fingerprints GpiDAPH3 
and Tanimoto similarity measure. 
e2D-similarity search was performed with MOE (http://www.chemcomp.com) against diazepam 
and flumazenil, respectively, using MACCS fingerprint keys and Tanimoto similarity measure. 
fShape-similarity search was performed with Phase (http://www.schrodinger.com) using 
diazepam and flumazenil as templates, respectively. Conformations were generated ‘on-the-fly’ 
within Phase. 
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Supplementary Table 12 – Prospective virtual screening ranks of novel and  
experimentally validated benzodiazepine site ligands and fragment hits 
cpd pharmacophore 
models 
2D fingerprint (FP) search shape-
similarity 
searche 
closest 2D-
similarity to  
BDZ site 
ligandf 
structure
-based 
(CBM I)a 
ligand 
basedb 
pharmacophore 
FP 
(GpiDAPH3c) 
substructural 
FP 
(MACCS)d 
15 245 5108 53333 48446 2866 0.50 (cpd. 37) 
15b 313 3441 58873 61808 597 0.56 (cpd. 46) 
19 - g - g -g  - g - g 0.58 (cpd. 39)  
20 - g - g -g - g - g 0.55 (cpd. 55) 
aRank in protein-based pharmacophore screening with LigandScout 3.070 based on CMB I 
diazepam (pharmacophore D, Supplementary Fig. 10a) and flumazenil (pharmacophore F, 
Supplementary Fig. 10b) poses. 
bLigand-based pharmacophore models were generated based on the structures of diazepam 
and flumazenil (Supplementary Methods) using LigandScout 3.070. Conformational 
database was created using default values within OMEGA toolkit release 2.3.3 
(http://www.openeye.com/omega). Virtual screening was performed within LigandScout 
3.070. 
cRank in 2D-similarity search of the DUD library against the template structures diazepam 
and flumazenil, using the pharmacophore graph triangle fingerprints GpiDAPH3 
(http://www.chemcomp.com). 
dRank in 2D-similarity search of the DUD library against the template structures diazepam 
and flumazenil, based on MACCS fingerprint keys. 
eRank in Phase(www.schrodinger.com) shape-based similarity search based on diazepam 
and flumazenil structures. 
fHighest Tanimoto similarity to any of the 41 benzodiazepine binding site ligands 
(Supplementary Table 10) based on MACCS fingerprint keys using Tanimoto similarity 
measure (ligand name with highest Tanimoto similarity score is give between brackets). 
gHits15 and 15b derive from screening of DUD database against protein-based 
pharmacophore models of CBM I, while hits 19 and 20 are identified by docking-based 
virtual screening of another library of 1010 fragment-like compounds using CBM I derived 
bound complexes. 
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The interaction finger print (IFP) bit string of the poses of 19 and 20 are compared to 
the reference IFP of diazepam and flumazenil. For reasons of clarity, the bit strings 
of only seven residues (out of 31) are shown as an example. Compounds 19 and 20 
place their phenyl and thiazol groups in the same tight aromatic binding pocket 
between α1H101, α1Y159, and α1Y209 as occupied by the L1 ring (Fig. 1c) of 
diazepam 1 and flumazenil 11, and stack with the same γ2F77 residue as the 
reference ligands as indicated by the IFP bit-string. Interestingly, the amide carbonyl 
oxygen atom of cpd 20 does not align with the ether carbonyl oxygen atom of 
flumazenil 11 but accepts an H-bond from the same α1S204 residue. The interaction 
types are color coded: gray – hydrophobic, dark green – aromatic face to face, bright 
green – aromatic edge to face, pink – H-bond (donor- acceptor) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 13 - Interaction Finger Prints  
  α1H101 α1Y159 α1S204 α1T206 
 diazepam 1  1 0 1 0 0 0 0 1 1 1 0 0 0 0 1 0 0 1 0 0 0 1 0 0 1 0 0 0 
 cpd 19 1 0 1 0 0 0 0 1 1 1 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 
 flumazenil 11 1 0 1 0 0 0 0 1 1 1 0 0 0 0 1 0 0 1 0 0 0 1 0 0 0 0 0 0 
 cpd 20 1 0 1 0 0 0 0 1 1 1 0 0 0 0 1 0 0 1 0 0 0 1 0 0 0 0 0 0 
 
                      
      
       α1Y209 γ2F77 γ2T142 
        diazepam 1  1 1 0 0 0 0 0 1 0 1 0 0 0 0 1 0 0 1 0 0 0 
        cpd 19 1 1 0 0 0 0 0 1 0 1 0 0 0 0 1 0 0 0 0 0 0 
        flumazenil 11 1 1 0 0 0 0 0 1 0 1 0 0 0 0 1 0 0 1 0 0 0 
        cpd 20 1 1 0 0 0 0 0 1 0 1 0 0 0 0 1 0 0 0 0 0 0 
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Supplementary Results - Supplementary Figures 
 
 
 
 
Supplementary Fig. 3 – View of the binding site from slightly below loop C to 
illustrate model variability. The left panel shows the entire model pool (each model in 
line ribbon mode), the right panel shows the final six models used in this study. By 
selecting models that provide docking poses with high lipophilic saturation regardless 
of the bound state geometry, the conformations of the loops A, B and C are reduced 
from a wide variety to a set of nearly identical models. Only one interface geometry 
(see Supplementary Table 3) was found to consistently feature well saturated 
lipophilic ligand interactions. In contrast, the minus side remains more uncertain: 
Segments D, E, and G are within 1 (Ångstrom) RMSD in all final models. But the 
region pre-E loop and the loop F region still vary significantly. This is consistent with 
the observation that these segments are not directly involved in diazepam binding. 
See Supplementary Table 4 for more detailed information on the variability in final 
models. 
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Supplementary Fig. 4 – Dendrogram of the cluster analysis by “ligands common 
scaffold RMSDs” (resulting in 30 parent clusters). Poses are grouped according to 
similar orientation of the common scaffold in the pocket structure.  In order to depict 
the variety in ligand orientation, six dissimilar clusters were selected (a, b, c, d, e 
and f) and their respective centroid pose is depicted in Supplementary Fig. 5.  Only 
three clusters, parent clusters I-III, fulfil the criteria for a common binding mode 
containing all core ligands. Parent cluster II corresponds to a, parent cluster I to d 
and parent cluster III to e in Supplementary Figs. 4 and 5.   
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Supplementary Fig. 5 – Sampling space of the initial pose pool represented by the 
centroids of six dissimilar clusters (a-f)  shown in Supplementary Figure 4. The 
letter on the images corresponds with that of the respective cluster. The alpha 
subunits are shown in yellow ribbon representation, the gamma subunits are shown 
in blue. In all panels, the 5-aryl-1,4-benzodizepine scaffold of the centroid pose is 
depicted. The L1 forming annealed benzene group is depicted in red and the L3 
forming pendant phenyl group in green. Color codes used for the 7-ring: gray for C 
and blue for N. 
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Supplementary Fig. 6 – CBM I poses of compound 5 comfortably accommodate the 
spacer that is linked to the N1-position of the diazepam scaffold and connecting the 
affinity chromatography bait with the agarose bead. However, substituents in the N1-
position, such as the diethylamine of flurazepam, are fully buried in CBM I poses and 
correspond to the small portion of the linker that is seen in this rendering to be 
buried.  
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Supplementary Fig. 7 – Representative CBM I poses of cpds. 1-9 
 
Nature Chemical Biology: doi:10.1038/nchembio.917
- 129 -
  
 
Supplementary Fig. 8 – (a) Rotamer constellation of α1Y159/Y209 (stick 
representation) as seen in CBM I poses,overlaid with all template structures used in 
this study. The templates’ amino acid side chains that are homologous with 
α1Y159/Y209 are shown in fine line. The Trp that is homologous with GABAAR 
α1Y159 is seen to be in a highly conserved position. The Y on loop C appears to 
feature a conserved rotamer throughout the superfamily, and probably serves as 
transduction element for induced fit conformations in the flexible loop C tip.  (b) 
Rotamer constellation of α1Y159/Y209 (stick representation) as seen in CBM II 
poses. The overlay shows that the pattern seen in other superfamily members is 
lacking, this GABAA R’ model features a completely distinct topology. Quantitative 
analysis of the entire pose pool that was used in this study revealed that the pattern 
depicted in panel (a) is unique for CBM I poses, and not found in any other pose 
group.  
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Supplementary Fig. 9 – (a) Representation of a CBM I  Ro15-8670 pose. 
Interestingly, in this pose, γ2F77 adapts a rotameric state that allows the 
phenylalanine-ring to interact with the ester-moiety. Consequently, a γ2F77Y 
mutation (hydroxyl-group position is indicated by the white star) would not clash the 
pendant phenyl ring (compare with Fig. 3, main text). This observation is completely 
consistent with the finding that in the γ2F77Y mutant only a 6x reduction was found 
for Ro15-8670, while a 250x reduction in affinity was seen for diazepam74 which 
lacks an ester-moiety. Thus, this structure offers a hypothesis for the observed 
affinity changes in F77Y by an induced fit. In contrast to the γ2F77Y mutation, the 
γ2F77I mutation should affect both ligands. Indeed this was shown by (b) inhibition of 
[3H]flunitrazepam binding by Ro 15-8670 in wild-type α1β3γ2 (black curve) and point 
mutated α1β3γ2F77I (red curve) receptors. Data represent means ± SD from an 
experiment performed in triplicate. The affinity loss of Ro15-8670 by the mutation 
γ2F77I is comparable to the one published for diazepam (see text), thus again 
supporting similar interactions. 
a 
b 
c 
* 
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(c)The same CBM I Ro15-8670 from another perspective focusing on the position of 
the ester moiety. This pose contains strong structural support for several findings. A 
α1T206V substitution in loop C caused a 7-fold reduction in affinity of diazepam, but 
a 16-fold increase in affinity of Ro15-867074. Assuming a common binding mode of 
these compounds, in CBM I the imine nitrogen of the seven membered ring of 
diazepam or Ro15-8670 forms a hydrogen bond with α1S204, and the imidazo-
group of Ro15-8670 interacts with γ2T142. The carbonyl oxygen of diazepam with its 
two lone pairs interacts with α1T206, as previously proposed as well as with γ2T142 
(see also main text Fig. 3). In receptors containing the α1T206V mutation, diazepam 
is losing an H-bond partner and Ro15-8670 is gaining hydrophobic interactions from 
the T206V mutant as the valine makes favourable contacts with the ester moiety. 
This is visualized by an interaction potential map created with a MOE built-in 
application which draws upon the work of GRID121,122. The map graphically illustrates 
where a hydrophobic probe (dashed green) or an H-bond donating probe (dashed 
magenta) has favourable interactions with the molecular surface, here depicted for 
the ester-moiety of Ro15-8670. While the areas in plane of the ester-moiety favour 
hydrophilic interactions, the areas above and below this moiety favour hydrophobic 
interactions. Based on this map, the finding that the α1T206V mutation leads to a 
16fold gain in affinity is fully consistent with the pose, as the –OH group of the wt 
T206 “penetrates” the hydrophobic interaction surface, indicating an unfavourable 
interaction potential.  
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Supplementary Fig. 10 – Depiction of structure-based pharmacophore models 
based on CBM I diazepam (panel a, Pharmacophore D) and flumazenil (panel b, 
Phamacophore F) bound structures. Yellow spheres represent hydrophobic features, 
blue slices represent aromatic features and red arrows indicate h-bond acceptor 
features. Grey spheres represent exclusion volumes and roughly resemble steric 
binding site topology.  
 
b 
a 
b 
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Supplementary Fig. 11 – Structure of the 3-hydroxy-oxindole 15, and its action on 
GABAA receptors.(a) Chemical structure. (b) Inhibition of 2nM [3H]flunitrazepam 
binding to mouse cerebellar membranes by 15. Data represent means±SD from 
three experiment performed in triplicate (c) Dose response curve of 15 on GABA 
EC3 currents in the absence (■), or presence of100nM flumazenil (●), obtained from 
Xenopus laevis oocytes expressing recombinant GABAA receptors composed of 
α1β3γ2 subunits. Data represent means±SD from three separate experiments 
performed in different oocytes from 2 different batches. It can be seen that the 
modulatory action of 15 is incompletely blocked by co-application of the 
benzodiazepine null modulator flumazenil. (d) Effect of compound 15 at 1 µM and 10 
µM concentration on α1β3 and α1β3γ2 (rat) receptors recombinantly expressed in 
Xenopus laevis oocytes at GABA EC3 (n=4-6). The gamma-subunit independent 
action seen in α1β3 receptors indicates a second site of interaction of this compound 
with these receptors and is consistent with the incomplete flumazenil sensitivity of 
modulation seen in (c). 
 
 
 
 
 
 
 
 
  
Nature Chemical Biology: doi:10.1038/nchembio.917
- 134 -
Supplementary References 
 
 
49. Notredame, C., Higgins, D.G. & Heringa, J. T-Coffee: A novel method for fast and 
accurate multiple sequence alignment. J. Mol. Biol. 302, 205-217 (2000). 
50. Shi, J., Blundell, T.L. & Mizuguchi, K. FUGUE: sequence-structure homology 
recognition using environment-specific substitution tables and structure-dependent 
gap penalties. J. Mol. Biol. 310, 243-257 (2001). 
51. Sali, A. & Blundell, T.L. Comparative protein modelling by satisfaction of spatial 
restraints. J. Mol. Biol. 234, 779-815 (1993). 
52. Huang, N., Shoichet, B.K. & Irwin, J.J. Benchmarking sets for molecular docking. J. 
Med. Chem. 49, 6789-6801 (2006). 
53. Irwin, J.J. & Shoichet, B.K. ZINC--a free database of commercially available 
compounds for virtual screening. J. Chem. Inf. Model. 45, 177-182 (2005). 
54. Brejc, K. et al. Crystal structure of an ACh-binding protein reveals the ligand-binding 
domain of nicotinic receptors. Nature 411, 269-276 (2001). 
55. Celie, P.H.N. et al. Nicotine and carbamylcholine binding to nicotinic acetylcholine 
receptors as studied in AChBP crystal structures. Neuron 41, 907-914 (2004). 
56. Unwin, N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. 
J. Mol. Biol. 346, 967-989 (2005). 
57. Hansen, S.B. et al. Structures of Aplysia AChBP complexes with nicotinic agonists 
and antagonists reveal distinctive binding interfaces and conformations. EMBO J. 24, 
3635-3646 (2005). 
58. Dellisanti, C.D., Yao, Y., Stroud, J.C., Wang, Z. & Chen, L. Crystal structure of the 
extracellular domain of nAChR alpha1 bound to alpha-bungarotoxin at 1.94 A 
resolution. Nat. Neurosci. 10, 953-962 (2007). 
59. Hibbs, R.E. & Gouaux, E. Principles of activation and permeation in an anion-
selective Cys-loop receptor. Nature 474, 54-60 (2011). 
60. Salvadori, P., Bertucci, C., Ascoli, G., Uccello-Barretta, G. & Rossi, E. Direct 
resolution, characterization, and stereospecific binding properties of an atropisomeric 
1,4-benzodiazepine. Chirality 9, 495-505 (1997). 
61. Gilman, N.W., Rosen, P., Earley, J.V., Cook, C. & Todaro, L.J. Atropisomers of 1,4-
benzodiazepines. Synthesis and resolution of a diazepam-related 1,4-benzodiazepine. 
J. Am. Chem. Soc. 112, 3969-3978 (1990). 
62. Gilman, N.W. et al. Atropisomers of 1,4-benzodiazepines. 2. Synthesis and resolution 
of imidazo[1,5-a][1,4]benzodiazepines. J. Org. Chem. 58, 3285-3298 (1993). 
63. Lee, S. et al. Axial chirality and affinity at the GABA(A) receptor of pyrimido[1,2-
a][1,4]benzodiazepines and related compounds. Bioorg. Med. Chem. 16, 9519-9523 
(2008). 
64. Blount, J.F., Fryer, R.I., Gilman, N.W. & Todaro, L.J. Quinazolines and 1,4-
benzodiazepines. 92. Conformational recognition of the receptor by 1,4-
benzodiazepines. Mol. Pharmacol. 24, 425-428 (1983). 
65. Simonyi, M.s. et al. Conformational recognition by central benzodiazepine receptors. 
Bioorg. Chem. 18, 1-12 (1990). 
66. Maksay, G., Tegyey, Z. & Simonyi, M. Central benzodiazepine receptors: in vitro 
efficacies and potencies of 3-substituted 1,4-benzodiazepine stereoisomers. Mol. 
Pharmacol. 39, 725-732 (1991). 
Nature Chemical Biology: doi:10.1038/nchembio.917
- 135 -
67. Ernst, M., Bruckner, S., Boresch, S. & Sieghart, W. Comparative models of GABAA 
receptor extracellular and transmembrane domains: important insights in 
pharmacology and function. Mol. Pharmacol. 68, 1291-1300 (2005). 
68. Krissinel, E. & Henrick, K. Secondary-structure matching (SSM), a new tool for fast 
protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 
60, 2256-2268 (2004). 
69. Mysinger, M.M. & Shoichet, B.K. Rapid context-dependent ligand desolvation in 
molecular docking. J. Chem. Inf. Model. 50, 1561-73 (2010). 
70. Wolber, G. & Langer, T. LigandScout: 3-D pharmacophores derived from protein-
bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 45, 160-
169 (2005). 
71. Rarey, M., Kramer, B., Lengauer, T. & Klebe, G. A fast flexible docking method 
using an incremental construction algorithm. J. Mol. Biol. 261, 470-489 (1996). 
72. Claussen, H., Buning, C., Rarey, M. & Lengauer, T. FlexE: efficient molecular 
docking considering protein structure variations. J. Mol. Biol. 308, 377-395 (2001). 
73. Larkin, M.A. et al. Clustal W and Clustal X version 2.0. Bioinformatics 23, 2947-
2948 (2007). 
74. Sigel, E., Schaerer, M.T., Buhr, A. & Baur, R. The benzodiazepine binding pocket of 
recombinant alpha1beta2gamma2 gamma-aminobutyric acidA receptors: relative 
orientation of ligands and amino acid side chains. Mol. Pharmacol. 54, 1097-1105 
(1998). 
75. Sieghart, W. & Schuster, A. Affinity of various ligands for benzodiazepine receptors 
in rat cerebellum and hippocampus. Biochem. Pharmacol. 33, 4033-4038 (1984). 
76. Sigel, E., Mamalaki, C. & Barnard, E.A. Isolation of a GABA receptor from bovine 
brain using a benzodiazepine affinity column. FEBS Lett. 147, 45-48 (1982). 
77. Zhang, W., Koehler, K.F., Harris, B., Skolnick, P. & Cook, J.M. Synthesis of benzo-
fused benzodiazepines employed as probes of the agonist pharmacophore of 
benzodiazepine receptors. J. Med. Chem. 37, 745-757 (1994). 
78. Kilpatrick, G.J. et al. CNS 7056: a novel ultra-short-acting Benzodiazepine. 
Anesthesiology 107, 60-66 (2007). 
79. Berezhnoy, D. et al. On the benzodiazepine binding pocket in GABAA receptors. J. 
Biol. Chem. 279, 3160-3168 (2004). 
80. Kucken, A.M., Teissére, J.A., Seffinga-Clark, J., Wagner, D.A. & Czajkowski, C. 
Structural requirements for imidazobenzodiazepine binding to GABA(A) receptors. 
Mol. Pharmacol. 63, 289-296 (2003). 
81. Tan, K.R. et al. Proximity-accelerated chemical coupling reaction in the 
benzodiazepine-binding site of gamma-aminobutyric acid type A receptors: 
superposition of different allosteric modulators. J. Biol. Chem. 282, 26316-26325 
(2007). 
82. Tan, K.R., Baur, R., Charon, S., Goeldner, M. & Sigel, E. Relative positioning of 
diazepam in the benzodiazepine-binding-pocket of GABA receptors. J. Neurochem. 
111, 1264-1273 (2009). 
83. Wang, R., Lai, L. & Wang, S. Further development and validation of empirical 
scoring functions for structure-based binding affinity prediction. J. Comput. Aided 
Mol. Des. 16, 11-26 (2002). 
84. Labute, P. The generalized Born/volume integral implicit solvent model: Estimation 
of the free energy of hydration using London dispersion instead of atomic surface 
area. J. Comput. Chem. 29, 1693-1698 (2008). 
Nature Chemical Biology: doi:10.1038/nchembio.917
- 136 -
85. Wei, B.Q., Baase, W.A., Weaver, L.H., Matthews, B.W. & Shoichet, B.K. A model 
binding site for testing scoring functions in molecular docking. J. Mol. Biol. 322, 339-
355 (2002). 
86. Huang, Q. et al. Pharmacophore/receptor models for GABA(A)/BzR subtypes 
(alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a 
comprehensive ligand-mapping approach. J. Med. Chem. 43, 71-95 (2000). 
87. Im, W.B. et al. Differential affinity of dihydroimidazoquinoxalines and 
diimidazoquinazolines to the alpha 1 beta 2 gamma 2 and alpha 6 beta 2 gamma 2 
subtypes of cloned GABAA receptors. Br. J. Pharmacol. 110, 677-680 (1993). 
88. Ulrich Schacht, G.B. Effects of clobazam in benzodiazepine-receptor binding assays. 
Drug Dev. Res. S1, 83-93 (1982). 
89. Jennings, A.S. et al. Imidazo[1,2-b][1,2,4]triazines as alpha2/alpha3 subtype selective 
GABA A agonists for the treatment of anxiety. Bioorg. Med. Chem. Lett. 16, 1477-
1480 (2006). 
90. Atack, J.R. et al. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-
yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylme thoxy)-pyrazolo[1,5-d]-[1,2,4]triazine 
(MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. J. 
Pharmacol. Exp. Ther. 331, 470-484 (2009). 
91. Sethy, V.H. & Oien, T.T. Role of cGMP in the mechanism of anxiolytic activity of U-
78875. Pharmacol. Biochem. Behav. 39, 379-382 (1991). 
92. Mickelson, J.W. et al. High-affinity alpha-aminobutyric acid A/benzodiazepine 
ligands: synthesis and structure-activity relationship studies of a new series of 
tetracyclic imidazoquinoxalines. J. Med. Chem. 39, 4654-4666 (1996). 
93. Hanson, S.M., Morlock, E.V., Satyshur, K.A. & Czajkowski, C. Structural 
requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid 
type-A (GABAA) receptor are different. J. Med. Chem. 51, 7243-7252 (2008). 
94. Lewis, R.T. et al. A pyridazine series of alpha2/alpha3 subtype selective GABA A 
agonists for the treatment of anxiety. J. Med. Chem. 49, 2600-2610 (2006). 
95. Cox, E.D. et al. Synthesis and evaluation of analogues of the partial agonist 6-
(propyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic acid ethyl ester (6-PBC) 
and the full agonist 6-(benzyloxy)-4-(methoxymethyl)-beta-carboline-3-carboxylic 
acid ethyl ester (Zk 93423) at wild type and recombinant GABAA receptors. J. Med. 
Chem. 41, 2537-2552 (1998). 
96. Primofiore, G. et al. 3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic 
heteroaromatic derivatives as a new class of benzodiazepine receptor ligands. J. Med. 
Chem. 43, 96-102 (2000). 
97. Dubinsky, B. et al. 5-ethoxymethyl-7-fluoro-3-oxo-1,2,3,5-
tetrahydrobenzo[4,5]imidazo[1,2a]pyr idine-4-N-(2-fluorophenyl)carboxamide (RWJ-
51204), a new nonbenzodiazepine anxiolytic. J. Pharmacol. Exp. Ther. 303, 777-790 
(2002). 
98. Wegner, F. et al. GABAA receptor pharmacology of fluorinated derivatives of the 
novel sedative-hypnotic pyrazolopyrimidine indiplon. Eur. J. Pharmacol. 580, 1-11 
(2008). 
99. Guerrini, G. et al. Benzodiazepine receptor ligands. 8: synthesis and pharmacological 
evaluation of new pyrazolo[5,1-c] [1,2,4]benzotriazine 5-oxide 3- and 8-disubstituted: 
high affinity ligands endowed with inverse-agonist pharmacological efficacy. Bioorg. 
Med. Chem. 14, 758-775 (2006). 
100. Primofiore, G. et al. Novel N-(arylalkyl)indol-3-ylglyoxylylamides targeted as ligands 
of the benzodiazepine receptor: synthesis, biological evaluation, and molecular 
Nature Chemical Biology: doi:10.1038/nchembio.917
- 137 -
modeling analysis of the structure-activity relationships. J. Med. Chem. 44, 2286-
2297 (2001). 
101. Lager, E. et al. 4-quinolone derivatives: high-affinity ligands at the benzodiazepine 
site of brain GABA A receptors. synthesis, pharmacology, and pharmacophore 
modeling. J. Med. Chem. 49, 2526-2533 (2006). 
102. Takada, S. et al. Synthesis and structure--activity relationships of fused 
imidazopyridines: a new series of benzodiazepine receptor ligands. J. Med. Chem. 39, 
2844-2851 (1996). 
103. Selleri, S. et al. Synthesis and benzodiazepine receptor affinity of pyrazolo[1,5-
a]pyrimidine derivatives. 3. New 6-(3-thienyl) series as alpha 1 selective ligands. J. 
Med. Chem. 46, 310-313 (2003). 
104. Primofiore, G. et al. High affinity central benzodiazepine receptor ligands: synthesis 
and biological evaluation of a series of phenyltriazolobenzotriazindione derivatives. J. 
Med. Chem. 48, 2936-2943 (2005). 
105. Kahnberg, P. et al. Refinement and evaluation of a pharmacophore model for flavone 
derivatives binding to the benzodiazepine site of the GABA(A) receptor. J. Med. 
Chem. 45, 4188-4201 (2002). 
106. De Sarro, G. et al. Benzodiazepine receptor affinities, behavioral, and anticonvulsant 
activity of 2-aryl-2,5-dihydropyridazino[4,3-b]indol- 3(3H)-ones in mice. Pharmacol. 
Biochem. Behav. 65, 475-487 (2000). 
107. Marcel, D., Bardelay, C. & Hunt, P.F. Lesion of noradrenergic neurones with DSP4 
does not modify benzodiazepine receptor binding in cortex and hippocampus of rat. 
Neuropharmacology 25, 283-286 (1986). 
108. Lippa, A. et al. Selective anxiolysis produced by ocinaplon, a GABA(A) receptor 
modulator. Pro.c Natl. Acad. Sci. U S A 102, 7380-7385 (2005). 
109. Ogris, W. et al. Affinity of various benzodiazepine site ligands in mice with a point 
mutation in the GABA(A) receptor gamma2 subunit. Biochem. Pharmacol. 68, 1621-
1629 (2004). 
110. Bare, T.M. et al. Synthesis and structure-activity relationships of a series of 
anxioselective pyrazolopyridine ester and amide anxiolytic agents. J. Med. Chem. 32, 
2561-2573 (1989). 
111. Szekeres, H.J. et al. 3,4-Dihydronaphthalen-1(2H)-ones: novel ligands for the 
benzodiazepine site of alpha5-containing GABAA receptors. Bioorg. Med. Chem. 
Lett. 14, 2871-2875 (2004). 
112. Carling, R.W. et al. 3-phenyl-6-(2-pyridyl)methyloxy-1,2,4-triazolo[3,4-
a]phthalazines and analogues: high-affinity gamma-aminobutyric acid-A 
benzodiazepine receptor ligands with alpha 2, alpha 3, and alpha 5-subtype binding 
selectivity over alpha 1. J. Med. Chem. 47, 1807-1822 (2004). 
113. Chambers, M.S. et al. 6,7-Dihydro-2-benzothiophen-4(5H)-ones: a novel class of 
GABA-A alpha5 receptor inverse agonists. J. Med. Chem. 45, 1176-1179 (2002). 
114. Griebel, G. et al. SL651498: an anxioselective compound with functional selectivity 
for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) 
receptors. J. Pharmacol. Exp. Ther. 298, 753-768 (2001). 
115. Crawforth, J. et al. Tricyclic pyridones as functionally selective human GABAA alpha 
2/3 receptor-ion channel ligands. Bioorg. Med. Chem. Lett. 14, 1679-1682 (2004). 
116. Davies, L.P., Barlin, G.B., Ireland, S.J. & Ngu, M.M. Substituted imidazo[1,2-
b]pyridazines. New compounds with activity at central and peripheral benzodiazepine 
receptors. Biochem. Pharmacol. 44, 1555-1561 (1992). 
Nature Chemical Biology: doi:10.1038/nchembio.917
- 138 -
117. Mehta, A.K. & Shank, R.P. Interaction of abecarnil, bretazenil, and RO 19-8022 with 
diazepam-sensitive and -insensitive benzodiazepine sites in the rat cerebellum and 
cerebral cortex. Life Sci. 57, 2215-2222 (1995). 
118. Atack, J.R. et al. TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-
ylmethoxy)-3-(2-fluor ophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective 
for alpha2- and alpha3-containing GABAA receptors, is a nonsedating anxiolytic in 
rodents and primates. J. Pharmacol. Exp. Ther. 316, 410-422 (2006). 
119. Wada, T. et al. Pharmacologic characterization of a novel non-benzodiazepine 
selective anxiolytic, DN-2327. Jpn. J. Pharmacol. 49, 337-349 (1989). 
120. Jain, A.N. & Nicholls, A. Recommendations for evaluation of computational 
methods. J. Comput. Aided Mol. Des. 22, 133-139 (2008). 
121. Boobbyer, D.N., Goodford, P.J., McWhinnie, P.M. & Wade, R.C. New hydrogen-
bond potentials for use in determining energetically favorable binding sites on 
molecules of known structure. J.Med. Chem. 32, 1083-1094 (1989). 
122. Goodford, P.J. A computational procedure for determining energetically favorable 
binding sites on biologically important macromolecules. J. Med. Chem. 28, 849-857 
(1985). 
 
 
Nature Chemical Biology: doi:10.1038/nchembio.917
- 139 -
II. A residue close to α1 loop F disrupts modulation of 
GABAA receptors by benzodiazepines while their 
binding is maintained 
 
 
 
 
 
 
 
Contribution of the thesis author to this article: 
The author of the thesis performed a computational analysis on a homology model of the 
α1β2γ2 GABAA receptor (homology models were generated by Margot Ernst and Werner 
Sieghart).  In more detail the intra molecular protein-protein H-bond networks in 
proximity to the benzodiazepine binding site of the GABAA receptor model were 
investigated. The results aided in the selection of α1Y168 as a candidate for receptor 
mutation.   
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In the family of ligand-activated ion channels that includes
nicotinic acetylcholine receptors, GABA type A (GABAA)
receptors, glycine receptors and serotonin 5-HT3 receptors,
binding of the agonist is followed by a conformational change
leading to the opening of the inherent ion channel. The
mechanism by which binding leads to channel opening is
highly controversial. One concept envisages a direct func-
tional link between the binding site and the channel region by
a random coil polypeptide stretch called loop F. The function
of loop F in linking binding and gating is disputed some
observations pointing in favor of the hypothesis (Lyford et al.
2003; Newell and Czajkwski 2003; Hansen et al. 2005;
Thompson et al. 2006; Williams et al. 2009) and others
against (Khatri et al. 2009; Pless and Lynch 2009). This
controversy has recently been reviewed (Khatri and Weiss
2010). Beside loop F, residues located at the outer membrane
surface have been implicated in the binding/gating process
(Sigel et al. 1999; Brejc et al. 2001; Kash et al. 2003;
Lummis et al. 2005; Unwin 2005; Mercado and Czajkowski
2006), but it is far from clear how the information of binding
site occupancy is transferred to these residues.
GABA type A receptors are pseudosymmetric proteins
consisting of ﬁve subunits, thus containing ﬁve F loops. The
pharmacological properties of a GABAA receptor depend on
subunit composition (Sieghart and Sperk 2002) and arrange-
ment (Minier and Sigel 2004). In this study we concentrated
on the major form of adult GABAA receptors a1b2c2
(Macdonald and Olsen 1994; Rabow et al. 1995; Sieghart
1995), whose subunits are arranged a1c2b2a1b2 counter-
clockwise around the central ion channel (Baumann et al.
2001, 2002; Baur et al. 2006). In the GABAA receptor, the F
Loop of the a1 subunit as well as the F loop of the b2 subunit
have been reported to play an important role in linking
binding to gating of the GABAA receptor (Newell and
Czajkwski 2003; Williams et al. 2009).
Many drugs act at GABAA receptors among them
benzodiazepines. Benzodiazepines are clinically important
Received August 31, 2010; revised manuscript received September 24,
2010; accepted October 5, 2010.
Address correspondence and reprint requests to Erwin Sigel, Institute
of Biochemistry and Molecular Medicine, University of Bern, Bu¨hlst-
rasse 28, CH-3012 Bern, Switzerland. E-mail: erwin.sigel@mci.unibe.ch
1These authors contributed equally to this study.
Abbreviations used: DMCM, methyl 6, 7-dimethoxy-4-ethly-beta-
carboline-2-carboxylate; GABAA receptor, GABA type A receptor;
HEK, human embryonic kidney.
Abstract
Benzodiazepines act at the major isoforms of GABA type A
receptors where they potentiate the current evoked by the
agonist GABA. The underlying mechanism of this potentia-
tion is poorly understood, but hypothesized to be related to
the mechanism that links agonist binding to channel opening
in these ligand activated ion channels. The loop F of the a1
and the b2 subunit have been implicated in channel gating,
and loop F of the c2 subunit in the modulation by ben-
zodiazepines. We have identiﬁed the conservative point
mutation Y168F located N-terminally of loop F in the a1
subunit that fails to affect agonist properties. Interestingly, it
disrupts modulation by benzodiazepines, but leaves high
afﬁnity binding to the benzodiazepine binding site intact.
Modulation by barbiturates and neurosteroids is also unaf-
fected. Residue a1Y168 is not located either near the binding
pockets for GABA, or for benzodiazepines, or close to the
loop F of the c2 subunit. Our results support the fact, that
broader regions of ligand gated receptors are conforma-
tionally affected by the binding of benzodiazepines. We infer
that also broader regions could contribute to signaling from
GABA agonist binding to channel opening.
Keywords: benzodiazepine binding, benzodiazepine modu-
lation, channel gating, F loop, GABA, GABAA receptor.
J. Neurochem. (2010) 115, 1478–1485.
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drugs and are used mainly for their sedative/hypnotic and
anxiolytic action. They bind to a high afﬁnity binding site,
located at the a/c subunit interface, that is homologous to the
two GABA agonist sites, located at b/a subunit interfaces
(for review see Sigel and Buhr 1997). Benzodiazepines
potentiate responses of the major GABAA receptor isoforms
to the agonist GABA. In this case high afﬁnity binding of
benzodiazepines induces a structural change to the receptor,
leading to potentiation. Again, the underlying structural
change is poorly understood. In this case, loop F of the c2
subunit has been suggested to be involved in this process
(Hanson and Czajkowski 2008; Padgett and Lummis 2008).
Residues located at the outer membrane surface may also
play a role (Boileau and Czajkowski 1999).
We report here on a conservative point mutation located at
the N-terminal end of loop F in the a1 subunit of the GABAA
receptor, which does not affect the response to GABA and
high afﬁnity binding of benzodiazepines to their site, but
strongly decreases modulation by benzodiazepines. This
residue is distant from loop F of the c2 subunit, arguing for
the fact that receptor regions outside this loop F are essential
for signaling from the benzodiazepine binding site to the
channel portion. We hypothesize that the same may be the
case for signaling from agonist binding to channel opening in
the ligand gated ion channel family.
Methods
Construction of the mutated receptor subunit
The mutant subunit a1Y168F was prepared using the QuikChange
TM
mutagenesis kit (Stratagene, Agilent Technologies, Basel, Switzer-
land). For cell transfection, the cDNAs were subcloned into the
polylinker of pBC/CMV (Bertocci et al. 1991). This expression
vector allows high-level expression of a foreign gene under control of
the cytomegalovirus promoter. The a subunit was cloned into the
EcoRI and the b and c subunits were subcloned into the SmaI site of
the polylinker by standard techniques.
Expression in Xenopus oocytes
Capped cRNAs were synthesized (Ambion, Applied Biosystems,
Rotkreuz, Switzerland) from the linearized vectors containing the
different subunits, respectively. A poly-A tail of about 400 residues
was added to each transcript using yeast poly-A polymerase (United
States Biologicals, Cleveland, OH, USA). The concentration of the
cRNAwas quantiﬁed on a formaldehyde gel using Radiant Red stain
(Bio-Rad Laboratories, Reinach, Switzerland) for visualization of
the RNA. Known concentrations of RNA ladder (Invitrogen, Basel,
Switzerland) were loaded as standard on the same gel. cRNAs were
precipitated in ethanol/isoamylalcohol 19 : 1, the dried pellet
dissolved in water and stored at )80C. cRNA mixtures were
prepared from these stock solutions and stored at )80C.
Xenopus laevis oocytes were prepared, injected and defollicu-
lated as described previously (Sigel 1987; Sigel and Minier 2005).
They were injected with 50 nL of the cRNA solution containing
wild type or mutated a1 and wild type b2 and c2 subunits at a
concentration of 10 nM : 10 nM : 50 nM (Boileau et al. 2002), and
then incubated in modiﬁed Barth’s solution [10 mM HEPES, pH
7.5, 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 0.82 mM
MgSO4, 0.34 mM Ca(NO3)2, 0.41 mM CaCl2, 100 units/mL
penicillin, 100 lg/mL streptomycin] at 18C for at least 24 h before
the measurements.
Functional characterization in Xenopus oocytes
Currents were measured using a home-built two-electrode voltage
clamp ampliﬁer in combination with a XY-recorder (90% response
time 0.1 s) or digitized at 100 Hz using a MacLab/200 (AD
Instruments, Spechbach, Germany). Tests with a model oocyte were
performed to ensure linearity in the larger current range. The
response was linear up to 20 lA. Electrophysiological experiments
were performed at a holding potential of )80 mV. The perfusion
medium contained 90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM
CaCl2, and 5 mM Na-HEPES (pH 7.4). The perfusion solution
(6 mL/min) was applied through a glass capillary with an inner
diameter of 1.35 mm, the mouth of which was placed about 0.4 mm
from the surface of the oocyte (Baur and Sigel 2007). The
experiments were performed after the measured currents became
constant. Concentration response curves for GABA were ﬁtted with
the equation I(c) = Imax/(1 + (EC50/c)
n), where c is the concentration
of GABA, EC50 the concentration of GABA eliciting half maximal
current amplitude, Imax is the maximal current amplitude, I the
current amplitude and n the Hill coefﬁcient. Allosteric modulation
via the benzodiazepine site were measured at a GABA concentration
eliciting 2–5% of the maximal GABA current amplitude. GABA
was applied for 20 s alone or in combination with allosteric
compound. The prototype positive allosteric modulator diazepam,
the prototype negative allosteric modulator methyl 6, 7-dimethoxy-
4-ethyl-beta-carboline-2-carboxylate (DMCM) and the prototype
benzodiazepine antagonist Ro15-1788 were used. Additionally, a
positive modulator with a different chemical structure from classic
benzodiazepines, the imidazobendiazepine zolpidem was tested.
Relative current potentiation by benzodiazepines (BZ) was deter-
mined as (I1 lM BZ + GABA/IGABA – 1) * 100%. The perfusion system
was cleaned between drug applications, by washing with dimeth-
ylsulfoxide to avoid contamination.
Transfection of recombinant GABAA receptor in cultured cells
The cells were maintained in minimum essential medium
(Invitrogen, Basel, Switzerland) supplemented with 10% fetal calf
serum, 2 mM glutamine, 50 units/mL penicillin and 50 lg/mL
streptomycin by standard cell culture techniques. Equal amounts
(total of 20 lg DNA/90 mm dish) of plasmids coding for GABAA
receptor subunits were transfected into human embryonic kidney
(HEK) 293 cells (ATCC no. CRL 1573) by the calcium phosphate
precipitation method (Chen and Okayama 1987). After overnight
incubation, the cells were washed once with serum free medium and
reefed with medium.
Membrane preparation
Approximately 60 h after transfection the cells were harvested by
washing with ice-cold phosphate-buffered saline, pH 7.0, and
centrifuged at 150 g. Cells were washed with buffer containing
10 mM K phosphate, 100 mM KCl, 0.1 mM K EDTA, pH 7.4.
Cells were homogenized by sonication in the presence of 10 lM
 2010 The Authors
Journal of Neurochemistry  2010 International Society for Neurochemistry, J. Neurochem. (2010) 115, 1478–1485
a1Y168F disrupts benzodiazepine modulation of GABAA receptors | 1479
- 142 -
phenyl-methyl-sulfonyl-ﬂuoride and 1 mM EDTA. Membranes
were collected by three centrifugation-resuspension cycles
(100 000 g for 20 min), and then used for ligand binding or stored
at )20C.
Binding assays
Binding assays were carried out as before (Baur et al. 2008). Brieﬂy,
resuspended cell membranes (0.2–0.5 mL) were incubated for
60 min on ice in the presence of [3H]Ro15-1788 (87 Ci/mmol,
PerkinElmer, Schwerzenbach, Switzerland) or [3H]ﬂunitrazepam
(86 Ci/mmol, PerkinElmer) and various concentrations of competing
ligands. Membranes were collected by rapid ﬁltration on GF/C ﬁlters
(Whatman, Dassel, Germany). After three washing steps with 5 mL of
buffer, the ﬁlter-retained radioactivity was determined by liquid
scintillation counting. Non-speciﬁc binding was determined in the
presence of 10 lM Ro15-1788 or 20 lM ﬂunitrazepam, respectively.
Displacement assays were carried out with [3H]Ro15-1788 as
radioactive ligand and increasing concentrations of diazepam or
DMCM. Data were ﬁtted by using a nonlinear least-squares method
to the equation B(c) = Bmax/(1 + Kd/c) for binding curves and
B(c) = Bmax/(1 + (c/IC50)) for displacement curves, where c is the
concentration of ligand, B, binding, Bmax, maximal binding, Kd,
dissociation constant and n, Hill coefﬁcient. All ﬁtting procedures were
performed with the Kaleidagraph software. IC50 values of displacement
curves were converted to Ki values according to the Cheng-Prusoff
equation (Cheng and Prusoff 1973).
Alignment and model building
A multiple sequence alignment was performed using the clustalX
(Thompson et al. 1994) program. Based on this sequence alignment
and the X-ray crystal structure of acetylcholine binding protein
(AChBP) (Hansen et al. 2005), the homology model was built by
MODELLER (Sali and Blundell 1993) as described in Ernst et al.
(2005).
Results
Response to GABA
The conservative mutation to Phe was introduced into
residue a1Y168. Tyrosine side chains differ from phenylal-
anine side chains by the potential to form a hydrogen bridge.
The mutated subunit was expressed together with b2 and c2
subunits in Xenopus oocytes and the resulting receptor
compared to wild type receptors. The mutation did not
signiﬁcantly affect functional expression levels (not shown)
and only weakly affected the response to GABA (Fig. 1).
The concentration-response curves of wild type a1b2c2 and
mutant a1Y168Fb2c2 receptors were characterized by EC50s
of 16 ± 2 lM (n = 6) and 18 ± 10 lM (n = 7) and a Hill
coefﬁcients of 1.36 ± 0.06 and 1.06 ± 0.18, respectively.
To ensure presence of the c2 subunit in both receptors, we
performed concentration-response curves for wild type a1b2
and mutant a1Y168Fb2 receptors. Omission of the c2 subunit
is known to lead to a shift of the concentration response
curve for GABA to the left (Sigel et al. 1990). These curves
were characterized by EC50s of 2.1 ± 0.8 lM (n = 5) and
2.6 ± 0.7 lM (n = 5) and Hill coefﬁcients of 1.36 ± 0.12
and 1.36 ± 0.13, respectively (Fig. 1). Thus, in mutant
a1Y168Fb2c2 receptors a similar leftward shift of the
concentration-response curves was observed as in wild type
a1b2c2 receptors, conﬁrming the presence of the c2 subunit in
both receptors.
Potentiation by ligands of the benzodiazepine binding site
Large differences between wild type and mutant receptors
were observed for the potentiation by diazepam. Current
traces are shown in Fig. 2. Potentiation of about 200% in
wild type a1b2c2 receptors was reduced to 30% in mutant
a1Y168Fb2c2 receptors. This decrease in potentiation was
also observed for other ligands of the benzodiazepine binding
site (Fig. 3). A quantitative analysis showed that current
potentiation was reduced by the mutation for 1 lM diazepam
from 200 ± 44% in wild type receptors to 28 ± 26% in
mutant receptors, for 1 lM ﬂunitrazepam from 187 ± 13% to
28 ± 12% and for 1 lM zolpidem from 424 ± 21% to
64 ± 30%. Inhibition by DMCM was reduced from )60 ±
1% to 0 ± 11% (Fig. 3). All data were derived from four
experiments carried out with oocytes from two independent
batches. Ro15-1788 did not signiﬁcantly affect the current
amplitudes elicited by GABA. Data shown below indicate
that Ro15-1788 binds with high afﬁnity irrespective of the
mutation. Thus, Ro15-1788 is an antagonist in both wild type
and mutant receptors (Fig. 3).
Fig. 1 Concentration response curves forGABAatwild type a1b2c2 and
a1b2 and mutant a1Y168Fb2c2 and a1Y168Fb2 receptors. Receptors
were expressed in Xenopus oocytes and exposed to increasing con-
centrations of GABA. Individual curves were ﬁrst normalized to the
observed maximal current amplitude and subsequently averaged.
Mean ± SDof at least ﬁve experiments carried outwith different oocytes
from at least two batches for each subunit combination is shown.
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The concentration dependence of the potentiation by
diazepam and zolpidem at wild type a1b2c2 and mutant
a1Y168Fb2c2 receptors was also determined (Fig. 4). Poten-
tiation by diazepam was ﬁtted with an EC50 of 0.059 ±
0.013 lM (n = 3) and a maximal potentiation of 285 ± 29%
for wild type receptors, and 3.7 ± 2.4 lM (n = 4) and
53 ± 9% for mutant receptors (Fig. 4a). Potentiation by
zolpidem was ﬁtted with an EC50 of 0.17 ± 0.01 lM (n = 3)
and a maximal potentiation of 392 ± 29% for wild type
receptors, and 5.8 ± 2.6 lM (n = 3) and 64 ± 14% for
mutant receptors (Fig. 4b). Thus, for both ligands of the
benzodiazepine binding site, there was a decrease in apparent
afﬁnity amounting to more than 30-fold, and a decrease in
the maximal potentiation amounting to more than 5-fold. It
was interesting to see whether the apparent decrease in
afﬁnity for function was reﬂected in a decrease in binding
afﬁnity.
Radioactive ligand binding to the benzodiazepine binding
site
Wild type a1b2c2 and mutant a1Y168Fb2c2 receptors were
expressed in HEK293 cells and their benzodiazepine binding
sites probed with several ligands. Radioactive ligands were
tested in binding assays and non-radioactive ligands in
displacement assays. Figure 5(a) shows as an example the
binding of [3H]Ro15-1788 to mutant receptors. The afﬁnity
Fig. 3 Ligands of the benzodiazepine binding site potentiate
a1Y168Fb2c2 receptors less than wild type receptors. Similar experi-
ments as shown in Fig. 2 were carried out with 1 lM diazepam, 1 lM
ﬂunitrazepam, 1 lM zolpidem, 1 lM DMCM or 1 lM Ro15-1788.
Means ± SD of experiments carried out with four oocytes from two
batches for each subunit combination are shown.
(a)
(b)
Fig. 4 Concentration-dependent potentiation of wild type a1b2c2 and
mutant a1Y168Fb2c2 receptors by diazepam and zolpidem. Receptors
were expressed in Xenopus oocytes and exposed to 0.5 lM or 1.0 lM
GABA in combination with increasing concentrations of diazepam (a)
or zolpidem (b), respectively. Individual curves were ﬁrst normalized to
the observed maximal current amplitude and subsequently averaged.
Mean ± SD of experiments carried out with four oocytes from two
batches for each subunit combination are shown.
Fig. 2 Diazepam potentiates a1Y168Fb2c2 receptors less than wild
type receptors. Receptors were expressed in Xenopus oocytes and
exposed twice to 1 lM GABA alone followed by combined application
of 1 lM GABA and 1 lM diazepam.
 2010 The Authors
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of mutant receptors was with 0.8 nM in the range of that of
wild type receptors, indicating that the point mutation did not
disrupt the binding afﬁnity. Displacement by diazepam of
[3H]Ro15-1788 binding also remained unaffected by the
mutation (Fig. 5b). Table 1 summarizes these experiments.
Wild type and mutant receptors were compared in their
respective afﬁnities for [3H]Ro15-1788, [3H]ﬂunitrazepam,
diazepam and DMCM. For none of the tested ligands more
than a 1.8-fold difference between wild type and mutant
receptors was observed.
Lack of an effect of mutation of the homologous residue in
the b2 subunit
The homologous residue to a1Y168 in the b2 subunit, F166
was mutated to Y. a1b2F166Yc2 receptors were expressed in
Xenopus oocytes and functionally characterized. Neither the
EC50 for GABA nor modulation by 1 lM diazepam was
affected by the mutation (results not shown). Very similar
results were obtained with mutation of the neighboring
residues of b2F166, b2E165D and b2Y167F.
Lack of an effect of the mutation a1Y168Y on channel
gating and modulation by pentobarbital, neurosteroids and
inhibition by zinc ions
The mutation a1Y168Ymutation did not affect channel gating
by GABA or binding of benzodiazepines, but disrupted
modulation of the channel by benzodiazepines. It was
interesting to see if the action of other modulatory compounds
was affected by the mutation or whether the effect was speciﬁc
for modulation by benzodiazepines. Therefore, we investi-
gated if channel modulation by pentobarbital, the neurosteroid
THDOC (3a,21-dihydroxy-5a-pregnan-20-one) or inhibition
by zinc ions was affected by the a1Y168Ymutation. As Fig. 6
shows, neither concentration dependent gating (Fig. 6a) or
potentiation (Fig. 6b) by pentobarbital, nor concentration
dependent gating (Fig. 6c) or potentiation (Fig. 6d) of the
channel, nor its concentration dependent inhibition by zinc
ions was affected (not shown). Inhibition by 1 lM and 1 mM
Zn2+ was 24 ± 11% (n = 3) and 86 ± 1% (n = 3) for wild
type receptors and 22 ± 10% (n = 3) and 82 ± 6% (n = 3) for
mutant receptors, respectively.
(a)
(b)
Fig. 5 Binding of [3H]Ro15-1788 to (a) and displacement of
[3H]Ro15-1788 by diazepam from (b) wild type a1b2c2 and mutant
a1Y168Fb2c2 receptors. Receptors were expressed in HEK293 cells,
membranes harvested and subjected to a radioactive ligand binding
assay. Individual experiments are shown. Fitted curves for wild type
and mutant receptor overlap. Mean ± SD from experiments carried
out in triplicate.
Table 1 Summary of the binding properties of the benzodiazepine binding site in wild type a1b2c2 and mutant a1Y168Fb2c2 receptors
Receptor [3H]Ro15-1788, Kd (nM) [
3H]ﬂunitrazepam, Kd (nM) Diazepam, Ki (nM) DMCM, Ki (nM)
a1b2c2 0.70 ± 0.11 2.0 ± 0.4 14.5 ± 3.7 1.3 ± 0.3
a1Y168Fb2c2 0.73 ± 0.05 1.6 ± 0.3 8.2 ± 2.0 2.1 ± 0.4
Binding of [3H]Ro15-1788 and of [3H]ﬂunitrazepam to and displacement of [3H]Ro15-1788 by diazepam and DMCM was determined. Receptors
were expressed in HEK293 cells, membranes harvested and subjected to a radioactive ligand binding assays. Individual curves were ﬁrst
normalized to the observed maximal binding level and subsequently averaged. Mean ± SD from two to four experiments each carried out in
triplicate.
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Location of a1Y168 in the receptor
Figure 7 is based on a homology model of part of the
extracellular domain of the a1b2c2 GABAA receptor. The a1
subunit is shown in yellow and the c2 subunit in bright blue.
The amino acid residue a1Y168 (atoms as spheres) is neither
located in the binding site for GABA or that for benzodiaze-
pines, nor is it located in the loop F of the c2 subunit (dark
blue). It is located neighboring the N-terminal end of loop F
as deﬁned in Hanson and Czajkowski (2008) in the a1
subunit (orange).
Discussion
We made observations relevant for the question how the
signal induced by binding of benzodiazepines is propagated
to an altered channel function in GABAA receptors. As
amino acid residues located in the benzodiazepine binding
site are homologous to amino acid residues located in the
agonist site for GABA (reviewed in Sigel and Buhr 1997)
our observations may be relevant for the question how the
signal induced by binding of GABA is propagated to the ion
channel. If this is the case, the experimental ﬁndings could
concern the entire cys-loop ligand-activated receptor family.
Introduction of the conservative point mutation a1Y168F
into a1b2c2 leaves channel gating by GABA and high afﬁnity
binding of benzodiazepines unaltered while channel modu-
lation by benzodiazepines is strongly reduced. Channel
gating and modulation by pentobarbital and THDOC and
current inhibition by zinc ions are all unaffected by the
mutation, pointing to a speciﬁcity of the mutation for
benzodiazepine modulation. We observe a strong reduction
of efﬁcacy and potency of the current potentiation by
(a) (b)
(c) (d)
Fig. 6 Modulation of wild type a1b2c2 and mutant a1Y168Fb2c2
receptors by pentobarbital and THDOC (3a,21-dihydroxy-5a-pregnan-
20-one) (a) Increasing concentrations of pentobarbital were applied to
wild type and mutant receptors in the absence GABA. (b) Increasing
concentrations of pentobarbital were applied to wild type and mutant
receptors in combination with 1.5 lM GABA. (c) Increasing concen-
trations of THDOC were applied to wild type and mutant receptors in
the absence GABA. (d) Increasing concentrations of THDOC were
applied to wild type and mutant receptors in combination with 1.5 lM
GABA. Mean ± SD of experiments carried out with three oocytes for
each subunit combination are shown.
 2010 The Authors
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diazepam and zolpidem. Interestingly, not only positive but
also negative allosteric modulators were affected.
The mutation has little inﬂuence on the binding properties
of benzodiazepines to recombinant a1b2c2 GABAA receptors
expressed in HEK293 cells. As the observations on receptor
function were made with receptors expressed in Xenopus
oocytes, it may be argued that the c2 subunit essential for the
formation of the benzodiazepine binding pocket was missing
in the large majority of these receptors. We therefore
expressed a1b2 and a1Y168Fb2 receptors and compared
their apparent agonist afﬁnities with a1b2c2 and
a1Y168Fb2c2 receptors. Inclusion of the c2 subunit lowered
the afﬁnity in a similar way in wild type and mutant
receptors, showing its presence in wild type and mutant
receptors.
The amino acid residue a1Y168 locates outside of the
binding pocket for benzodiazepines and does not take part in
the formation of loop F of the c2 subunit. It is also not
located in theoretical lines projecting from binding site
towards the ion channel. Intriguingly, it is located neighbor-
ing the N-terminal end of the loop F of the a1 subunit. It
could be argued that the mutation allosterically affects loop F
of the c2 subunit. However, in spite of the location of the
mutation at the N-terminal to the end of loop F of the a1
subunit, somewhat unexpectedly gating of the channel by
GABA remains unaffected. This loop has been implicated in
the signaling from agonist site to channel. Newell and
Czajkwski (2003) used the substituted cysteine accessibility
method to characterize Pro174-Asp191 of the F-loop of the
a1 subunit. They suggested that this protein segment is
aqueous-exposed and adopts a random coil conformation.
Their ﬁndings also indicate that a part of this segment may
act as a dynamic element during channel-gating transition.
Occupation of the binding site for benzodiazepines in wild
type receptors leads to an increase in the afﬁnity for GABA
binding. It may be hypothesized that a1Y168 is involved in
this process. Speciﬁcally a hydrogen bridge between the side
chain of residue 168 with some unknown partner may be
important as the mutation from Y to F compromises the
ability of this side chain to form such a bridge. Indeed, in the
mutant receptor potentiation by benzodiazepines is strongly
blunted and consequently an increase in the apparent afﬁnity
for GABA may also be blunted.
Padgett and Lummis (2008) introduced point mutations
independently into the C-terminal residues of loop F of the c2
subunit, Asp192-Arg197. Radioactive ligand binding of
benzodiazepines to receptors expressed in HEK293 cells
was unaffected by the mutations. In contrast, after expression
in Xenopus oocytes, apparent afﬁnity and maximum of
modulation by diazepam was affected by mutation of each
residue. The authors concluded that loop F contributes to the
modulation by benzodiazepines and that its mobility may be
a key to modulation.
On the basis of similar work, Hanson and Czajkowski
(2008) also suggested, that ‘c2 Loop F is a speciﬁc transducer
of positive benzodiazepine modulator binding’. They reached
this conclusion by studying receptors in which all residues of
loop F of the c2 subunit were individually mutated to
cysteine. After expression in HEK293 cells, binding prop-
erties for benzodiazepine ligands remained unaffected, while
after expression in Xenopus oocytes mutation of some
selected residues led to an increase or decrease in ﬂurazepam
potency and/or efﬁcacy of modulation.
Our observations do not conﬁrm or contradict observations
that implicate loop F of the c2 subunit in linking binding of
benzodiazepines to channel communication. But they chal-
lenge the notion that the conformational change linking
binding and channel modulation is restricted to loop F of the
c2 subunit. More likely, a large portion of the receptor is
conformationally affected by the binding of benzodiazepines
and contributes to signaling to the channel portion. Similar
considerations may apply to the question, how the binding of
agonists of the ligand gated ion channel family is commu-
nicated to receptor activation.
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C. Concluding Discussion 
The main part of this thesis (Richter et al., 2012, B.I) is concerned with the elucidation of the 
binding mode of 1,4-benzodiazepines at the benzodiazepine binding site in α1β2γ2 GABAA 
receptors. In the absence of a crystal structure of the ligand-bound benzodiazepine binding 
site of GABAA receptors, protein homology modeling and computational ligand docking are 
the only source of structure-based hypotheses for the interaction of benzodiazepines with their 
binding site. However, accurate prediction of membrane protein structures and ligand 
interactions remains a challenge1, and requires accurate modeling of structurally divergent 
regions and extensive use of experimental evidence, as shown recently in a community-wide 
GPCR structure prediction assessment. In the article (Richter et al., 2012, B.I) the workflow 
for identifying the binding mode of 1,4-benzodiazepines can be divided into two steps in 
order to overcome the obstacles of "homology model ambiguity" (exploration step) and 
"docking scoring deficiences" (selection step).  
In the first exploration step, the local uncertainty resulting from structurally divergent regions 
of related cys-loop receptor family members was compensated by constructing a variety of 
homology models from different templates, resulting in an array of homology models with 
varying backbone conformations. Further variability was added by enabling flexible 
sidechains during the docking procedure and retaining the 100 best ranked poses per ligand 
per model. Inevitable this ends up with a multitude of possible binding modes, but with a 
high likelihood of generating the correct ligand-receptor complex. 
The great challenge of the subsequent step, the selection step, was the identification of this 
correctly generated ligand-receptor complex out of an ocean of docking poses. The first 
selection criterion was based on the common binding mode (CBM) hypothesis. The CBM 
assumes that diazepam and its close structural analogues exhibit a common binding mode 
within the benzodiazepine binding pocket. Indeed,clustering of ligand poses according to a 
similar orientation of their common structure as well as according to similar interactions with 
pocket amino acid residues finally led to three common binding mode geometries, CBM I – 
III. The CBM hypothesis accomplished to integrate experimental knowledge (mutagenesis 
data, labeling data, structure-activity relationships) deriving from different ligands and even 
from an additional ligand class (flumazenil, belonging to the class of imidazobenzodiazepines 
) for binding mode evaluation.  
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Here, CBM I is convincingly supported by a large variety of structural, computational 
and experimental evidence and taken together, overwhelming evidence  indicates that CBM 
I is the correct binding mode of diazepam in the benzodiazepine binding pocket.  
Previous studies also featured docking poses of diazepam or its analogues. Overall, however, 
conclusions remained contradictory.  Thus, in one study2 a flunitrazepam orientation similar 
to CBM III poses was reported. Another study3 identified a diazepam pose vaguely similar to 
CBM I, but apparently with a very different interaction pattern due to a different pocket 
topology. A pharmacophore derived diazepam pose4 is in a position intermediate between 
CBM II and I. Most recently, binding modes vaguely resembling our CBM II were proposed 
based on modeling structures from a single template and covalently incorporated ligands.5 In 
a study more concerned with zolpidem6, flunitrazepam poses featured the P-conformation, 
which has been demonstrated to be inactive at the benzodiazepine binding site.  
Ultimately, two virtual screening runs were applied based on the structures of CBM I ligand-
receptor complexes that finally lead to the identification of three new, experimentally 
validated, benzodiazepine binding site ligand classes. The first screen was based on a 
structure-based pharmacophore model derived from CBM I while the second was a docking-
based virtual screening run against CBM I structures. This was, for the very first time, the 
application of structure-based methods in the successful identification of new benzodiazepine 
binding site ligands. Further exploration of in silico screening results presumably will identify 
additional novel ligand classes for the benzodiazepine binding site. 
 
Next to the identification of the binding mode, the structural model of the benzodiazepine 
binding site was also used for investigating the mechanism of the allosteric transduction from 
modulator binding to altered channel gating. For this reason, a computational analysis of the 
intra-molecular protein-protein interactions in the proximity to the benzodiazepine binding 
site was undertaken. This procedure finally aided in the selection of α1Y68 as a candidate for 
receptor mutation. Subsequent experimental studies then proved that α1Y168 plays an 
important role in the allosteric coupling mechanism. The whole study was published in the 
article of Baur et al.7(B.II), with the thesis author contributing as a co-author. 
 
In order to gain more detailed insights into the allosteric coupling mechanism, molecular 
dynamic studies will identify the flexible and rigid parts of the pocket and define their ligand-
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pocket interactions as well as the mechanism of allosteric modulation of positive, negative 
and neutral interactors.  
 
In a broader view, the gained structural model of the benzodiazepine binding site (Richter et 
al., 2012)8 can also be used for modelling of the benzodiazepine-binding sites of other 
GABAA subtypes. Docking of unselective and subtype-selective ligands into their binding 
sites will ultimately lead to an improvement of our understanding of the molecular 
determinants for subtype selectivity of ligands on GABAA receptors. This knowledge will aid 
the development of subtype selective benzodiazepine binding site ligands, avoiding 
interactions with subtypes known to be responsible for benzodiazepine addiction9. 
Finally, the underlying computational workflow can stimulate other groups, aiming to 
integrate various information sources for binding mode evaluation of structurally unresolved 
membrane proteins.       
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